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ABSTRACT 
Protein S has an established role in the protein C anticoagulant pathway as a 
cofactor for anticoagulant protein C (APC) and has also recently been shown to 
serve as a cofactor enhancing the anticoagulant activity of tissue factor pathway 
inhibitor (TFPI). Despite its physiological role and clinical importance, the 
molecular bases of its functions are not fully understood. The aim of my thesis 
was to clarify the molecular mechanisms involved in the protein S interaction with 
APC and TFPI. More than 30 point or composite protein S variants were 
constructed and analysed during this project. These variants spanned the Gla, 
thrombin sensitive region (TSR), epidermal growth-factor1 (EGF1) and EGF2 
domains of protein S. Protein S was expressed in mammalian cells and was 
purified by chromatography, as required. Protein S was characterised by size, 
cleavage, multimerisation, γ-carboxylation of the Gla domain, binding to 
phospholipids and to domain specific monoclonal antibodies. Variants were 
evaluated for their APC and TFPI cofactor activities both by calibrated automated 
thrombography and in purified FVa inactivation or FXa inhibition assays, 
respectively. The protein S variant, protein S D95A, with substitution in EGF1 was 
found to be largely devoid of functional APC cofactor activity and I believe that 
this residue plays an important role in protein S anticoagulant function. It was γ-
carboxylated and bound phospholipids and domain specific monoclonal 
antibodies with an apparent dissociation constant similar to that of wild type 
protein S. Importantly, protein S D95A enhanced the anticoagulant activity of 
TFPI, suggesting that distinct residues in protein S mediate its APC and TFPI 
cofactor activity. Two composite mutants in the protein S EGF1 domain had 
partially reduced TFPI cofactor activity in plasma. However, none of the more 
than 30 variants spanning the Gla-TSR-EGF1-EGF2 domain of protein S 
completely disrupted the protein S cofactor activity towards TFPI. Collectively, 
these results shed light on the molecular basis of protein S cofactor function and 
suggest distinct residues in protein S are involved in the binding to APC and to 
TFPI. 
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1 INTRODUCTION 
1.1 Haemostasis 
The cardiovascular system has a vital importance in distributing nutrients and 
oxygen, while also, removing toxic metabolites. It maintains blood homeostasis by 
regulating variables such as body temperature, pH, pressure and the 
concentration of transported molecules. 
The integrity of the cardiovascular system is preserved by a highly regulated 
process called haemostasis. Under normal circumstances, circulating blood is 
maintained fluid by the physiological anticoagulants acting at the surface of 
endothelial cells and by the lack of procoagulant stimuli. In case of injury of the 
blood vessel, there are three major phases that serve to prevent blood loss and 
enable vessel repair which are all regulated both spatially and temporally, primary 
haemostasis (or platelet plug formation), secondary haemostasis (or coagulation) 
and fibrinolysis. Balanced haemostasis results in rapid occlusion of the damaged 
tissue avoiding bleeding, infiltration of pathogens in the blood and allowing 
enough time to the injured vasculature to repair. The main components regulating 
haemostasis are blood vessels, platelets and coagulation factors. These 
components cooperate, through multiple positive and negative feedback 
mechanisms, to maintain circulating blood fluid and to stop bleeding in case of 
injury. 
 
1.1.1 Primary haemostasis 
Primary haemostasis is the initial response to vascular injury. Following damage 
of the endothelial cell layer the subendothelial extracellular matrix (ECM) is 
exposed to the bloodstream. This results in the lack of the anticoagulant 
endothelial surface and exposure of the adhesive macromolecules of the ECM 
such as collagen, fibronectin, laminin, thrombospondin and vitronectin. While 
platelets are able to interact directly with the ECM, this interaction is greatly 
enhanced by von Willebrand Factor (VWF).1 VWF is a large multimeric adhesive 
glycoprotein found in plasma and is secreted by endothelial cells and activated 
platelets.2-4 When collagen is exposed to the bloodstream VWF binds to it, and 
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shear stress induces unravelling of the globular VWF, making its A1 domain 
accessible to platelets.5 Circulating platelets bind loosely to VWF through the 
receptor complex GPIb-V-IX, causing the platelets to roll along the VWF 
multimer.6 This rolling enables platelets to come into contact with exposed 
collagen and to bind to it through their GPVI receptor. Binding of collagen induces 
intracellular signalling that augments the affinity of cell surface receptors termed 
integrins for their ligands, causing adherence, aggregation and activation of 
platelets.7 Activated platelets release additional VWF resulting in a positive 
feedback loop that leads ultimately to the formation of a primary loose platelet 
plug.8 During activation, the platelet membrane composition is altered exposing 
negatively charged phospholipids, such as phosphatidylserine, that are confined 
to the inner phospholipid layer in the inactivated cell.9 This serves as a surface for 
the activation and assembly of coagulation factors. 
 
1.1.2 Secondary haemostasis 
Secondary haemostasis involves coagulation and requires activation of multiple 
zymogens to active serine proteases, as well as activation of cofactors. The 
coagulation cascade can be initiated through two different pathways, the contact 
activation pathway and the tissue factor (TF) pathway. 10 While the physiological 
relevance of the contact pathway is still debated, the TF pathway is now 
recognised as the principal physiological initiator of coagulation. The following 
paragraphs will only consider the TF pathway. Once coagulation is triggered there 
is a first stage of initiation of coagulation producing only traces of thrombin, which 
through positive feedback activation leads to propagation of coagulation resulting 
in more thrombin and the formation of an insoluble fibrin clot.10 
 
1.1.2.1 Initiation of coagulation 
The major initiator of coagulation is TF, a transmembrane protein expressed on 
the surface of cells at extravascular sites. Following vessel damage, TF is 
exposed to the blood.10 While clotting factors with an enzymatic activity usually 
circulate as inactive zymogens, a small amount (~1%) of factor VII (FVII) 
circulates in its partially active form, FVIIa.11 Both FVII and FVIIa are able to bind 
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to TF, but only the TF/FVIIa complex activates FIX and FX (Figure 1.1). In the 
absence of its cofactor, FVa, FXa converts only a small amount of prothrombin 
into thrombin.  
 
Figure 1.1 Initiation of the coagulation cascade. 
Circulating FVIIa binds to TF exposed to the bloodstream. The TF/FVIIa complex activates FX 
and FIX. FXa generates trace amounts of thrombin (FIIa). 
 
 
1.1.2.2 Feedback activation 
The small amount of thrombin that is generated during the initiation phase 
produces a positive feedback reaction by activating FVIII and FV12, the cofactors 
of FIXa and FXa, respectively (Figure 1.2). The FIXa/FVIIIa complex assembled 
upon phospholipids is also termed the tenase complex as it activates FX. This 
leads to an amplification of FXa production bypassing the requirement for 
TF/FVIIa activity. The FXa/FVa complex on phospholipids, or the prothrombinase 
complex, converts prothrombin into thrombin up to 278000 times more efficiently 
than FXa alone.13-15 Once the damaged tissue and subendothelial cells start to be 
covered by the platelet plug, it has been proposed that secondary haemostasis is 
allowed to continue by the adherence of alternatively spliced soluble TF or 
circulating microparticles containing TF to the surface of activated platelets.16-18 
This results in the propagation of both primary and secondary haemostasis. 
Assembly of the functional tenase and prothrombinase complex upon negatively 
charged phospholipids (such as those exposed on activated platelets) depends 
on domain-specific phospholipid interaction sites such as those provided by the 
Gla domain, of prothrombin, FVII, FIX, and FX or the C domains of FV and 
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FVIII.19-22 In addition to spatially confining these complexes, it also results in 
accelerated formation of the proteases FXa and thrombin.  
Once feedback activation of coagulation has taken place, sufficient thrombin is 
generated for efficiently conversion of fibrinogen into fibrin, (Figure 1.2) which is 
cross-linked by FXIIIa to form an insoluble fibrin clot.23 The fibrin clot prevents the 
loss of blood, the entrance of pathogens into the blood stream and allows the 
damaged endothelium and subendothelial layers to repair.  
Thrombin plays a central role in regulating haemostasis, acting both as a 
procoagulant enzyme by generating a feedback activation of itself, and as an 
anticoagulant enzyme by proteolytically activating protein C.24 
 
Figure 1.2 Propagation of the coagulation cascade. 
Thrombin (FIIa) generated during the initiation stage excerts a feedback mechanism activating 
FVa and FVIIIa, the cofactors of FXa and FIXa respectively. This leads to a massive generation of 
thrombin which converts fibrinogen into fibrin.  
 
 
1.1.3 Regulation of coagulation by anticoagulant pathways 
The procoagulant pathway is tightly regulated by three major anticoagulant 
pathways, the tissue factor pathway inhibitor (TFPI) pathway, the protein C 
pathway and the antithrombin (AT) pathway (Figure 1.3).25 These three pathways 
are each critical for the regulation of the haemostatic plug. Each pathway targets 
quite different components of the coagulation cascade regulating haemostasis 
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both temporally and spatially. 
TFPI is a Kunitz type serine protease inhibitor. TFPI inhibits the extrinsic 
coagulation pathway by inhibiting TF/FVIIa and FXa on the subendothelial cells 
and on the growing platelet plug. TFPI targets the initiation of coagulation, as 
once enough thrombin is formed the necessity of TF/FVIIa for generating FXa is 
by-passed by the FIXa/FVIIIa complex.26 
The activation of protein C by thrombin complexed to thrombomodulin (TM) on 
surrounding intact endothelial cells enables activated protein C (APC) to act at 
the edge of the plug formation inhibiting expansion of fibrin deposition, by 
inactivating FVa and FVIIIa. As activation of protein C requires the formation of 
thrombin, APC is probably only generated during the propagation phase.27  The 
anticoagulant activity of APC is greatly enhanced by a cofactor, protein S, the 
central focus of this thesis. 
AT is a serine protease inhibitor circulating at a plasma concentration of ~2-5 
µM.28 It inhibits multiple serine proteases in the TF pathway (thrombin, FXa, FIXa 
and FVIIa) by forming a stable 1:1 stoichiometric complex, trapping them in a 
form in which their active site is not accessible to their usual substrate.29 The 
inhibitory activity of AT is greatly enhanced by its binding to heparan sulphate on 
intact endothelial cells surrounding the tissue damage. Binding of AT to heparan 
sulphates also results in a conformational change of the former, increasing 
greatly the rate of inactivation of FXa, FIXa and FVIIa.30,31 AT efficiently inhibits all 
of the free serine proteases that escape the immediate proximity of plug 
formation, assuring the latter remains localised throughout the haemostatic 
response.32 
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Figure 1.3 Regulation of the coagulation cascade by the anticoagulant pathways. 
The coagulation cascade is tightly regulated by the three main anticoagulant pathways, TFPI, 
APC and AT. Protein S (PS) acts as a cofactor both for TFPI and APC. Protein S/TFPI inhibits 
TF/FVIIa and FXa. The protein S/APC complex inactivates FVa and FVIIIa. AT inhibits multiple 
serine proteases. For simplicity in this diagram only inhibition of thrombin (FIIa) is shown. 
 
 
1.1.4 Fibrinolysis 
Fibrinolysis, the final phase of haemostasis, is the process by which the fibrin clot 
is remodelled and dissolved once the damaged blood vessel has been repaired. 
Tissue-type plasminogen activator (t-PA) and urinary plasminogen activator (u-
PA) are the two major activators of plasminogen.33,34 Plasminogen is activated to 
plasmin, the enzyme which degrades fibrin. Under normal circumstances where 
there is no fibrin, t-PA and plasminogen circulate in the blood. As soon as fibrin is 
formed, it acts as a template bringing t-PA and plasminogen into proximity, 
enhancing plasminogen activation ~1000-fold. These proteases are 
counterbalanced by fibrinolysis inhibitors such as thrombin activatable fibrinolysis 
inhibitor (TAFI), plasminogen activator inhibitor (PAI)-1 and PAI-2.33,34 
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1.1.5 The haemostatic balance 
Haemostasis represents a fine balance with respect to procoagulant and 
anticoagulant factors. Coagulation disorders result either in haemorrhage or in 
thrombosis. Inherited deficiencies in procoagulant factors result in bleeding 
disorders, the most commonly known are von Willebrand Disease (VWF 
deficiency), haemophilia A (FVIII deficiency) and haemophilia B (FIX 
deficiency).35,36 In contrast, inherited deficiencies in anticoagulant factors result in 
an increased risk of thrombosis, the most commonly known are AT, protein C and 
protein S deficiencies as well as FV Leiden (FV resistance to inactivation by 
activated protein C).37 Because my thesis is primarily concerned with 
anticoagulant pathways, I will describe these in more detail in what follows. 
 
1.2 TFPI 
1.2.1 TFPI gene 
TFPI is expressed mainly by endothelial cells, but also by vascular smooth 
muscle cells, megakaryocytes, monocytes, mesangial cells, fibroblasts and 
cardiomyocytes.38-40 The human TFPI gene is localized on chromosome 2 where 
it spans approximately 70 kilobase (kb) and consists of 9 exons.41 The TFPI 
transcript is alternatively spliced giving origin to two isoforms, TFPI-α and TFPI-β. 
The physiological role of TFPI-β has not yet been determined and most results 
have been derived from in vitro experiments. It is, however, known that TFPI-β 
contains an alternatively spliced C-terminal domain and associates to endothelial 
cells through glycosyl phosphatidylinositol (GPI)-anchors, possibly within 
caveolae.42 Interestingly, it has been shown to still exert an anticoagulant function 
by inhibiting FXa and TF/FVIIa.43 TFPI-α is the most abundant transcript and the 
one on which my project will focus.24 TFPI-α is translated into an unprocessed 
precursor of 304 amino acids with a predicted molecular weight (MW) of 35 
kilodaltons (kDa). Cleavage of the 28 amino acid signal peptide and post-
translational modifications, result in mature full-length TFPI protein of 276 amino 
acids and a MW of 43 kDa. If not indicated otherwise in this thesis the term TFPI 
will hereafter refer to the α-isoform. 
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1.2.2 TFPI structure  
The full-length TFPI protein derived from the TFPI- α transcript has a negatively 
charged N-terminal region (amino acids 1-12), 3 Kunitz domains (K1, amino acids 
13-78; K2, amino acids 92-150; K3, amino acids 182-241) separated by 2 linker 
regions and a positively charged C-terminal region (amino acids 242-273) (Figure 
1.4).44 It is N-linked glycosylated at Asn117 and Asn167 and O-linked 
glycosylated at Ser174 and Thr175. Truncated forms of TFPI derived from the 
TFPI- α transcript are also present in plasma. Truncation usually results in TFPI 
variants lacking their C-terminal tail and often also part of their K3 domain.45 The 
physiological origin of these truncated forms is not known but it has been shown 
in vitro that TFPI can be cleaved by proteases that TFPI may encounter in vivo, 
such as thrombin, plasmin, neutrophil elastase and some matrix 
metalloproteinases.46-49 
 
 
Figure 1.4 Schematic representation of full-length TFPI. 
The N-terminal region contains negatively charged residues (yellow), while the C-terminal region 
contains positively charged residues (red). N-linked glycosylations are shown as black squares, 
O-linked glycosylations as gray circles. P1 residues in the respective Kunitz domains are indicated 
by arrows (Figure from Crawley and Lane, 2008).
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 The usually reported sequence contains a Y in 
position 115, G in position 121 and L in position 197. 
 
 
The majority of TFPI (~80%) is associated with the endothelial cell surface 
(Figure 1.5). It has been reported that the mechanism of this association is mainly 
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(~75%) through an indirect binding to GPI in the caveolae.42,50-53 As TFPI does 
not contain a GPI anchor sequence it has been hypothesised that TFPI is 
associated to the cell surface indirectly through a GPI binding protein.54 The 
remaining amount (~25%) of TFPI associated to the endothelial cell surface does 
so through a direct interaction with cell surface glycosaminoglycans (GAG) 
mediated by its C-terminal tail.55 This pool of TFPI is released following heparin 
injection augmenting 2-4-fold the amount of circulating full-length TFPI.40,56-59 
The remaining TFPI (~20%) is either located inside platelets or circulates at a 
plasma concentration of ~2.5 nM (Figure 1.5).55 The small amount (~5%) of 
plasma TFPI localised inside platelets is in storage granules that are distinct from 
α-granules.60 This TFPI can be released following dual stimulation of platelets 
with collagen and thrombin which leads to platelet activation.61-63 Of plasma TFPI, 
only ~10% is in its full-length 43 kDa form and represents the fraction of TFPI 
immediately available to counterbalance the procoagulant response. A small 
amount (~5%) of TFPI circulates as free truncated TFPI. The remaining plasma 
TFPI (~80%) is bound to lipoproteins.64,65  
 
 
Figure 1.5 Distribution of TFPI. 
Schematic representation of the distribution of TFPI in plasma and on the endothelial cell surface. 
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1.2.3 TFPI function 
TFPI binds to and directly inhibits FXa and, in a FXa-dependent way, inhibits the 
TF/FVIIa complex by forming a quaternary, inactive FXa/TFPI/TF/FVIIa 
complex.66-68 By inhibiting TF/FVIIa, TFPI inhibits the initiation phase of 
coagulation. The need for TFPI to bind and to inhibit FXa to effectively inhibit 
TF/FVIIa ensures that the TFPI pathway only regulates coagulation once it has 
started.69 
 
1.2.3.1 TFPI mediated inhibition of FXa 
FX is composed of a Gla domain responsible for its binding to phospholipids, two 
epidermal growth factor (EGF) domains required for protein-protein interaction 
and a serine protease domain responsible for the enzymatic activity of FXa. FX 
circulates as an inactive zymogen at a plasma concentration of ~136 nM and is 
activated following proteolysis by TF/FVIIa or by FVIIIa/FIXa.70 
TFPI is a slow, tight-binding competitive inhibitor. TFPI binds FXa in a 1:1 
stoichiometry, occupying its active site through its P1 residue, Arg107, in the K2 
domain.66 TFPI reversibly inhibits FXa by binding FXa in its active site. TFPI acts 
as a competitive inhibitor preventing FXa from binding to and activating 
prothrombin. It has been shown that FXa is able to hydrolyse TFPI after its P1 
residue in the K3 domain, however, the physiological significance of this still 
needs to be evaluated.71 
The kinetic mechanism of TFPI mediated inhibition of FXa is described as a two 
step reaction (Equation (Eq) 1).72 
 
The first step describes the rapid formation of a loose initial FXa/TFPI complex. 
This is followed by a slower step resulting in formation of a final tight-binding of 
the enzyme to the inhibitor (FXa/TFPI* complex). Tight-binding is characterised 
by inhibition occuring at concentrations of inhibitor close to that of the enzyme. 
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The first step is described by the inhibition constant Ki 
(Ki=[FXa]*[TFPI]/[FXa/TFPI]) and the overall reaction by the inhibition constant Ki* 
(Ki*=[FXa]*[TFPI]/([FXa/TFPI]+[FXa/TFPI*])). 
It has been shown that both phospholipids and FVa can enhance TFPI mediated 
inhibition of FXa.72,73 Phospholipids are likely to co-localise FXa and TFPI on its 
surface, as FXa binds phospholipids through its Gla domain and it has been 
suggested that the positively charged C-terminal tail of TFPI can interact with 
negatively charged phospholipid surfaces and cell surfaces.74-76 TFPI inhibition of 
FXa in the prothrombinase complex is, however, inhibited by the presence of sub-
physiological concentrations of prothrombin.73,77 It is likely that this is a result of 
prothrombin competing for the active site of FXa. 
It has been shown that TFPI truncated, either after its K3 domain (lacking the K3 
domain and the C-terminal tail) or lacking the C-terminal tail, is not as potent 
inhibitor of FXa as full-length TFPI.78-80 It has been suggested that the K3 domain 
and C-terminal tail of TFPI might interact with phospholipids and cell surfaces,74-76 
and that the C-terminal tail of TFPI might interact with the Gla domain of FXa79,80 
possibly partially explaining the reduced activity of truncated TFPI. More recently, 
it was shown that protein S acts as a cofactor towards full-length TFPI mediated 
inhibition of FXa but not towards TFPI lacking its K3 and C-terminal domain.81 
 
1.2.3.2 TFPI mediated inhibition of TF/FVIIa 
TFPI inhibits TF/FVIIa in a FXa dependent way.66-68 As described in section 
1.2.3.1 TFPI is a slow, tight-binding competitive inhibitor. It reversibly inhibits 
TF/FVIIa by binding the active site of FVIIa through its P1 residue (Lys36) in the 
K1 domain.66 It has been shown that the intact Gla domain of FXa is required for 
TFPI mediated inhibition of TF/FVIIa.82,83 One study used a plate binding assay 
and showed that FXa enhanced the binding of TFPI to phospholipids.76 It has 
been suggested that the Gla domain and EGF1 domain of FXa are important for 
interactions with the TF/FVIIa complex, potentially explaining its importance in 
TFPI mediated inhibition of TF/FVIIa.84,85 
Inhibition of TF/FVIIa is usually described as a two-step process, in which TFPI 
first binds to FXa (this being the rate-limiting step) and then inhibits TF/FVIIa by 
binding to FVIIa (Figure 1.6 left). Kinetic studies, however, favour the binding of 
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TFPI to FXa that is already bound to TF/FVIIa (Figure 1.6 right).68 The resulting 
inactive quaternary TFPI/FXa/TF/FVIIa complex leads to inhibition of the initial 
procoagulant stimuli. Although the K3 domain and C-terminal tail of TFPI are not 
absolute requirements for inhibition of FXa/TF/FVIIa, their presence appreciably 
enhances the TFPI anticoagulant activity.78,79 
 
 
Figure 1.6 TFPI binds to and inhibits FXa and TF/FVIIa. 
Inhibition of TF/FVIIa is frequently described as a two-stage process (left) in which TFPI first binds 
FXa and then the TFPI/FXa complex binds and inhibits TF/FVIIa. However, kinetic studies favour 
a model whereby TFPI binds to newly activated FX prior its release from the TF/FVIIa/FXa 
complex (right). In both cases the resulting inactive quaternary complex is TFPI/FXa/TF/FVIIa. 
 
 
1.3 Protein C/APC 
1.3.1 PROC  
Protein C is a plasma protein that is synthesised and secreted by hepatocytes. 
PROC, the gene that encodes protein C, is localised on chromosome 2 and 
contains 9 exons.86 Translation of the messanger ribonucleic acid (mRNA) results 
in an immature protein of 461 amino acids.87 Post-transcriptional modifications 
include γ-carboxylation, β-hydroxylation, glycosylation and removal of the Lys156-
Arg157 dipeptide by proteolysis which results in conversion of protein C from a 
single chain to a two-chain protein. Following removal of the pro- and pre-peptide 
protein C is secreted as a mature zymogen of 419 amino acids with a MW of 62 
kDa. 
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1.3.2 Protein C structure  
Protein C circulates as a zymogen at a plasma concentration of ~65 nM. It is 
composed of a Gla domain, two EGF domains, an activation peptide (AP) and a 
serine protease domain (Figure 1.7).88 The Gla domain (amino acids 1-45) 
contains 9 γ-carboxylated Glu (Gla) residues (Gla6, 7, 14, 16, 19, 20, 25, 26, and 
29).87,89 These are essential for coordination of Ca2+ ions and binding to 
negatively charged phospholipids surfaces.19 It has also been shown that Leu8, 
which is part of the hydrophobic ω-loop, is essential for binding to the endothelial 
protein C receptor (EPCR).90 In addition, substitution of Asp36/Leu38/Ala39 
results in a APC variant that can not be enhanced by protein S. The two EGF 
domains are predicted to be important for protein-protein interactions but no 
definitive role has so far been reported in the literature. EGF1 (amino acids 46-
92) is β-hydroxylated at Asp71 and this residue in conjunction with Asp46 and 
Asp48 coordinates a Ca2+ ion.91 A study using a Fab fragment against this region 
suggested that the EGF1 of protein C might be important for interactions with 
protein S.91 EGF2 (amino acids 93-137) is glycosylated at Asn97 and this has 
been reported to be important for effective secretion of protein C.92 The serine 
protease domain (amino acids 138-419) is composed by a catalytic triad (His211, 
Asp257 and Ser360), and contains loop 225 and loop 70 involved in Na+ and Ca2+ 
binding, respectively.93 It has been shown that binding of one ion to its loop 
increases the affinity of the other ion.93 The serine protease domain also contains 
loop 37, loop 60 and loop 148. Basic residues in loop 37, loop 70 and loop 148 are 
believed to form an exosite for binding to FVa and FVIIIa.94-98  
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Figure 1.7 Schematic structure of protein C.  
The complete model of zymogen protein C was made by combining the crystal structure of the 
Gla-domainless APC with the Gla domain modelled from the crystal structure of the TF/FVIIa 
complex.
88
 The AP was introduced by homology modelling. The serine protease domain is 
coloured in red, with the catalytic triad showed by the darker red spheres. The EGF2 is colured in 
dark blue, the EGF1 in cyan and the Gla domain in orange. The 9 Gla residues in the Gla domain 
are shown as sticks and coordinate calcium ions (yellow spheres). The Leu8 residue is shown in 
olive green and the Asp36/Leu38/Ala39 residues in the bright orange spheres. 
 
 
1.3.3 Protein C activation 
Cleavage of the negatively charged AP (Asp158-Arg169) of protein C by thrombin 
results in activation of protein C. Activated protein C is a two chain protein 
composed of a light (Gla-EGF1-EGF2) and heavy (AP and serine protease 
domain) chain connected through a disulphide bond (Cys141 and Cys277). 
Protein C is activated only once a sufficient amount of thrombin is generated. 
Thrombin that escapes the site of injury can bind to TM on intact endothelial cells 
adjacent to the site of vascular injury. TM is composed of a C-terminal 
cytoplasmic tail, a transmembrane region, a serine-threonine rich domain, 6 EGF 
domains and an N-terminal type C lectin-like domain.99 Thrombin binds TM in the 
EGF5 and EGF6 domains through its exosite I.100,101 It has also been shown that 
a chondroitin sulfate moiety of TM can interact with the exosite II of thrombin.102 
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As exosites I and II of thrombin are required for the activation of procoagulant 
factors FVa and FVIIIa,12,103-106 binding of thrombin to TM results in a loss of its 
procoagulant functions. Instead, the specificity of thrombin is altered and the 
anticoagulant properties of thrombin are enhanced. The ability of thrombin to 
activate protein C is enhanced by 2000-fold following binding to TM.107 Thrombin 
activates protein C by cleaving after Arg169 removing its AP. TM also binds the 
serine protease domain in the loops 37, 60, 70 and 148 of protein C through its 
EGF4 domain (Figure 1.8).107-109 The activation of protein C is appreciably 
enhanced (more than 5-fold) by the presence of EPCR which binds the Leu8 in 
the Gla domain of protein C localising protein C to the endothelial surface close to 
the thrombin/TM complex.90,110-113 This increases the local concentration of 
protein C available for activation. 
 
Figure 1.8 Activation of protein C.  
Thrombin (light purple) binds to EGF5 and EGF6 of TM through its excosite I domain. EPCR (dark 
purple) binds the Gla domain of protein C resulting in the alignment of protein C with the 
thrombin/TM complex. EGF4 of TM is able to interact with loops 37, 60, 70 and 148 (not shown) of 
protein C bringing the AP of protein C in proximity of the active site of thrombin. Cleavage after 
Arg169 of protein C by thrombin activates protein C. Figure modified from Dahlbäck and 
Villoutreix.
114
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1.3.4 APC function 
APC downregulates coagulation by proteolytical inactivation of FVa and FVIIIa, 
the non-enzymatic cofactors of FXa and FIXa, respectively.27 FV and FVIII have a 
highly homologous domain structure containing an N-terminal A1 and A2 domain, 
a B domain, and a C-terminal A3 domain followed by a C1 and C2 domain. The 
C2 domains possibly also the C1 domains are responsible for FV and FVIII 
binding to phospholipids.20-22 The A2 and A3 domains of FVa and FVIIIa are 
important for the interaction with FXa and FIXa respectively.115-118 
 
1.3.4.1 APC mediated inactivation of FVa 
Activation of FV occurs by the cleavage of peptide bonds in the B domain by 
either thrombin or FXa (Figure 1.9). This leads to dissociation of the B domain 
resulting in a two-chain molecule. The heavy chain (A1-A2 amino acids 1-709) 
and the light chain (A3-C1-C2 amino acids 1546-2196) remain associated by a 
non covalent complex between the A1 and A3 domains. While the association 
between the domains was believed to be through a high affinity Ca2+ interaction 
this has recently been questioned.20 FVa can be inactivated by APC by proteloytic 
cleavage. APC can cleave FVa after Arg306, Arg506 and Arg679 (Figure 1.9).119 
 
Figure 1.9 Activation of FV by thrombin and inactivation of FVa by APC. 
Thrombin activates FV by proteolytic cleavage in its B domain. The heavy and light chains of FVa 
are associated through a high affinity binding to a calcium ion. APC inactivates FVa by proteolytic 
cleavage after Arg306, Arg506 and Arg679. Structure/figure of FV based on Kane et al. 1986, 
Kane et al. 1987, Jenny et al. and Laffan.
120-123
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While the physiological relevance of Arg679 cleavage is still being debated it is 
widely accepted that APC inactivates FVa in plasma by cleavage at Arg506 and 
Arg306. Cleavage at Arg506 is enhanced and cleavage at Arg306 dependent 
upon the presence of phospholipids, with phosphatidylserine and 
phosphatidylethanolamine both being important for the stimulation of APC 
mediated inactivation of FVa.124-128 In FVa variants created for in vitro studies 
additional cleavage sites (Lys309, Arg313, Arg316, Arg317 and Arg505) have 
been identified.129,130 However, the physiological role of these cleavage sites is 
questionable. Following cleavage after Arg506 and Arg306 the A2 domain of FVa 
dissociates resulting in complete inactivation of FVa. Inactivation of FVa is 
biphasic.128,131,132 This is a consequence of the different rates of APC cleavage 
after Arg506 and Arg306. Arg506 is the first and kinetically most favoured 
cleavage site of APC and results in an intermediate FVa form which have been 
reported to have approximately 40% of intact FVa cofactor activity.128 The second 
cleavage of FVa by APC occurs after Arg306 but is ~20-fold slower than the first 
cleavage at Arg506.128 It has been shown that cleavage after Arg506, but to a 
minor extent also cleavage after Arg306, results in a significant decrease of FVa 
affinity for FXa and prothrombin.128,133,134 It is unresolved whether complete loss 
of FVa activity occurs following Arg506 and Arg306 cleavage (before dissociation 
of the A2 domain) or only after dissociation of the A2 domain.133,135  
It is known that FVa is protected from APC mediated proteolytic inactivation 
following binding to FXa136-139 and prothrombin.140-142 It has been shown that 
binding of FXa to FVa specifically inhibits APC cleavage after Arg506 by 
approximately 20-fold137,138 and it has been recently suggested that FXa can 
stimulate APC cleavage at Arg306.137 Binding of prothrombin to FVa has been 
shown to inhibit both APC mediated cleavage at Arg306 and Arg506 of FVa, 
however prothrombin did not inhibit APC mediated inactivation of FVIIIa.141,142 
 
1.3.4.2 APC mediated inactivation of FVIIIa 
FVIII circulates in plasma bound to VWF which act as a carrier protein increasing 
the half life of FVIII.143-145 FVIII is activated following proteolytical cleavage by 
thrombin or FXa in the B domain. Only after activation FVIIIa dissociates from 
VWF.146,147 Similarly to FV activation, activation of FVIII results in a two chain 
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molecule with a light and heavy chain. However, an additional cleavage between 
the A1 and A2 domains by thrombin leads to a weak association between the A1 
and A3 domain which are linked by a Cu2+ ion.148-150 Binding to Ca2+ or Mn2+ is 
also required to yield active FVIIIa.150-152 FVIIIa is unstable and spontaneous 
dissociation of the A2 domain results in loss of activity.153,154 Incorporation of 
FVIIIa into the tenase complex stabilises FVIIIa and also protects it from APC 
mediated inactivation.155,156 APC inactivates FVIIIa by proteolytical cleavage after 
Arg336 and Arg562. Cleavage occurs preferentially at Arg336 and thereafter at 
Arg562, resulting in dissociation of the A2 domain and complete loss of function 
of FVIIIa.157,158  
 
1.4 Protein S 
1.4.1 PROS1  
Protein S is encoded by the PROS1 gene on chromosome 3 (p11.1), which spans 
more than 100 kb and gives rise to an mRNA of 3292 bases.159,160 Following 
transcription the 676 amino acid long protein is directed to the endoplasmic 
reticulum (ER) by its hydrophobic signal peptide. Here, protein S goes through 
several post-transcriptional modifications, including γ-carboxylation, glycosylation 
and β-hydroxylation. γ-carboxylation is carried out by the vitamin K-dependent γ-
carboxylase which recognises and binds to the propeptide of protein S. Prior to 
secretion both the signal peptide and propeptide are proteolytically removed 
generating a mature protein of 635 amino acids with a reported molecular weight 
of 69-77 kDa.161,162  
Protein S is synthesised and secreted into the blood stream mainly by 
hepatocytes but also by endothelial cells, megakaryocytes and vascular smooth 
muscle cells.163-166 The resulting concentration of protein S in plasma is ~0.35 
μM.167 Of plasma protein S, 60% circulates as a non-covalent, high-affinity 
complex with C4b-binding protein (C4BP) while the remaining 40% is free.168 
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1.4.2 Protein S structure  
The mature protein S is composed of an N-terminal Gla domain (amino acids 1-
46), a thrombin sensitive region (TSR, amino acids 47-75), four EGF domains 
(EGF1, amino acids 76-116; EGF2 amino acids 117-160; EGF3, amino acids 
161-202; EGF4, amino acids 203-242) and a C-terminal Sex Hormone Binding 
Globulin-like domain (SHBG) (amino acids 243-635) containing two laminin G 
(LG)-type domains (Figure 1.10).169,170 
The N-terminal Gla domain of protein S contains one disulphide bond (Cys17-
Cys22) and 11 glutamic acid residues (Glu 6, 7, 14, 16, 19, 20, 25, 26, 29, 32 and 
36) that are γ-carboxylated by the vitamin K-dependent γ-carboxylase in the 
ER.171 The resulting N-terminal Gla residues coordinate 8 calcium ions which 
induce an appropriate conformational change in protein S for activity.19,171,172 
Folding of the Gla domain enables protein S to bind to phospholipids through the 
insertion of its hydrophobic ω-loop into the membrane and ionic interactions 
between positively charged calcium ions and the negatively charged phospholipid 
surface.19,171,172 Binding of protein S to phospholipid surfaces localises protein S 
to activated endothelial cells and activated platelet surfaces and is required for 
both its anticoagulant and non-anticoagulant activity (see section 1.4.3). 
The TSR is formed by two α-helixes brought in close contact through a disulphide 
bond between Cys47 and Cys72 and is a domain unique to protein S. Its name 
derives from the observed cleavage of this region by thrombin. While cleavage at 
Arg49 and Arg70 by thrombin has been observed in vitro, this only occurs in the 
absence of Ca2+ and phospholipids, suggesting that this is not of physiological 
importance.173 FXa has also been shown to be able to cleave the TSR at Arg60. 
Recently, it was shown that the TSR domain of protein S could bind to FXa in the 
presence of phospholipids.174 Although FXa cleavage is both Ca2+ and 
phospholipid dependent, it is unlikely to occur in vivo due to its slow kinetics and 
the inability of FXa to cleave protein S when bound to its cofactor FVa or when in 
presence of prothrombin.173 It is, however, interesting to notice that cleavage of 
the TSR has been observed to inhibit the APC-dependent cofactor activity of 
protein S.175-177 The effect of cleavage upon the protein S APC-independent 
activity is still not clear, but it has been suggested that it is abolished only 
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following cleavage after both Arg49 and Arg70.176 It has been reported that 
approximately 10% of plasma protein S circulate in its cleaved form.178 
The EGF1 domain of protein S contains 3 disulphide bonds and is β-hydroxylated 
at Asp95.171 This domain has to date not been found to bind Ca2+ and β-
hydroxylation is thought not to be a requisite for protein S function.179 
The EGF2-4 domains all contain 3 disulphide bonds each and a β-
hydroxyasparagine residue (Hyn 136, Hyn 178 and Hyn 217). Each domain also 
contains a high affinity Ca2+ binding site180 (dissociation constant (Kd) nM range), 
which is thought to include the modified Asn residue. Binding of Ca2+ to these 
domains have been shown to be important for the function of protein S. In 2006 
Rezende and colleagues demonstrated that the abolition of binding of Ca2+ to 
EGF4 impaired both the structure and function of EGF1.181 It has also been 
suggested that a naturally occurring deletion mutation in EGF4 (deletion 
I203D204) alters the conformation and function of the Gla domain,182 while 
deletion or replacement of the entire EGF2 domain results in a significant loss of 
activity.183 
The C-terminal SHBG domain of protein S represents more than half of its amino 
acids and is kept in its globular state through 3 disulphide bonds. It contains 3 
potential N-linked glycans at Asn458, Asn468 and Asn489 and is also predicted 
to contain Ca2+ binding sites.184,185 As anticipated, 60% of protein S circulates as 
a non-covalent, high-affinity complex with C4BP. This interaction is mediated 
through the SHBG domain of protein S.184,186 C4BP is a 570 kDa multimeric 
protein consisting of 6 or 7 identical α-chains with one or no β-chain held together 
by disulphide bonds. It is this β-chain which contains the binding site for protein 
S.187 The net plasma concentration of C4BP is ~260 nM. Of this only ~80% (~208 
nM) has the β-chain and is able to bind to protein S with a 1:1 stoichiometry.187 
The amount of unbound or free circulating protein S is equal to the molar excess 
of protein S over β-chain containing C4BP (~145 nM) and represents the pool of 
protein S with major anticoagulant function.188 
Multimerisation of protein S has been documented in the literature. Protein S is 
generally thought to exist in plasma in its monomeric form (although some have 
reported multimeric forms of protein S in plasma) and multimerisation has been 
attributed at least in part to in vitro manipulation.189-192 
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Figure 1.10 Schematic representation of protein S and its domains. 
Protein S contains a N-terminal Gla domain that is responsible for binding to phospholipid 
surfaces. This is followed by a TSR domain, 4 EGF domains and a SHBG domain. The figure in 
the box has been created from the Gla-TSR-EGF1 model of protein S.
193
 The Gla domain is 
coloured in yellow, with the 11 Gla residues shown as sticks and the 8 calcium ions shown as 
orange spheres in the box at the right. The ω-loop of protein S can be seen underneath the 
calcium ions. The TSR is shown in green and the EGF1 domain in cyan. 
 
 
1.4.3 Protein S functions 
Protein S is a multifunctional protein involved in coagulation, the classical 
complement pathway and apoptotic clearance.194-196 It is also thought to stimulate 
vascular injury repair by acting as a mitogen towards smooth muscle cells and 
has recently been found to have a neuroprotective effect during ischemic brain 
injury in mice.197-200 
The most studied protein S function is its anticoagulant activity, which is also the 
focus of my thesis. Protein S has an important role in vivo, as is shown clinically 
by infants with complete deficiency, who suffer purpura fulminans despite 
treatment of anticoagulants, and by heterozygous carriers of PROS1 gene 
deletions and point mutations, who are at enhanced risk of venous 
thromboembolism.201-203 Hereditary protein S deficiency is an uncommon 
autosomal dominant disorder. It is classified into type I, type II and type III 
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deficiencies. Type I and type III deficiencies are defined as quantitative 
deficiencies of total and free protein S, respectively, and correspond to ~96% of 
all protein S deficiencies.202 The remaining ~4% are represented by type II 
deficiencies. This subtype is classified as a qualitative deficiency.202 Acquired 
protein S deficiencies are more common and occur as a consequence of oral 
anticoagulant therapy, oral contraception, liver disease, nephritic syndrome and 
pregnancy.202,204 Protein S deficiencies, inherited or acquired, both lead to an 
increased risk of thrombotic events.205 The importance of protein S has also been 
demonstrated in murine knockouts, which fail to survive development.206,207 
Protein S is best known for its anticoagulant activity towards APC. Protein S was 
discovered in 1977 by Richard DiScipio and was 3 years later shown to be the 
cofactor of APC.208 Protein S was, however, also suggested to have an APC-
independent activity in 1988.209 In the early 1990’s it was demonstrated that 
protein S could bind to FVa,116,210-212 FXa174,213,214 and FVIIIa215 inhibiting both the 
tenase and prothrombinase complex in an APC-independent manner. It was 
shown that the observed inhibition of the tenase and prothrombinase complex 
was due to competition of protein S multimers for binding to limiting phospholipid 
surfaces.191,192,216,217 However, it was later shown that protein S had an APC-
independent activity in plasma also when saturating amounts of phospholipids 
were present, but which could be demonstrated only at low concentrations of 
TF.218 
 
1.4.3.1 Protein S enhances the anticoagulant activity of APC 
1.4.3.1.1 Protein S enhancement of APC mediated inactivation of FVa 
Protein S enhances the APC mediated inactivation of FVa in a phospholipid 
dependent manner.124,208,219 It does so by selectively enhancing by approximately 
20-fold the slow cleavage at Arg306 of FVa.125,138 The use of FV variants FV 
R306Q/R679Q and FV R506Q/R679Q, that can be cleaved only in Arg506 and 
Arg306, respectively, has been useful to characterise the effect of protein S and 
other components on the individual cleavage sites.125,137,220 Through the use of 
such variants it has recently been suggested that protein S can also enhance ~5-
fold APC mediated cleavage at Arg506.125 
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Protein S has been proposed to enhance APC mediated inactivation of FVa in 3 
distinct ways. It has been shown to enhance APC binding to phospholipid 
surfaces, platelets and endothelial cells,127,221,222 consequently localising APC in 
close proximity to the membrane bound FVa and FVIIIa. This proposal is 
supported by the low affinity of APC for phospholipids. While the apparent 
dissociation constant (Kd(app)) of protein S for phospholipids is between 4-15 
nM182,223-225 the Kd(app) of APC for phospholipids is around 2-7 µM,
226,227 which is 
well outside the range of the physiological plasma concentration of APC (~65 
nM). The second mechanism by which protein S is thought to enhance APC 
anticoagulant activity is through inducing an allosteric conformational change in 
APC.228,229 Yegneswaran et al. used fluorescence resonance energy transfer 
(FRET) and showed that the active site of APC was localised 94 Ångström (Å) 
above the membrane surface. However, in the presence of protein S the active 
site of APC was relocated to 84 Å from the membrane surface.229 It has been 
suggested that this shift in the active site of APC in the presence of protein S 
facilitates the preference of APC cleavage from Arg506 to Arg306. As described 
in section 1.3.4.1, FXa and prothrombin are able to protect FVa from APC 
mediated cleavage. The third mechanism by which protein S is thought to 
enhance APC mediated inactivation of FVa is through overcoming the protective 
effect of FVa.137,219 It is still being debated whether protein S competes with the 
binding of FXa to FVa or not.116,137,138 Depending on this, protein S could either 
act by competing with FXa binding116 to FVa. Alternatively, protein S could 
enhance cleavage of free FVa resulting in depletion of free FVa and dissociation 
of FXa/FVa complexes.137 An other study showed that the binding sites of protein 
S and FXa on FVa are distinct and that protein S is likely to enhance APC 
mediated cleavage at Arg306 of FVa even when the latter is bound to FXa.138 A 
recent paper suggests that not only protein S but also FV can act as a cofactor for 
APC mediated inactivation of FVa.230 
While it was previously thought that only free protein S could act as a cofactor for 
APC, recent work shows that protein S bound to C4BP is able to enhance 
cleavage of FVa.231 However, while cleavage after Arg306 by this complex is 
enhanced 10-fold (compared to ~20-fold by free protein S), cleavage after Arg506 
is inhibited 3-4-fold (compared to no or little influence of free protein S).231 
Consequently, bound protein S enhances APC cleavage of FVa, but is 6-8-fold 
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less effective that free protein S, potentially explaining why in prior experiments 
the addition of C4BP resulted in a decreased APC activity.  
 
1.4.3.1.2 Protein S enhancement of APC mediated inactivation of FVIIIa 
It has been shown that protein S can enhance both the slow cleavage at Arg562 
by ~3-fold and cleavage at Arg336 by ~2-fold. 232,233 However, FV cleaved at 
Arg506 also acts in synergy with protein S as a cofactor enhancing ~10-fold APC 
mediated inactivation of FVIIIa.157,233,234 Both free protein S and protein S bound 
to C4BP act as cofactors for APC mediated inactivation of FVIIIa.235 However, it 
has been reported that while free protein S acts in synergy with FV in the APC 
mediated inactivation of FVIIIa, bound protein S does not.235  
It is believed that protein S exerts its cofactor activity through increasing the 
binding of APC to phospholipid surfaces, platelets and endothelial cells, as 
described in section 1.4.3.1.1. 127,221,222 
Similar to FVa in the prothrombinase complex, when FVIIIa is assembled in the 
tenase complex cleavage is protected by FIXa. Protein S can overcome the 
protective action of FIXa by competing with its binding to FVIIIa.236  
 
1.4.3.2 Protein S enhances the anticoagulant activity of TFPI 
1.4.3.2.1 Protein S enhancement of TFPI mediated inactivation of FXa 
In 2006 Hackeng et al. showed that protein S enhances the anticoagulant activity 
of TFPI, potentially providing a molecular explanation behind the APC-
independent activity observed in plasma.81 Since it had been shown that the 
APC-independent activity of protein S was visualised only at low concentrations 
of TF,218 their investigation hypothesised that protein S had an effect on TF 
mediated activation of FX. Hackeng et al. analysed thrombin generation by 
calibrated automated thrombography (CAT). They showed that in normal plasma, 
in the presence of polyclonal antibodies against APC, antibodies against protein 
S increased thrombin generation. The same effect was, however, not observed in 
TFPI depleted plasma, suggesting the anticoagulant activity of protein S was 
dependent upon the presence of TFPI. This was confirmed by supplementing the 
plasma with TFPI. They also performed a FXa inhibition assay. This was a 
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purified assay in which FXa hydrolysis of a chromogenic substrate was measured 
over time. It was observed that protein S could potentiate the TFPI mediated 
inhibition of FXa by enhancing the formation of the initial FXa/TFPI complex (see 
section 1.2.3.1). Little effect was seen on the transition from the loose FXa/TFPI 
complex to the tightly bound FXa/TFPI* complex. The effect of protein S was 
phospholipid dependent and resulted in a 10-fold reduction of the Ki (see section 
1.2.3.1), from 4.4 nM to 0.5 nM, with little effect on the Ki*.
81 Ndonwi and Broze 
confirmed that protein S enhances TFPI inhibition of FXa.237 Hackeng et al. also 
showed that protein S was not able to enhance the activity of TFPI lacking its K3 
domain and C-terminal tail, and that protein S bound to C4BP only exerted 60% 
of the activity of free protein S.81 Ndonwi et al. recently showed that the K3 
domain of TFPI and in particular its P1 residue were necessary for protein S 
binding and cofactor activity towards TFPI.238 
Rosendaal and colleagues observed that higher plasma concentrations of protein 
S resulted in a higher anticoagulant activity of TFPI.239 Recently, it has been 
shown that the impaired protein S enhancement of TFPI is potentially an 
important component in patients with protein S deficiency.240 Interestingly, it has 
been suggested that protein S binds to TFPI in plasma and that this might 
account for the observed decrease in TFPI antigen levels in protein S deficient 
patients.241 The detailed molecular mechanisms of the TFPI-dependent protein S 
anticoagulant activity were unknown and form an important part of the 
investigation carried out in my thesis. 
Even though the APC-independent activity of protein S now has a plausible 
explanation (it acts as a cofactor of TFPI), Heeb and colleagues have reported 
that protein S also has a “direct” activity, independent of both APC and TFPI, 
exerted by direct binding to and inhibition of FXa and TF/FVIIa.189,190,242 
 
1.4.3.2.2 Protein S enhancement of TFPI mediated inactivation of TF/FVIIa 
Studying the protein S cofactor activity on TFPI mediated inactivation of TF/FVIIa 
is complicated by the difficulty in distinguishing between enhanced TF/FVIIa 
inhibition and enhanced inhibition of FXa. While it was initially suggested that 
protein S could enhance TFPI inhibition of TF/FVIIa activation of FX,81 Ndonwi 
and Broze suggested that this was not the case.237 The latter support the 
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proposal that TFPI predominantly binds to FXa already bound to TF/FVIIa, rather 
than the previously suggested two-step mechanism by which TFPI first binds FXa 
and FXa/TFPI subsequently binds TF/FVIIa (see section 1.2.3.2). Consequently, 
Ndonwi and Broze suggested the major role of protein S enhancement of TFPI 
was to down-regulate any FXa that escapes TF/FVIIa/FXa inhibition by TFPI. 
 
1.5 Domains of protein S which mediate functional interactions 
While the functions of the domains of protein S have been extensively studied, 
the APC cofactor function and the recently discovered TFPI cofactor activity of 
protein S remain poorly understood at the molecular level. A number of basic and 
clinical studies have confirmed that alteration of protein S can disrupt 
phospholipid binding and thereby impair function of protein S.182,223 Consequently, 
variants with impaired cofactor function need to be evaluated for their ability to 
bind to phospholipids and those that clearly alter phospholipid binding can be 
discounted from further investigation. A search of the literature has suggested the 
domains of protein S that are most likely involved in APC and TFPI cofactor 
activity (see sections 1.5.1 and 1.5.2 below).  
 
1.5.1 Domains of protein S reported to be important for APC cofactor 
activity 
Saller et al. prepared protein S/prothrombin chimeras and on the basis of 
functional studies supported by molecular modelling, identified a cluster of protein 
S Gla domain residues (termed Face2) which they proposed would provide an 
APC interaction site.224 Additional studies have focused on the possible role of 
TSR and EGF domains. Several studies have reported that cleavage in the TSR 
of protein S affects its APC-dependent and APC-independent cofactor activity.175-
177 Dahlbäck et al. used domain specific monoclonal antibodies directed against 
protein S and their Fab fragments and suggested that the TSR and EGF1 
domains may be involved in APC cofactor activity.243 The TSR and EGF1 domain 
of protein S have also been reported to be responsible for APC species 
specificity.244 By using EGF-like modules Stenberg et al. concluded the EGF1 
module to be crucial for interaction with APC.245 Hackeng et al. demonstrated that 
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the isolated EGF1 domain of protein S could inhibit full-length protein S 
anticoagulant enhancing function for APC: direct binding of the domain to APC 
was also demonstrated.246 Mille-Baker et al. prepared EGF2 domain deletion and 
substitution variants of protein S and demonstrated reduced APC anticoagulant 
cofactor activity, in the presence of normal phospholipid binding.183 Collectively, 
these investigators have suggested Gla, TSR, EGF1 and EGF2 domains may 
each contain recognition elements on protein S needed for APC cofactor function.  
 
1.5.2 Domains of protein S that are potentially important for TFPI cofactor 
activity 
Work presented in preliminary form at the ISTH congress in Geneva by Hackeng 
et al., who had carryied out an in silico molecular docking experiments of protein 
S and TFPI, suggested that the TSR of protein S might be involved in the 
interaction with TFPI. Recent reports suggest that free protein S, but not protein S 
bound to C4BP, form a reversible interaction with free full-length TFPI in 
plasma.241 In addition, free protein S seems to act more efficiently as a cofactor 
for TFPI than protein S in complex with C4BP.81 Collectively, these results would 
suggest that the N-terminal domains of protein S are more likely to be involved in 
an interaction with TFPI than the C-terminal domains, which can be bound to 
C4BP. 
 
1.6 Aims of my thesis 
The aims of my project were to determine the domains and residues of protein S 
involved in the interaction with both APC and TFPI. Following selection of the 
domains, over 30 point or composite variants in these domains were made. Wild 
type (WT) protein S and protein S variants were expressed in human embryonic 
kidney fibroblast (HEK) cells and purified as required. The functional cofactor 
activity of protein S variants towards APC and TFPI anticoagulant activities was 
evaluated and compared to that of WT protein S in various functional assays 
including calibrated automated thrombography (CAT), FVa inactivation assay and 
FXa inhibition assay. 
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2 METHODOLOGY 
A schematic overview of the sequence of methods used during this project and 
the sections in which they are described is shown in Figure 2.1. 
 
 
Figure 2.1 Overview of the Methodology of this thesis. 
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2.1 Generation of protein S mutant expression vectors 
2.1.1 Mammalian protein S expression vector and composite mutants 
generated 
A pcDNA6/protein S vector (Figure 2.2) containing the complimentary 
deoxyribonucleic acid (cDNA) for the WT protein S sequence had previously been 
generated in our lab by Dr S.M. Rezende (Universidade Federal de Minas Gerais, 
Brazil).247 The V5 epitope and the polyhistidine tag were excised from the 
pcDNA6/V5-HisB vector (Invitrogen) by digestion with the NheI restriction enzyme 
(New England Biolabs). The cDNA of protein S, amplified by polymerase chain 
reaction (PCR) with primers containing the restriction site for NheI, was digested 
with the restriction enzyme and ligated into the vector. The resulting 
pcDNA6/protein S vector contains the SV40 origin of replication, cytomegalovirus 
(CMV) and T7 promoters, and resistance to ampicillin and blasticidine. The 
plasmid was used as a template to produce single point mutations by PCR 
mediated site-directed mutagenesis. Newly produced cDNA with point mutations 
were subsequently used as a template to introduce additional mutations resulting 
in single and composite mutants.  
 
Figure 2.2 Protein S expression vector.  
The cDNA for protein S has been inserted into the vector through ligation of the NheI digested 
ends of the insert to the vector. The vector contains resistance to ampicillin for selection of 
transformed bacteria and the CMV promoter for expression in mammalian cells. The restriction 
sites BsmBI and BspEI are used for subcloning of the mutants generated (see section 2.1.6). bp; 
base pair. 
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2.1.2 Generation of protein S mutants by site-directed mutagenesis 
Complementary primer pairs with the desired base pair substitutions (for amino 
acid residues mutated see Table 3.1, for primer sequences see Appendix) were 
manufactured by Thermo Scientific. PCR reactions were performed using 
Stratagene’s QuickChange XL Site-Directed Mutagenesis Kit. In detail, final 
concentrations of 100 ng of protein S vector, 65 ng of forward primer, 65 ng of 
reverse primer, 0.5 μl deoxynucleoside triphosphate (dNTP) mix, 1X reaction 
buffer, 1.5 μl of QuikSolution and 1.25 U of high fidelity Pfu ultra deoxyribonucleic 
acid (DNA) polymerase were used in a final volume of 25 μl. 
Alternatively, mutagenesis was performed with the KOD hot start DNA 
polymerase (Novagen). In detail, final concentrations of 100 ng of dsDNA 
template, 0.3 μM of forward primer, 0.3 μM of reverse primer, 0.2 mM dNTPs, 0.5 
μl DMSO, 1.5 mM MgSO4, 1X reaction buffer and 0.5 U KOD hot start DNA 
polymerase were used in a final volume of 25 μl.  
Cycling parameters for Pfu ultra and KOD hot start DNA polymerase are outlined 
in Table 2.1 and Table 2.2 respectively. 
After PCR, parental dsDNA template was digested with 5 U of DpnI at 37°C for 1 
hour before transforming bacteria. 
 
Stage Phase Cycles Temperature (°C) Time 
Denaturation  1 95 2 minutes 
Amplification 
Denaturation 
18 
95 50 seconds 
Annealing 60 50 seconds 
Extension 68 
1 min/kb 
plasmid 
Final extension  1 68 7 minutes 
 
Table 2.1 PCR cycle parameters for Pfu ultra DNA polymerase.  
PCR cycle parameters used to generate protein S mutants by site-directed mutagenesis. Min; 
minute. 
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Stage Phase Cycles Temperature (°C) Time 
Denaturation  1 95 5 minutes 
Amplification 
Denaturation 
18 
94 15 seconds 
Annealing 60 30 seconds 
Extension 72 
20 sec/kb 
plasmid 
Final extension  1 72 5 minutes 
 
Table 2.2 PCR cycle parameters for KOD hot start DNA polymerase.  
PCR cycle parameters used to generate protein S mutants by site-directed mutagenesis. Sec; 
seconds. 
 
 
2.1.3 Transformation of competent cells 
Competent cells (XL-10 gold ultracompetent cells from Stratagene, One shot 
TOP10 competent cells from Invitrogen or NEB Turbo competent cells from New 
England Biolabs) were transformed with the mutated protein S vector according 
to the manufacturer’s instructions. In detail, 45 μl of cells were thawed on ice. XL-
10 gold ultracompetent cells were incubated with 2 μl of β-mercaptoethanol for 10 
minutes, gently swirling the tube every 2 minutes. Competent cells were 
incubated with 2 μl of DpnI treated DNA; the tube was swirled and incubated on 
ice for 30 minutes. Cells were heat-pulsed in a water-bath at 42°C for 30 seconds 
and placed on ice for an additional 2 minutes. Transformed bacteria were grown 
in 0.25-0.5 ml of preheated S.O.C. medium at 37°C for 1 hour with shaking. 
Bacteria were subsequently plated out on an LB-agar (Invitrogen) plate containing 
100 μg/ml ampicillin and incubated at 37°C over night. Ampicillin-resistant clones 
were picked and grown in 5 ml LB-broth (Invitrogen) with 100 μg/ml ampicillin 
over night at 37°C with shaking. 
 
2.1.4 Generation of glycerol stocks 
Of the 5 ml of bacteria in section 2.1.3, 700 μl were mixed with 300 μl of 
autoclaved 50% glycerol solution. The resulting mix was vortexed and stored at -
80°C. This could be partially thawed when additional transformed bacteria were 
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required. The remaining 4.3 ml of bacteria were used to extract plasmid DNA by 
miniprep. 
 
2.1.5 Plasmid miniprep and sequencing 
Plasmid DNA was extracted with the Qiagen Miniprep kit according to 
instructions. Mutations were confirmed by sequencing the protein S vector with 
the T7 primer 5’-TAA TAC GAC TCA CTA TAG GG-3’ (MRC Genomics Core 
Facility). 
 
2.1.6 Subcloning of the protein S mutants into the pcDNA6/Protein S 
vector 
Prior to mammalian expression, the mutated cDNA was sequenced with 
additional primers spanning the whole cDNA of protein S to make sure no 
unwanted mutations had been introduced (see Appendix for sequencing primers). 
Alternatively, the cDNA region containing the mutation was subcloned into the 
original WT vector. To perform such subcloning, the vector with the protein S 
mutation (40 μl, ~16 μg) and the WT vector (1 μg) were digested with BsmBI 
(New England Biolabs) at 55°C for 2 hours and subsequently with BspEI (New 
England Biolabs) at 37°C for 2 hours 30 minutes in buffer 3 (New England 
Biolabs) in a total volume of respectively 50 and 25 μl (Table 2.3).  
 
 Digestion of: 
 Protein S mutant vector WT vector 
DNA 40 μl (16 μg) 0.77 μl (1μg) 
BsmBI (10 U/μl) 1 μl 0.2 μl 
BspEI (10 U/μl) 1 μl 1 μl 
Buffer 3 5 μl 2.5 μl 
Water 3 μl 20.53 μl 
Total volume 50 μl 25 μl 
 
Table 2.3 Enzymatic digestion of WT and mutated pcDNA6/PS vector.  
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Digested DNA products were run on a 1% agarose gel containing SYBRSafe in 
tris borate ethylenediaminetetraacetic acid (TBE) buffer. Samples and marker (1 
kb or 100 bp) were electrophoresed for 20-40 minutes at 80 V. The DNA bands of 
interest were excised and purified using the QIAquick Gel extraction kit (QIAGEN) 
according to the manufacturer’s instructions.  
The linearised pcDNA6/Protein S vector was dephosphorylated with 0.01 U of 
Calf Intestinal Alkaline Phosphatase (CIAP) as described in Table 2.4, according 
to the manufacturer’s instructions (Invitrogen). The reaction was performed at 
37°C for at least 1 hour and the dephosphorylated vector was subsequently 
purified using QIAquick PCR purification Kit protocol (QIAGEN).  
 
Dephosphorylation 
DNA (~0.48 pmol) 25 μl  
10X dephosphorylation buffer 4 μl 
Water 10 μl 
CIAP (0.01 U/μl) 1 μl 
Total volume 40 μl 
 
Table 2.4 Dephosphorylation of the linearised WT vector. 
 
2.1.7 DNA ligation 
Approximately 60 fmol of the DNA fragment containing the mutation were ligated 
into 20 fmol of the dephosphorylated vector (molar ratio insert:vector, 3:1) with 
0.1 U of T4 DNA ligase in a total volume of 20 μl, at 23-26°C for 1 hour as 
described in Table 2.5. 
 
Ligation reaction 
Vector 3 μl (20 fmol) 
Insert 0.5 μl (60 fmol) 
5X ligase buffer 4 μl 
T4 ligase (0.1 U/μl) 1 μl 
Water 11.5 μl 
Total volume 20 μl 
 
Table 2.5 Ligation of the mutated protein S region into the WT protein S vector. 
 50 
 
2.1.8 Transformation of competent cells with subcloned mutants 
The ligation product was used to transform One shot TOP10 (Invitrogen) or NEB 
turbo chemically competent cells (New England Biolabs) according to the 
manufacturer’s instructions. Transformed bacteria were plated out on LB-
agar/ampicillin plates over night at 37°C. Ampicillin resistant-colonies were picked 
and grown in 5 ml Luria-Bertani medium (LB) broth over night. The plasmid was 
extracted with the Qiagen Miniprep kit and sequenced (for primers see Appendix) 
as outlined previously (MRC Genomics Core Facility). Clones were sequenced 
across both restriction sites to confirm correct ligation.  
 
2.1.9 DNA maxiprep/megaprep and quantification 
Bacteria containing the successfully mutated protein S vector were cultured on a 
large scale (200-500 ml) to obtain sufficient amounts of plasmid (extracted with a 
Qiagen Maxiprep or Megaprep kit) for transfection of mammalian cells.  
The DNA was quantified with the Quant-IT™ nucleic acid Assay Kit (Invitrogen) 
according to manufacturer’s instructions or with a NanoDrop spectrophotometer 
by measuring the absorbance at 260 nm. 
 
2.2 Expression of protein S 
2.2.1 Mammalian cell culture 
HEK293T and HEK293 cells (ATCC) were used respectively for transient and 
stable transfections. Cells were cultured at 37°C, 5% CO2, in complete media; 
minimum essential media (MEM, Invitrogen) supplemented with 10% foetal calf 
serum (FCS) (Biosera), 2 mM L-glutamine (Invitrogen), 50000 U penicillin/ 50000 
μg streptomycin and 1X non-essential amino acids (Invitrogen), and were 
generally grown in T175 flasks or T175 triple flasks. When confluent, cells were 
washed with phosphate buffered saline (PBS; 10 mM phosphate buffer, 2.7 mM 
potassium chloride, 137 mM sodium chloride) (5 ml/T175 flask) split 1:3 using 1 
ml trypsin/T175 flask to detach cells and grown to confluence again in 3 days. 
Vitamin K (10 μg/ml) was added to complete MEM media, at least 24 hours prior 
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expression of protein S. This allows cells to take up vitamin K which is essential 
for the γ-carboxylation of protein S. Protein S was expressed in OptiMEM I 
(Invitrogen) reduced serum-medium supplemented with 10 μg/ml vitamin K and 
100 mg/L CaCl2 for 3 days.  
 
2.2.2 Transient transfection of HEK293T cells 
Protein S was transiently expressed in HEK293T cells. Cells were cultured in 
T175 triple flasks and grown in complete media. When cells reached ~60-70% 
confluency, the media was changed and supplemented with 10 μg/ml vitamin K. 
Cells were grown in the vitamin K containing media for at least 24 hours before 
being transfected. On the day of transfection, for one T175-triple flask, 257 µl of 
linear Polyethylenimine (PEI) (Polysciences,Inc) (1 mg/ml) were diluted into 3.75 
ml of 0.15 M autoclaved NaCl. The resulting PEI solution was added drop wise to 
3.75 ml of 0.15 M autoclaved NaCl containing 114 μg DNA and the mix was 
incubated at room temperature for 15-20 minutes. The DNA-PEI solution was 
added to 75 ml OptiMEM supplemented with 10 μg/ml vitamin K and 100 mg/L 
CaCl2. Each T175-triple flask was washed with PBS and cells were grown in the 
82.5 ml of OptiMEM containing the transfection solution. Media containing the 
secreted protein S was harvested after 3 days. 
 
2.2.3 Stable transfection of HEK293 cells 
A heterogeneous stable HEK293 cell line expressing WT protein S had already 
been generated in our lab by Dr S.M. Rezende (Universidade Federal de Minas 
Gerais, Brazil). Heterogeneous stable cell lines expressing protein S variants of 
interest were produced during this project. HEK293 cells were seeded in a 6 well 
plate in complete media and were allowed to reach 85-95% confluence before 
being transfected. Ten μl of Lipofectamine 2000 (Invitrogen) was mixed with 250 
μl OptiMEM (GIBCO) and incubated for 5 minutes at room temperature. Following 
incubation, 4 μg of DNA pre-diluted into 250 μl OptiMEM were added drop-wise to 
the Lipofectamine 2000 solution. The resulting DNA-Lipofectamine 2000 mix was 
incubated for 5 minutes at room temperature before being added to the cells 
previously washed with PBS. Cells were incubated at 37°C, 5% CO2 for 4-6 
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hours, after which the media was replaced by complete MEM media. After 24-48 
hours cells were split 1:10 and seeded in complete MEM media containing 5 
μg/ml Blasticidine-HCl (Invitrogen). Stably transfected HEK293 cells were 
selected by culturing the cells in selective media at a confluence below 60% for 4 
weeks. A stable cell line expressing full-length TFPI was also set up in HEK293 
cells. These stably transfected cells were selected for with 500 μg/ml G418 as the 
expression vector for TFPI contained the neomycin resistance cassette. TFPI in 
conditioned media was concentrated, quantified (by my colleague Verity Hockey) 
and used in the plasma assay (see section 2.5.3). 
 
2.2.4 Cryopreservation of mammalian cells 
HEK293T, HEK293 and protein S stable cell lines were cryopreserved in liquid 
nitrogen. Once cells reached confluence in a T175 flask they were washed with 
PBS and trypsinised with 1 ml of trypsin. Trypsin was neutralised by adding 10-20 
ml complete media and cells were centrifuged at 1200 rpm for 5-10 minutes. The 
supernatant was discarded and cells were resuspended in 2 ml of cold complete 
media. Two ml of cold complete media with 10% dimethyl sulfoxide (DMSO) was 
added dropwise to the cells and the solution was mixed. Cells were aliquoted in 1 
ml fractions in cryovials and stored in a cryo freezing container (Nalgene) at -
80°C for a minimum of 3 hours and maximum over night prior to being transferred 
into liquid nitrogen. 
To recover cryopreserved cells, vials were transferred from the liquid nitrogen to 
ice and then thawed at 37°C. Cells were seeded into a T75 flask with 20-30 ml of 
complete media to dilute out the amount of DMSO.  
 
2.2.5 Expression and harvesting of WT and variant protein S 
Both stable and transiently transfected cells were cultured in triple T175 flasks 
containing 75 ml of OptiMEM (GIBCO) supplemented with 10 μg/ml vitamin K and 
100 mg/L CaCl2. After 3-4 days the media was harvested, centrifuged and filtered 
to remove cell debris, and concentrated using a labscale tangential flow filtration 
(TFF) system (Millipore) with 10 kDa cut off membrane. The same procedure was 
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repeated for non-transfected HEK293T cells to obtain media, not containing 
protein S, to be used as a negative control in functional assays. 
Stable cell lines were, in addition to being cultured in triple flasks, also cultured in 
CELLine adhere 1000 two-compartment bioreactors (IBS integra biosciences) 
according to the manufacturer’s instructions. The cell compartment contained 15 
ml OptiMEM, 10 μg/ml vitamin K, 100 mg/L CaCl2 and the media compartment 
contained 1 L complete MEM media supplemented with vitamin K. Media was 
changed weekly and OptiMEM from the cell compartment, containing protein S, 
was harvested. 
Media samples to be used in functional assays were dialysed with at least 3 
changes of buffer in 3-5 L of 20 mM Tris-HCl pH 7.5, 140 mM NaCl, for 1 hour 
each time at room temperature. Later during my project media samples (protein S 
variants 74A, KTK, NEDM and NNEDM) were dialysed in 20 mM Tris-HCl pH 7.5, 
140 mM NaCl, 3 mM CaCl2. Samples were concentrated by Amicon Ultra 
centrifugal filter devices with a cut off of 50 kDa (Millipore), aliquoted and stored 
at -80°C. 
 
2.3 Protein S purification 
2.3.1 Protein S purification by FPLC on an anion exchange QFF column 
and by immunoaffinity chromatography 
Protein S was purified by a two step method. Fast protein liquid chromatography 
(FPLC) was performed using an ÄKTApurifier UPC-10 (GE healthcare) and the 
Unicorn 5.1 (Build 407) software, strategy version 1.00 and consisted of a 
passage over an anion exchange Q Sepharose Fast Flow (QFF) column (section 
2.3.1.1) followed by a second passage over an immunoimmunoaffinity column 
(section 2.3.1.3). This purification procedure had previously been optimised by 
Sofia Carlsson (in Professor Björn Dahlbäck’s lab, Lund University, Malmö, 
Sweden). 
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2.3.1.1 Partial purification of protein S by FPLC on an anion exchange QFF 
column 
Concentrated and dialysed conditioned media containing protein S supplemented 
with 4 mM ethylenediaminetetraacetic acid (EDTA) was applied to an anionic 5 
mL of HiTrap QFF column (GE Healthcare) equilibrated with 20 mM Tris-HCl (pH 
7.4), 100 mM NaCl, 4 mM EDTA, and 5 mM benzamidine-HCl (Sigma-Aldrich). 
The column was washed with 20 mM Tris-HCl (pH 7.4), 100 mM NaCl, and 5 mM 
benzamidine-HCl to first elute weakly bound proteins. Protein S was eluted from 
the column with 20 mM Tris-HCl (pH 7.4), 0.5 M NaCl, and 5 mM benzamidine-
HCl. The Sepharose HiTrap™ QFF anion exchange column was stripped of more 
tightly bound proteins with 20 mM Tris-HCl, pH 7.4, 1 M NaCl and 5 mM 
Benzamidine-HCl. 
To prevent cross-contamination between protein S preparations, the column was 
cleaned with 2 M NaCl in a reversed flow direction for 15 minutes and 1 M NaOH 
for 1-2 hours. The column was then stored in 20% ethanol. 
 
2.3.1.2 Preparation of the immunoaffinity column 
An immunoaffinity column for protein S was made with 2.5 mg of monoclonal 
mouse anti-human protein S MK21 antibody.243 All monoclonal domain specific 
antibodies described in this thesis were kindly provided by Professor Björn 
Dahlbäck and Sofia Carlsson, Lund University, Malmö, Sweden and have been 
described in the literature.243 The MK21 antibody is a calcium dependent antibody 
specific for the Gla domain of protein S. The antibody was thoroughly dialysed in 
the coupling buffer (0.2 M NaHCO3, 0.5 M NaCl, pH 8.3). The antibody was 
coupled to a 1 ml HiTrap NHS-activated HP column (GE healthcare) according to 
manufacturer’s instructions and any excess active groups were deactivated with 
ethanolamine and acetate. The immunoaffinity column was stored in 20 mM Tris-
HCl pH 7.5, 150 mM NaCl, 0.1% sodium azide. 
 
2.3.1.3 Purification of protein S by FPLC on an immunoaffinity column 
To lower the ionic strength (from 500 mM NaCl to ~166 mM NaCl) and add CaCl2, 
two volumes of 7.5 mM CaCl2 were added to the elution fraction from the anion 
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exchange QFF column, before injecting the sample on the immunoaffinity column. 
The fraction eluted from the QFF column containing protein S was applied to the 
equilibrated column (equilibration buffer: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 
mM CaCl2). After washing with 1 M NaCl, the ionic strength was lowered by 
passing 3 column volumes of equilibration buffer over the column prior to elution 
of protein S with 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 10 mM EDTA. An 
excess of CaCl2 was present in the tubes collecting the eluted protein S to 
neutralise the EDTA. The column was regenerated by stripping with 0.1 M 
glycine-HCl pH 2.7. 
Samples to be used in functional assays were dialysed and concentrated as 
described in section 2.2.5. 
 
2.3.2 Protein S purification by barium citrate precipitation and by FPLC on 
an anion exchange DEAE column 
2.3.2.1 Barium citrate precipitation of protein S 
Protein S was partially purified by barium citrate precipitation as previously 
described.248 The conditioned media containing protein S that had previously 
been concentrated to 50 ml in the TFF (see section 2.2.5) was divided into two 50 
ml tubes, each containing 25 ml media, and incubated on ice. 1.13 ml of a 0.5 M 
stock of trisodium citrate was added to each tube containing concentrated 
conditioned media and incubated on ice for 10 minutes. 1.13 ml of a 1 M stock 
BaCl2 was added to each tube and the media was vortexed and incubated on ice 
for 1 hour. The sample was centrifuged at 5000 g for 30 minutes and the pellet 
that formed was resuspended in 25 ml of 100 mM BaCl2, 100 mM NaCl and 
incubated on ice for 1 hour. The sample was spun as before and the pellet was 
resuspended in 15-50 ml of 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 150 mM 
trisodium citrate.  
Barium citrate precipitated protein S was dialysed in 20 mM Tris-HCl pH 7.5, 140 
mM NaCl for at least 1 hour at room temperature before dialysing it at 4°C. 
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2.3.2.2 Purification of protein S by FPLC on an anion exchange DEAE column 
The purification of protein S on a diethylaminoethyl cellulose anion exchange 
(DEAE) column was optimised by my colleague Dr Josefin Ahnström. Briefly, a 5 
ml DEAE column (GE healthcare) was equilibrated with 20 mM Tris-HCl pH 7.5, 
150 mM NaCl. Barium citrate precipitated protein S was loaded onto the column 
at 1-1.5 ml/minute and protein S was eluted with a CaCl2 gradient from 0-20 mM. 
The anion exchange DEAE column was stripped of more tightly bound proteins 
with 20 mM Tris-HCl pH 7.5, 50 mM CaCl2, 1 M NaCl.  
The column was cleaned and stored as described for the QFF column in section 
2.3.1.1. 
 
2.4 Analysis and characterisation of protein S 
2.4.1 PNGase digestion 
To determine whether the double band observed when running protein S on 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
due to different glycosylation or cleavage, protein S was diluted to 8 ng/ul and a 
total of 10 µl were digested with 250 U of PNGase at 37°C over night. 
 
2.4.2 SDS-PAGE and Native PAGE 
SDS-PAGE under reducing (30% β-mercaptoethanol) and non-reducing 
conditions was performed to assess the purity of the different protein S 
preparations. Samples were heated at 70-90°C for 5-10 minutes. Electrophoresis 
was performed on 10% polyacrylamide cast gels, 4-12% or 10% precasted 
NuPAGE® Novex® Bis-Tris gels (Invitrogen) at 200 V for 30-40 minutes. 
Samples in a native state were run on NativePAGE™ Novex® 3-12% precast Bis-
Tris gels (Invitrogen), at 150 V for 90 minutes. Anode and cathode buffer were 
supplied by Invitrogen. 
Gels were washed 3 x 5 minutes with water, stained for 1 hour with blue safe 
protein stain (Thermo scientific) and then destained in ddH2O, stained by silver 
staining (see section 2.4.3) or used for Western blot analysis (see section 2.4.4). 
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2.4.3 Silver staining 
Electrophoresis was performed on SDS-PAGE gels as described in section 2.4.2. 
During all steps in the silver staining procedure (Table 2.6) volumes of 50 ml/gel 
were used and incubations were performed at RT with shaking. 
Proteins were fixed by incubating the gel for 30 minutes in 50% methanol, 10% 
glacial acetic acid (buffer A). An additional incubation in 5% methanol (buffer B) 
was performed for 15 minutes. The gel was washed with water 3 x 5 minutes and 
incubated with sodium thiosulphate (buffer C) for 2 minutes. After a second wash, 
3 x 30 seconds, the gel was stained with Silver Nitrate (buffer D). The gel was 
washed 3 x 1 minute and developed with buffer E for up to 10 minutes. The 
colour development was stopped with EDTA (buffer F). 
 
Buffer Composition 
A 50% CH3OH, 10% CH3COOH 
B 5% CH3OH 
C (made up fresh) 1.26 mM Na2S2O3*5H2O 
D 169.9 mM AgNO3 
E (per 50 ml, made up fresh) 283 mM Na2CO3, 25 μl of 37% HCOH, 1 ml solution C 
F 37.6 mM Na2EDTA 
 
Table 2.6 Composition of silver staining buffers. 
 
 
2.4.4 Western Blot 
Western blots were performed by transferring proteins separated in unstained 
polyacrylamide gels (section 2.4.2) to a Hybond-ECL nitrocellulose membrane 
(Amersham Biosciences) or a PVDF-plus membrane (Osmonics INC) for SDS-
PAGE and Native PAGE, respectively. Proteins were transferred to the hybond-
ECL nitrocellulose membrane in a transfer buffer composed of 25 mM tris base, 
190 mM glycine, 20% methanol. The PVDF-plus membrane was preincubated in 
methanol for 30 seconds, washed in water and immerged in the supplied transfer 
buffer (Invitrogen).  
The transfer, for both types of membranes, was performed at 30 V for 60-75 
minutes. Membranes were blocked with 4% milk for 40-60 minutes. Protein S was 
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detected with 20 ml of 0.588 μg/ml polyclonal rabbit anti-protein S antibody 
(DAKO) for 40-60 minutes. Following a 3 x 5 minutes wash with PBS, 0.1% 
Tween, membranes were incubated with 20 ml of 0.175 μg/ml peroxidise 
conjugated polyclonal goat anti-rabbit antibody (DAKO or Sigma Aldrich) for 40-
60 minutes. The membrane was washed 4 x 5 minutes and developed with the 
chemiluminescent horseradish peroxidise (HRP) substrate Immobilon (Millipore) 
and Amersham Hyperfilm ECL (GE healthcare). Alternatively, to detect only γ-
carboxylated protein S, 5 μg/ml (20 ml) of a monoclonal mouse antibody directed 
against γ-carboxyglutamic residues (American Diagnostica INC) was used as a 
primary antibody and 20 ml of 2.352 μg/ml polyclonal goat anti-mouse IgG HRP 
labelled antibody as a secondary antibody (DAKO). 
 
2.4.5 Quantification of total protein 
To quantify the total protein concentration in protein S preparations the 
absorbance at 280 nm was read in a NanoDrop spectrophotometer. Beer-
Lambert law for concentration c=A/ ε L with an extinction coefficient ε 1% 9.5 was 
used.161 The total protein concentration was then compared with the Enzyme-
linked immunosorbent assay (ELISA) results to determine the % purity of protein 
S. 
 
2.4.6 In-house ELISA with an in-house detection antibody  
Protein S concentrations in conditioned media were determined using an in-
house ELISA. A polyclonal rabbit anti-protein S antibody (1 µg/ml, DAKO) was 
immobilised onto 96-well Nunc Maxisorp microplates in 50 mM sodium carbonate 
buffer pH 9.6 at 4°C over night. All incubations were carried out in a plate shaker 
at 37°C for 1 hour unless stated otherwise. Washing steps were performed in 
triplicate with 250 μl PBS 0.1% Tween between each step. Wells were blocked 
with PBS containing 3% bovine serum albumin (BSA, Sigma or Santa Cruz) for 2 
hours. A standard curve, 0-2 nM protein S, was made by either diluting normal 
plasma or plasma purified protein S (Enzyme Research Laboratories). Normal 
plasma is known to contain 25 µg/ml protein S. The reported MW of protein S 
ranges from 69-77 kDa.161,162 In this thesis a MW of 69000 Da was assumed and 
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the concentration of protein S in normal plasma was calculated to be 362 nM. 
Protein S samples, 100 μl, were incubated in the wells for 1 hour. Bound protein 
S was detected by 4 nM of a mouse monoclonal antibody directed against the 
EGF3-4 domain of protein S (MK55) followed by 8 nM of an HRP-conjugated goat 
anti-mouse antibody (DAKO). PBS 0.5% BSA was used as buffer in which to 
dilute protein S and the antibodies. The plate was developed with 100 μl/well 
chromogenic substrate o-phenylenediamine dihydrochloride (OPD, Sigma), the 
enzymatic reaction was stopped with 50 μl/well 2 M H2SO4 and the absorbance 
was read at 492 nm. Data was analysed with GraphPad Prism 4.03 and data 
points were fitted to a sigmoidal dose response curve. Intra ELISA variability was 
determined by calculating the coefficient of variation (CV) between the same 
sample diluted to 2-3 different final concentrations in the same ELISA. Inter 
ELISA variability was determined by calculating the CV obtained for the same 
sample in (3-10) different ELISA. 
 
2.4.7 In-house ELISA with commercially available antibodies 
An in-house ELISA with commercially available antibodies was also developed to 
avoid dependence upon the availability of the MK55 antibody generously supplied 
by Professor Björn Dahlbäck. The assay was set up as described for the in-house 
ELISA in section 2.4.6 with the exception of 20 mM Tris-HCl pH 7.5, 140 nM 
NaCl, 3 mM CaCl2 being used as a buffer and that protein S was detected with 4 
nM of the mouse monoclonal antibody AHPS-5092 (Haematologic Technologies 
Inc). 
 
2.4.8 Preparation of phospholipid vescicles 
Activated platelets or cells exposing negatively charged phospholipids such as 
phosphatidylserine are required in vivo for coagulation to occur. In in vitro assays 
these are often replaced by phospholipid vescicles. Phospholipid vescicles were 
prepared during this project to be used as a procoagulant surface in functional 
assays and to assess protein S binding to phospholipids. 
All phospholipids were from Avanti Polar Lipids Inc. Phospholipid mixtures in 
chloroform were prepared and the chloroform evaporated under a nitrogen 
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stream. The phospholipids were resuspended in 20 mM Tris-HCl pH 7.5, 140 mM 
NaCl for the plasma and FXa inhibition assay or in 25 mM HEPES (N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid) pH 7.7, 150 mM NaCl (HN) for 
the FVa inactivation assays. Unilamellar phospholipids vesicles were obtained 
either by sonicating the phospholipids in an ice container at amplitude 22% for 7 
minutes or by extruding them as previously described.141 Briefly, extrusion was 
performed by passing the phospholipid mixture through a 100 nm polycarbonate 
membrane 19 times. Synthetic phospholipids 1,2-Dioleoyl-sn-glycero-3-
phosphocholine (DOPC), 1,2-Dioleoyl-sn-glycero-3-phosphoserine (DOPS), and 
1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were used in the plasma 
assay, the plate binding assay and the FXa inhibition assay. Natural 
phospholipids L-α-phosphatidylserine (PS, brain extract), L-α-
phosphatidylethanolamine (PE, egg extract) and L-α-phosphatidylcholine (PC, 
egg extract) were used in the FVa inactivation and prothrombinase assays. 
 
2.4.9 Binding of protein S to phospholipids 
As binding of protein S is a prerequisite for its function, binding of protein S and 
protein S variants to phospholipids was assessed.  
Phospholipids vesicles (DOPS/DOPC/DOPE, 20:60:20), 25 μg/ml, were coated 
onto 96-well Nunc Maxisorp microplates in 50 mM sodium carbonate buffer pH 
9.6 at 4°C over night. Washing steps were performed in triplicate with 250 μl/well 
20 mM Tris-HCl pH 7.5, 140 mM NaCl, 5 mM CaCl2, 0.3% BSA between each 
step and incubations were carried out in a plate shaker at 37°C. The same buffer 
was used to dilute protein S and the antibody in. Wells were blocked with 20 mM 
Tris-HCl pH 7.5, 140 mM NaCl, 5 mM CaCl2, 3% BSA for 2 hours. Protein S or 
protein S variants, 0-120 nM, partially purified by barium citrate precipitation, were 
incubated in the wells in duplicate for 2 hours and were detected with an HRP-
conjugated anti-protein S antibody (Affinity Biologicals) for 45 minutes. Controls 
were performed by assessing binding of protein S to phospholipids in the 
presence of 10 mM EDTA and by assessing aspecific binding to the plate in the 
absence of phospholipids and presence of CaCl2. The plate was developed, 
stopped and read as previously described for the ELISA. Data was analysed with 
GraphPad Prism 4.03 and curves were fitted to a one site binding hyperbola. The 
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Kd(app) for protein S binding to the phospholipids were derived and that of protein 
S variants was compared with that of WT protein S. 
 
2.4.10 Binding of protein S to domain specific monoclonal antibodies 
To assess the correct folding of protein S variants, their binding affinity to domain 
specific monoclonal antibodies was compared to that of WT protein S.  
Domain specific monoclonal antibodies MK21 (Gla domain), MK54 (EGF1 
domain) and MK61 (SHBG domain), 1 μg/ml, were coated on 96-well Nunc 
Maxisorp microplates as described for the ELISA. Washing steps were performed 
in triplicate with 250 μl 20 mM Tris-HCl pH 7.5, 140 mM NaCl, 3 mM CaCl2, 0.1% 
Tween between each step. Incubations were carried out in a plate shaker at 37°C 
for 1 hour unless stated otherwise. Wells were blocked with 200 µl 20 mM Tris-
HCl pH 7.5, 140 mM NaCl, 3 mM CaCl2, 3% BSA for 2 hours. Protein S, 0-160 
nM was incubated in the plate for 1 hour and was detected by a rabbit polyclonal 
antibody against protein S followed by a goat anti-rabbit HRP-conjugated 
antibody. Protein S and the antibody were diluted in a Tris-HCl pH 7.5, 140 mM 
NaCl, 3 mM CaCl2, 0.5% BSA buffer. The plate was developed, stopped and read 
as previously described for the ELISA. Data was analysed with GraphPad Prism 
4.03 and data was fitted to a one site binding hyperbola. The Kd(app) for protein S 
binding to the monoclonal antibodies were derived and that of protein S variants 
was compared with that of WT protein S. 
 
2.5 CAT assay 
2.5.1 Overview of CAT 
CAT is an assay that allows measurement of thrombin generation. It was used 
during this project to evaluate the different cofactor activity of protein S and 
protein S variants toward APC and TFPI. It is a plasma-based assay in which a 
coagulant response is initiated by the addition of TF, CaCl2 and phospholipids 
and the amount of thrombin generated is measured through the cleavage of its 
fluorogenic substrate over time and quantified by reference to a standard 
calibrator. Phospholipids are added into the reaction to provide a surface on 
which coagulation can occur once triggered by TF. As the plasma is citrated and 
 62 
most coagulation factors are calcium dependent the reaction does not start until 
calcium is added into the reaction. Calcium is added together with Z-Gly-Gly-Arg-
AMC (Bachem), a fluorogenic substrate of thrombin. Thrombin generation is 
described and quantified by the lag time (which approximates the clotting time), 
peak height (maximal velocity of thrombin generation) and the endogenous 
thrombin potential (ETP) which is the total amount of thrombin generated over 
time and corresponds to the area under the curve. 
 
2.5.2 Evaluation of the protein S-APC cofactor activity 
Protein S deficient plasma (Affinity Biologicals), 80 µL, was incubated with 65 µg 
of corn trypsin inhibitor (CTI, Haematologic Technologies Inc) per ml of plasma to 
inhibit contact activation, 50 µM phospholipid vesicles (DOPS/DOPC/DOPE, 
20:60:20), 1 pM TF (Dade Innovin; Dade Behring), 4 to 16 nM APC (Enzyme 
Research Laboratories) with 0-120 nM protein S, in a final volume of 100 µL (all 
concentrations are final). A polyclonal anti-TFPI antibody (Haematologic 
Technologies Inc), 100 nM, was used to inhibit any protein S cofactor activity 
toward TFPI. Polyclonal antibodies against protein S (1500 nM, DAKO) and 
protein C (130 nM, Sigma-Aldrich or Haematologic Technologies Inc) were used 
as further controls. All conditions were performed in duplicate and assays were 
performed at least twice. Thrombin generation was assessed using a Fluoroscan 
Ascent FL Plate Reader (Thermo Lab System) in combination with the 
Thrombinoscope software (SYNAPSE BV).  
Thrombin generation was initiated by automatic dispensation of 20 µL of 2.5 mM 
Z-GlyArg-AMC-HCl (Bachem), 2.5% Me2SO, 20 mM Tris-HCl (pH 7.5), 60 mg/mL 
BSA, 100 mM CaCl2 into each well. The reaction was performed at 37°C and 
measurements were performed with an excitation and emission wavelength of 
390 nm and 460 nm, respectively. To compare the cofactor activity of protein S 
and protein S variants towards APC, the changes in peak height and ETP were 
evaluated. 
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2.5.3 Evaluation of the protein S-TFPI cofactor activity 
To evaluate the ability of protein S to enhance the anticoagulant activity of TFPI, 
protein S deficient plasma (Affinity Biologicals, Hyphen Biomed or Enzyme 
Research Laboratories) was incubated with CTI, phospholipids, TF (as described 
in section 2.5.2), 0-10 nM TFPI (either purified, kind gift of the 
Chemoserotheraputic Institute Kaketsuken, or in concentrated conditioned media) 
and 0-120 nM protein S or protein S variants in a final volume of 100 µL (all 
concentrations are final). A polyclonal antibody against protein C (130 nM, Sigma-
Aldrich or Haematologic Technologies Inc) was included, as required, to inhibit 
protein S cofactor activity towards any protein C activated during the assay. To 
show the specificity of the system polyclonal antibodies against protein S (1500 
nM, DAKO) or polyclonal antibodies against TFPI (100 nM, Haematologic 
Technologies Inc) were used. All conditions were performed in duplicate and 
assays were performed at least twice. Thrombin generation was assessed as 
described in section 2.5.2. To compare the cofactor activity of protein S and 
protein S variants towards TFPI, the changes in peak and lag time were 
evaluated. 
 
2.6 FVa inactivation assay 
2.6.1 Overview of the FVa inactivation assay 
The FVa inactivation assay is an assay with pure components that was used 
during this project to assess the ability of protein S and protein S variants to 
enhance APC mediated FVa inactivation. FVa inactivation by APC is indirectly 
measured by performing a prothrombinase assay. The prothrombinase assay 
relies on the amount of FVa that has not been inactivated by APC and its ability to 
form a complex with FXa and activate prothrombin. The amount of thrombin 
generated is then measured by the rate at which it cleaves its chromogenic 
substrate S-2238 (Chromogenix). 
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2.6.2 FV activation 
To obtain a source of FVa to assess APC mediated FVa inactivation, FV was first 
activated. A previously prepared and reported125 double variant of FV, FV 
R506Q/R679Q, was activated with 0.5 U/ml human thrombin at 37°C for 10 
minutes. This variant can not be cleaved in Arg506 and Arg679 allowing 
evaluation of cleavage at Arg306 by APC which is the site mainly enhanced by 
protein S (see section 1.4.3.1.1). The reaction was stopped by the addition of 
hirudin (5 U/ml, final concentration). The activated FVa variant was used as a 
substrate for APC to determine the ability of protein S to enhance cleavage of 
Arg306 of FVa by APC.  
 
2.6.3 FVa inactivation 
The FVa inactivation was performed either by evaluating the cofactor activity of 
increasing amounts of protein S (0-100 nM) at 10 minutes or by evaluating the 
cofactor activity of a fixed concentration (50 nM) of protein S at different 
timepoints (0-20 minutes). 
The highly purified protein S preparations, 0-100 nM, were incubated with 0.5 nM 
APC, 25 μM phospholipids vesicles (PS/PC/PE, 10:70:20) and 0.8 nM FVa 
R506Q/R679Q in HN, 5 mM CaCl2, 5 mg/ml BSA (HNBSACa
2+, only high purity 
grade BSA from Sigma A7030 was used) in a total volume of 50 μl (all 
concentrations are final). The solution was incubated at 37°C for 10 minutes and 
the reaction was stopped by performing a 1:25-fold dilution in ice cold 
HNBSACa2+. The remaining FVa activity was measured in a prothrombinase 
assay. 
Time course experiments were performed to derive the rate constant of FVa 
cleavage. APC, 0.5 and 3 nM, and 50 nM protein S were used and aliquots were 
quenched at intervals between 0-20 minutes. The remaining FVa activity was 
measured in a prothrombinase assay. Controls containing FVa R506Q/R679Q in 
the absence of APC either in the presence or absence of protein S and protein S 
variants were performed. To calculate the pseudo-first order rate constant for  
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APC mediated cleavage at Arg306, the previously reported equation (Eq2)141 was 
used: 
 
Eq2. Vat=Va0*e
-k306*t+C*Va0*(1-e
-k306*t)  
 
Vat represents the cofactor activity determined at time t, Va0 is the cofactor 
activity determined at time point 0, C is the remaining procoagulant cofactor 
activity of FVa after cleavage at position 306, and k306 is the rate constant of 
cleavage at position 306. 
 
2.6.4 Prothrombinase assay 
The amount of FVa inactivated was indirectly measured by performing a 
prothrombinase assay. An aliquot, 25 μl, of the FVa inactivation reaction was 
incubated with phospholipid vesicles (PS/PC 10:90) and FXa in the presence of 
CaCl2. The reaction was initiated by the addition of prothrombin, in a final volume 
of 125 μl. The buffer contained HN and 0.5 mg/ml ovalbumin. Final 
concentrations were 50 µM PS/PC, 5 nM FXa and 0.5 µM prothrombin. The 
solution was incubated at 37°C for 2 minutes and the reaction was terminated by 
an 8-fold dilution in 50 mM Tris-HCl pH 7.9, 100 mM NaCl, 20 mM EDTA, 1% 
PEG 6000. The amount of thrombin generated was measured by cleavage of its 
chromogenic substrate S-2338 (Chromogenix) at 405 nm for 15 minutes at 30 
seconds intervals. The cofactor activity of protein S and protein S variants 
towards APC was compared. 
 
2.7 FXa inhibition assay 
2.7.1 Overview of the FXa inhibition assay 
The FXa inhibition assay was performed to assess the different cofactor activity of 
protein S and protein S variants towards TFPI mediated inhibition of FXa. In the 
FXa inhibition assay the ability of FXa to cleave its chromogenic substrate S-2765 
is measured over time. The ability of TFPI to inhibit FXa and of protein S to 
enhance the TFPI anticoagulant activity is measured as a change in the rate of 
 66 
substrate proteolysis. The cleavage of the chromogenic substrate S-2765 was 
measured for up to 1 hour at 1 minute intervals. 
 
2.7.2 FXa inhibition assay 
Purified human FXa (final concentration of 0.5 nM; Hyphen Biomed) was added 
to wells already containing the chromogenic substrate S-2765 (200 μM; 
Chromogenix), phospholipids (10 μM), CaCl2 (5 mM), in the presence or absence 
of varying concentrations of purified TFPI (0-10 nM, kind gift of the 
Chemoserotheraputic Institute Kaketsuken) and protein S or protein S variants (0-
160 nM). The reactions were set up in a buffer containing 20 mM Tris-HCl buffer 
pH 7.5, 140 mM NaCl, 5 mg/ml BSA (only high purity grade BSA from Sigma 
A7030 was used), with a final volume/well of 100 μl. The hydrolysis of S-2765 by 
FXa was followed over time by measuring the A405 at regular intervals for up to 1 
hour at room temperature. A control was obtained by incubating FXa and S-2765 
in the absence of TFPI, in the presence or absence of WT or variant protein S. A 
blank was obtained by including TFPI and S-2765 but not FXa. All conditions 
were performed in duplicate and assays were repeated at least twice. 
 
2.7.3 Kinetic data analysis of FXa inhibition by TFPI in the presence and 
absence of protein S 
To calculate the inhibition constant of TFPI for FXa in the presence and absence 
of protein S, 0-8 nM TFPI ± 100 nM protein S were used. The assay was either 
set up as described in section 2.7.2 by starting the assay with the addition of FXa 
or, alternatively, FXa was present in the wells and the reaction was started with 
the addition of TFPI and S-2765. 
Data was fitted with the previously described equation (Eq3):249 
 
Eq3. At = A0 + Vst + (V0 – Vs){1-exp(-kobst)}/kobs 
 
Where t represents time, At represents the absorbance at time point t, A0 the 
absorbance at time zero, V0 the initial velocity, Vs the final steady state velocity of 
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S-2765 conversion and kobs the apparent rate constant for the transition from V0 
to Vs. 
The maximum initial velocity Vmax (FXa conversion of S-2765 in the absence of 
TFPI) was divided by the initial velocities at each time point and the resulting 
Vmax/V0 value was plotted against the concentration of TFPI. Values were fitted 
with a linear regression and the x intercept was used to calculate the Ki value with 
the following formula (Eq4): 
 
Eq4. Ki = -xintercept/(1+[S]/Km) 
 
Where [S] represent the concentration of the chromogenic substrate and Km, the 
Michaelis-Menten constant, the concentration of substrate that results in half 
maximal cleavage by FXa. 
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3 RESULTS 
The results of this thesis are divided into 4 sections. The first (section 3.1) 
describes the mutagenesis, expression and purification of protein S. The protein 
S obtained either in concentrated conditioned media or purified was then 
quantified by ELISA and analysed for multimeric content and cleavage (section 
3.2). In the final two sections, 3.3 and 3.4, the cofactor activity of protein S and 
protein S variants towards APC and TFPI respectively are evaluated. 
 
3.1 Mutagenesis, expression and purification of protein S 
3.1.1 Selection and generation of protein S variants 
Based on the domains of protein S known from the literature to be important for 
APC and TFPI cofactor activity (outlined in section 1.5.1 and 1.5.2) protein S 
variants with substitutions in the Gla, TSR, EGF1 and EGF2 were produced. 
Composite variants in these N-terminal domains produced during this thesis 
were; protein S Face1, Face2, Gla1, TSR, NEDM, NNEDM and KTK. Twelve 
additional alanine point variants in the EGF1 domain and 12 alanine point 
variants in the EGF2 domain of protein S were made available through 
collaboration with Dr S.M. Rezende (Universidade Federal de Minas Gerais, 
Brazil). Additional point variants expressed during this project are protein S N74A, 
D78A, Q79A and D95N resulting in a total of 35 variants covering 49 amino acid 
residues of protein S.  
Table 3.1 lists the variants produced during this project and indicates in which 
domain the substitutions have been introduced. Single point variants were named 
according to the residue that was mutated. The name given to the composite 
variant is shown in Table 3.1.  
Table 3.2 shows the N-terminal amino acid residues of protein S highlighting 
those that have been mutated during this project. Variants were tested both for 
their APC cofactor activity and their TFPI cofactor activity.  
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Domain Name of variant Residues mutated 
Gla Face1 N33S/P35T/E36A/Y39V 
Gla Face2 
L21T/ 
N23S/K24Y/R28F/D34S/Y41W/L45T 
Gla/EGF1 Gla1 D38N/V46G/K97Q 
TSR/EGF1 TSR R49Q/R60Q/D68N/R70Q/D78N 
TSR  N74A 
EGF1 NEDM N86A/E87Q/D88A/M91A 
EGF1 NNEDM N74A/N86A/E87Q/D88A/M91A 
EGF1 KTK K94A/T103A/K105A 
EGF1  
(from Dr S.M. Rezende) 
 
K94,D95,K97,S99,T101,T103, 
K105,P106,W108,Q109,E111,K112 
EGF1  D78A,Q79A,D95N 
EGF2  
(from Dr S.M. Rezende) 
 
D135,N136,T137,Y141,H142,S144, 
K146,S153,N154,K155,K156,D157 
 
Table 3.1 Protein S variants produced during this thesis. 
Single or point variants of protein S were produced by site-directed mutagenesis targeting 
residues located in the Gla domain, TSR domain, EGF1 or EGF2 domain. 
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Table 3.2 N-terminal amino acid sequence of protein S, prothrombin and protein S variants.  
Amino acid residues of the Gla domain of protein S that are not conserved in prothrombin were swapped for those of prothrombin in the composite variants 
Face1 and Face2. No mutations in the first 20 amino acid residues of protein S were made in an attempt to not disrupt phospholipids binding. Gla1 and 
NEDM were made by mutating residues into similar non charged residues. TSR was created by substituting charged residues in the TSR domain with polar 
residues. KTK and all EGF1 and 2 point variants were mutated to alanine. NNEDM (not shown) were made by introducing the N74A substitution into NEDM. 
Domains are labelled below the Aa nr. Amino acids in the TSR and EGF2 domain are in italics in WT protein S. Aa nr, amino acid number; Proth, 
prothrombin; pm, point variants. 
7
0
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Protein S Face1 and Face2 variants, previously evaluated for their APC cofactor 
activity by Saller et al.224 are chimeras of the human protein S Gla domain and 
the human prothrombin Gla domain. These were produced in our lab by Ms Y. Yu 
by inverse PCR (KOD Hot Start DNA Polymerase Kit, Novagen) and site-directed 
mutagenesis (QuikChange site-directed mutagenesis Kit, Stratagene). 
To identify residues in the Gla and EGF1 domain that might interact with APC or 
TFPI, these domains were aligned with homologous domains of other coagulation 
factors. Non conserved amino acids were selected and clusters of amino acids 
with surface exposed R groups were selected. This was done by using the 
structural protein S model spanning the Gla domain to the EGF1 domain created 
by Villoutreix et al..193  
As the TSR is unique to protein S, no swap substitutions could be made. Hence, 
charged residues in the TSR were substituted with the most similar non-charged 
amino acid (R to Q and D to N), to minimize the risk of adverse conformational 
changes, resulting in the generation of the TSR variant.  
Dr S.M. Rezende (Universidade Federal de Minas Gerais, Brazil) mutated 
residues between the third/fourth and fifth/sixth Cys residues of EGF1 and EGF2 
as these regions on the EGF-like domains are likely to be involved in protein 
interaction as suggested by (i) the highly divergent sequence of the B region; (ii) 
the association of dysfunctional proteins with natural PROS1 mutations in these 
regions and (iii) the location of many mutations in these regions associated with 
dysfunctional proteins in genes coding for other EGF-containing coagulation 
proteins, such as FVII, FIX and protein C.202,250 
All mutations were confirmed by sequencing. Subcloned fragments were also 
sequenced across the ligation sites to confirm correct insertion. 
 
3.1.2 Expression of protein S 
Protein S was expressed by transient or stable transfection of HEK293T or 
HEK293 cells, respectively. The amount of protein S harvested from HEK293 
cells over time did not result in a decreased expression according to ELISA 
results, suggesting that all cells were stably transfected after the initial 4 weeks 
selection with blasticidine. 
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WT protein S expressed approximately at 1.5-2 µg/ml, as determined by ELISA, 
in triple flasks and on average at 60 µg/ml in the CELLine adhere 1000 two-
compartment bioreactor, with expression levels increasing over time in the latter. 
The high concentration obtained in the bioreactor is a consequence of harvesting 
the media after a week rather than after 3 days and of the bioreactor 
concentrating protein S in the cell compartment. Expression levels of the variants 
were not formally assessed against that of WT protein S in a dedicated 
experiment where number of cells and transfection efficiency were taken into 
account. However, the great majority of variant protein S preparations expressed 
well (1-2 µg/ml), with the notable exceptions of protein S T108A and protein S 
N136A, which expressed at lower than 0.5 µg/ml. Protein S expressed from 
transient transfections yielded up to 10 times less than protein S expressed from 
a stable cell line. Harvested protein S media was either dialysed, concentrated 
and assayed directly, or purified by FPLC. 
 
3.1.3 Purification of protein S by FPLC on an anion exchange QFF column 
and immunoaffinity column  
Harvested and concentrated media was supplemented with EDTA and protein S 
was partially purified on a Sepharose HiTrap QFF anion exchange column 
(elution buffer: 20 mM Tris-HCl pH 7.4, 0.5 M NaCl, 5 mM Benzamidine). Figure 
3.1A (left chromatogram) illustrates this purification step on WT protein S with the 
milli absorbance unit (mAU) at 280 nm displayed against the volume of liquid 
flowing through the column. As expected, it shows that large amounts of protein 
(mAU values of ~260) are present in the flowthrough, although these are diluted 
in a large volume (~20 ml in this representative chromatogram). A high and 
narrow elution peak was obtained, while very small washing and stripping peaks 
could be observed. Fractions of the flowthrough, washing, elution and stripping 
peaks from the anion exchange chromatography were analysed by SDS-PAGE. 
Proteins in the respective fractions were stained with Blue Safe protein stain 
(Figure 3.1B). Protein S was specifically detected by an anti-protein S antibody on 
a Western blot (Figure 3.1C). The stained SDS-PAGE gel shows a large amount 
of protein is present both in the flowthrough and elution fraction (Figure 3.1, Panel 
B, first 4 lanes after the marker). The bands of protein in the flowthrough fraction 
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are quite faint as proteins were diluted into a large volume (flowthrough volume of 
~20 ml). A large protein band is present in the elution fraction that migrates with 
the same mobility as commercially available plasma purified protein S (last lane 
of gel, labelled as Ctrl). Western blot analysis (Figure 3.1, Panel C, first 4 lanes) 
confirmed that protein S was present in the elution fraction. A faint band of higher 
molecular weight was also present in the elution fractions. A higher MW band was 
sometimes visualised on gels when high amounts of purified protein S was 
loaded and is likely to correspond to aspecific binding of the secondary antibody. 
Protein S was also detected in the flowthrough of the QFF anion exchange 
column using Western Blot (Figure 3.1C). According to ELISA results, the amount 
of protein S lost in the flowthrough and washing peak varied from batch to batch 
but was generally between 5-15%, while the majority of protein S (~80%) was 
found in the elution fraction. This is compatible with what can be seen in the 
elution fraction of the Western blot (Figure 3.1C). Protein S content and total 
amount of protein in the elution peak were measured, respectively, by ELISA and 
total protein assay and suggested a mean purity of ~25%.  
To obtain high purity protein S the elution fraction from the Sepharose HiTrap 
QFF anion exchange column was applied on an immunoaffinity column (elution 
buffer: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM EDTA). A representative 
chromatogram is shown in Figure 3.1A (right chromatogram). Fractions were 
collected and the flowthrough, washing peak, elution peak and stripping peak 
were analysed by SDS-PAGE. The proteins were visualised by Blue Safe protein 
staining (Figure 3.1B, lane 5-8 after the marker); protein S was specifically 
detected by polyclonal anti-protein S antibodies following Western blot (Figure 
3.1C, last four lanes). The elution fraction from the immunoaffinity column in the 
stained SDS-PAGE gel (Figure 3.1B) shows a single band migrating with the 
same mobility as plasma purified protein S (last lane of gel, labelled as Ctrl). 
Western blot analysis (Figure 3.1C) confirms that this is protein S, suggesting 
pure protein S could successfully be isolated following this two step purification 
procedure. It is observed that the majority of contaminants visualised in the 
elution fraction of the QFF anion exchange column (Figure 3.1B) are present in 
the flowthrough of the immunoaffinity column. Protein S was, however, also 
present in the flowthrough fraction and washing fraction of the immunoaffinity 
column (Figure 3.1C). It should be noted that ten fold more in terms of volume of 
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the washing fraction was loaded in comparison with the other fractions to 
determine whether this contained any protein S. The high amount of protein S in 
the flowthrough fraction partially explains why the absorbance on the 
chromatogram of this fraction is so high in comparison with that of the elution 
fraction (considering ~25% of the proteins loaded onto the immunoaffinity column 
should be protein S). However, the high absorbance in the flowthrough in 
comparison to the elution peak is also due to the presence of Benzamidine in the 
loaded sample (see section 2.3.1.1) as this absorbs at 280 nm. Benzamidine is, 
on the other hand, not present in the elution buffer.  
 
Figure 3.1 Purification of WT protein S by FPLC on a Sepharose HiTrap QFF anion 
exchange column followed by an immunoaffinity column and analysis of elution fractions.  
(A) Purification of protein S on sepharose QFF anion exchange purification (left chromatogram) 
followed by immunoaffinity purification (right chromatogram). The 280 nm absorbance (blue line) 
is plotted against the elution volume. The vertical green lines represent a change of buffer. Total 
protein content in the fractions was detected by Blue safe protein stain of an SDS-PAGE (B) and 
protein S was specifically detected with a polyclonal antibody against protein S (C). F, 
flowthrough; W, washing; E, elution; S, stripping. 
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To evaluate why so much protein S was present in the flowthrough fraction from 
the immunoaffinity column, γ-carboxylation of protein S was firstly assessed as 
the monoclonal MK21 antibody used for the purification recognises the Gla 
domain of protein S. Importantly, when fractions from the Sepharose HiTrap QFF 
anion exchange column were analysed by Western blot with a monoclonal anti-
Gla antibody (recognising only γ-carboxylated protein S), only protein S in the 
elution fraction was recognised by both antibodies (compare Figure 3.2, detection 
with monoclonal anti-Gla antibody with Figure 3.1C, detection with polyclonal 
antibody). This suggests that, non γ-carboxylated protein S is in the flowthrough, 
indicating that this method selectively purifies γ-carboxylated protein S. This was 
thought to be of considerable importance, as only γ-carboxylated protein S is 
functional. A consequence of this is that all protein S loaded onto the 
immunoaffinity column was γ-carboxylated. The finding that protein S in the 
elution and flowthrough fractions from the immunoaffinity column was γ-
carboxylated was confirmed by recognition by the monoclonal anti-Gla antibody 
(Figure 3.1C, detection with polyclonal antibody and Figure 3.2, detection with 
monoclonal anti-Gla antibody). Ten fold more of the washing fraction was loaded 
in the gel where protein S was detected with the polyclonal antibody in 
comparison with the one in which it was detected with the monoclonal antibody 
recognising only γ-carboxylated Gla domain. However, when ten fold more of the 
washing fraction was loaded (not shown) the washing fraction was recognised by 
the anti-Gla antibody. 
 
Figure 3.2 Western blot analysis of protein S in the fractions obtained during purification 
on the Sepharose HiTrap QFF and on the immunoaffinity column.  
Flowthrough (F), washing (W), elution (E) and stripping (S) peaks of, respectively, Sepharose 
HiTrap™ QFF purification (lane 1-4) and affinity purification (lane 5-8) were blotted with a 
monoclonal anti-Gla antibody recognising only γ-carboxylated Gla domains. 
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The finding of a single band in the elution fraction of the immunoaffinity column 
(Figure 3.1B), together with its identification as protein S by Western blot (Figure 
3.1C), demonstrates that pure protein S could successfully be isolated using this 
two-step purification method. The results of Figure 3.2 indicate that this purified 
protein S was γ-carboxylated. However, a large part of γ-carboxylated protein S 
was also present in the flowthrough of the immunoaffinity column. To investigate 
this further, a similar sample containing protein S was applied to the 
immunoaffinity column continuously over night at a greatly reduced flow rate of 
0.5 ml/minute to increase contact time. However, this did not appreciably increase 
the amount of protein S in the elution fraction. When the flowthrough fraction was 
reapplied to the immunoaffinity column, additional protein S could be purified and 
eluted with EDTA (results not shown), suggesting the protein S in the first 
flowthrough was more likely associated with low binding capacity of the 
immunoaffinity column. Consequently, the flowthrough was reapplied to the 
column until all protein S was purified and was no longer in the flowthrough. All 
fractions from the elution peak from the immunoaffinity column containing protein 
S were pooled, dialysed and concentrated on spin columns. This purification 
procedure was used during the early part of my work to purify WT protein S, 
protein S D95A, protein S Face2 and protein S TSR. 
 
3.1.4 Purification of protein S by barium citrate precipitation and by FPLC 
on an anion exchange DEAE column 
Due to the low binding capacity of the immunoaffinity column, an alternative 
purification method for protein S was developed. WT protein S and protein S 
N74A, protein S KTK, protein S NNEDM variants and some additional protein S 
D95A were purified according to this alternative protocol. 
For this, protein S was first partially purified from concentrated conditioned media 
by barium citrate precipitation. This favours precipitation of protein S that is γ-
carboxylated and allows removal of any non γ-carboxylated protein S.248 
Following barium citrate precipitation, protein S was then further purified by FPLC 
on a DEAE anion exchange column. This was optimised during the last year of 
my work by my colleague Dr Josefin Ahnström. A representative chromatogram is 
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shown in Figure 3.3A where WT protein S was eluted with a calcium gradient of 
0-20 mM CaCl2. Conditioned media, barium citrate precipitated protein S and the 
various fractions eluted from the DEAE anion exchange column were run on 
SDS-PAGE and analysed by silver staining or by Western blot (Figure 3.3B and 
C, respectively). The silver stained gel shows that barium citrate precipitation 
removes most of the contaminants present in the concentrated conditioned media 
(Figure 3.3B). The purity of the barium citrate precipitated protein S, however, 
varied. Protein S expressed in high amounts from stably expressed cells was 
relatively pure following barium citrate precipitation (as can be seen in Figure 
3.3B), while barium citrate precipitated protein S from transiently transfected cells 
contained more contaminants (results not shown). The lower band contaminant 
seen in the silver stain in the barium citrate precipitated material is partially 
removed following passage on the DEAE anion exchange column and can be 
seen in the flowthrough fraction (Figure 3.3B). The higher band in the barium 
citrate precipitated sample and the main band in the elution fractions were 
identified as protein S on the Western blot (Figure 3.3C). Fractions from the 
elution peak that contained protein S and trace amounts of contaminants were 
pooled, concentrated and used in functional assays. An overall yield, as 
determined by ELISA, after barium citrate precipitation and purification on a 
DEAE anion exchange column, of 10-30% was obtained. 
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Figure 3.3 Purification of barium citrate precipitated WT protein S on an anion exchange 
DEAE column and analysis by SDS-PAGE.  
(A) The 280 nm absorbance (blue line) is plotted against the ml of liquid passing through the 
column. The green lines represent a change of buffer; equilibration buffer (20 mM Tris-HCl pH 7.5, 
150 mM NaCl), elution buffer (20 mM Tris HCl pH 7.5, 150 mM NaCl, 0-20 mM CaCl2) and 
stripping buffer (20 mM Tris HCl pH 7.5, 1 M NaCl, 50 mM CaCl2). Peaks were collected and 
analysed. Total protein was detected by silver staining (B) and protein S was detected by a 
polyclonal antibody (C). Small fractions from the elution peak were collected separately and run 
on the gel. CM; conditioned media, bcp; barium citrate precipitated protein S, F; flowthrough, S; 
stripping. 
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3.2 Characterisation of recombinant protein S 
3.2.1 Quantification of protein S by ELISA 
The concentrations of purified protein S and protein S in conditioned media were 
determined by ELISA. A standard curve of 0-2 nM protein S was fitted to a 
sigmoidal dose-response curve and samples were diluted to ensure they fell in 
the linear part of the curve (generally between 0.25-1.5 nM protein S). The 
plasma purified protein S gave a higher absorbance reading than the 
corresponding concentration of protein S in normal plasma when detected with 
the monoclonal antibodies (Figure 3.4). This could potentially be due to slightly 
different amounts of protein S in the two standard preparations, to plasma protein 
S being monomeric and purified protein S multimeric (see section 3.2.3) or due to 
the fact that ~60% of plasma protein S is bound to C4BP and is less recognised 
by the monoclonal antibody. 
 
Figure 3.4 Standard curves of protein S used in the ELISA.  
Plasma purified protein S or protein S in normal plasma were used as a standard curve (0-2 nM) 
and were detected either with the MK55 monoclonal antibody (A) or with the commercially 
available monoclonal antibody AHPS 9052 (B). 
 
 
When protein S in normal plasma (362 nM) was analysed by Western blot 
alongside plasma purified protein S and detected by a polyclonal antibody, bands 
of similar intensity were obtained suggesting that the reason behind the difference 
in absorbance observed between plasma purified protein S and protein S in 
media was not due to different concentrations of protein S. When my quantified 
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recombinant protein S preparations (pure or in conditioned media) were analysed 
by Western blot, bands of equal intensity of purified protein S and protein S in 
conditioned media were only obtained if the concentration of pure protein S was 
determined with the plasma purified protein S standard and if protein S in 
conditioned media was determined with the normal plasma standard (results not 
shown). Since the monoclonal antibody MK55 recognises the EGF3-4 domains 
and the difference in detection of plasma protein S and purified plasma protein S 
by the monoclonal antibody AHPS 9052 is not 60% (difference between total and 
free protein S) it is unlikely that the differences in detection are due to the fraction 
of bound protein S in plasma. Multimerisation was analysed in section 3.2.3 and 
might account for the differences in detection between plasma protein S and 
purified protein S. 
The concentration of purified protein S was, therefore, determined with the 
plasma purified protein S standard curve; that of protein S in conditioned media 
was determined with the normal plasma standard curve. Intra and inter ELISA 
variability varied, with purified protein S preparations giving higher CV values than 
protein S in conditioned media. Generally, the intra-assay CV was less than 10% 
for purified protein S and less than 5% for protein S in media. The mean inter-
assay CV was 11% with samples being assessed by ELISA a minimum of 3 
times. 
 
3.2.2 Analysis of the purity of protein S 
SDS-PAGE and silver staining of purified protein S preparations were performed 
to assess purity. WT protein S and protein S variants analysed under non-
reducing conditions, irrespective of the purification method, migrated 
predominantly as a single band (Figure 3.5) of identical size to commercially 
available plasma purified protein S (see Figure 3.1B). A band of lower molecular 
weight than protein S was observed in some gels. This was, however, very faint 
in comparison with the protein S band and could only be visualised following long 
development of the silver stain. The concentration of purified protein S samples 
was assessed by absorbance at 280 nm, which corroborated the concentrations 
obtained by ELISA, suggesting that the protein S preparations were suitably pure 
for the in vitro experiments used in this project. 
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Figure 3.5 Silver staining of purified protein S samples.  
WT and variant protein S samples (100 ng/well) were stained by silver staining. WT1; WT protein 
S purified by QFF anion exchange chromatography followed by immunoaffinity chromatography. 
WT2; WT protein S purified by barium citrate precipitation followed by DEAE anion exchange 
chromatography.  
 
 
3.2.3 Multimerisation of protein S 
Multimerisation of protein S has been well documented in the literature and it has 
been reported that multimeric protein S binds to phospholipids with higher affinity 
than monomeric protein S.189-192,251 
To assess multimer formation of WT protein S, a Western blot was performed on 
a native PAGE gel. Protein S in dialysed concentrated conditioned media 
appeared to be monomeric (Figure 3.6A,B). Protein S partially purified by QFF 
anion exchange chromatography was mainly monomeric but also contained some 
dimers (Figure 3.6A). However, protein S partially purified by barium citrate 
precipitation (Figure 3.6B), fully purified protein S (Figure 3.6A) and plasma 
purified protein S (Figure 3.6B) all exhibited appreciable multimerisation. These 
results are consistent with previous reports.191,192 It was difficult to obtain high 
quality Western blots showing protein S multimers. Nevertheless, no major 
difference in multimer formation between barium citrate precipitated protein S, 
fully purified protein S (independently of the purification protocol) and plasma 
purified protein S was observed. 
To allow for potential differences in activity between monomeric and multimeric 
protein S, both protein S in concentrated conditioned media (monomeric) and 
purified protein S (multimeric) was used, where possible, in the functional assays.  
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Figure 3.6 Western blot of a native PAGE analysis to identify multimer formation occurring 
during the purification.  
Protein S in dialysed concentrated conditioned media (lanes 1 and 4) is predominantely 
monomeric (A,B). Protein S partially purified by QFF anion exchange column (2) exhibited some 
dimers while its subsequent passage over the immunoaffinity column lead to multimerisation (3) 
(A). Barium citrate precipitated protein S (5) and plasma purified protein S (6) were both 
multimeric (B). 
 
 
3.2.4 Cleavage of protein S 
Cleavage of protein S has previously been reported to occur after one or more of 
the 3 arginine residues (Arg49, Arg60, Arg70) in the TSR domain. Once cleaved, 
the disulphide bond between Cys47 and Cys72 keeps the Gla domain and the 
EGF1 domain together. However, under reducing conditions the disulphide bond 
is broken and the protein S fragment spanning from the cleavage site in the TSR 
to the SHBG domain is observed below the band of full-length protein S. The 
effect of protein S cleavage upon protein S function remains to be fully 
defined.175-177 
When partially purified protein S was analysed by Western blot under reducing 
conditions a doublet was observed. To investigate whether the two closely 
migrating bands were due to variable glycosylation or cleavage of protein S, 
partially purified protein S samples were incubated with or without PNGase. 
Western blot analysis (Figure 3.7) was performed both with a polyclonal anti 
protein S antibody (Panel A) and a monoclonal anti-Gla antibody (Panel B) under 
reducing conditions. Results in Panel A show that the double band was 
conserved after WT protein S and protein S Face2 are digested with PNGase, 
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suggesting that the difference in size is not due to differences in glycosylation. 
Protein S TSR was present only as one band in the blot revealed using a 
polyclonal antibody. Protein S TSR has all the arginines (after which protein S is 
cleaved) substituted to Gln. When protein S was detected with the anti-Gla 
antibody (Panel B) only one band was present. According to the MW, this band 
corresponds to the higher band of the duplets detected for WT and Face2 with 
the polyclonal antibody. The isolated Gla domain is not detected by the 
antibodies, probably because too small (~4.5 kDa) and present in too low 
amounts. This is consistent with previously reported results in the literature.252 
Together, these results suggest the doublet band observed under reducing 
conditions is due to cleavage of protein S in the TSR domain rather than variable 
glycosylation. Blots of protein S in conditioned media suggests that cleavage 
occurs during the course of protein S expression (results not shown). 
To account for any differences in activity due to cleavage of protein S, regular 
checks on every preparation of interest were made to ensure cleavage of the 
protein S variants was no more than that of WT protein S. 
 
Figure 3.7 Analysis of protein S cleavage.  
Protein S incubated (+) and not incubated (-) with PNGase was analysed by SDS-PAGE under 
reducing conditions and detected either by a polyclonal anti-protein S antibody (A) or a 
monoclonal anti-Gla antibody (B). 
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3.3 Evaluation of APC cofactor activity of protein S 
3.3.1 Preliminary experiments in protein S deficient plasma 
Before analysing the APC and TFPI dependent cofactor activity of protein S in 
plasma, TF concentration was titrated in the CAT assay for optimal analysis of the 
activity of endogenous protein C and TFPI in the plasma. Protein S deficient 
plasma is more procoagulant than normal plasma and it has been reported that 
only low amounts of TF (~1.4 pM) allow visualisation of the TFPI cofactor activity 
of protein S.218 To establish the concentration of TF to use, I performed a titration 
of TF from 0.0625 to 1 pM (Figure 3.8). This resulted in a prolongation of the lag 
time but thrombin peak height and ETP did not vary significantly. However, 
variability between the replicates (not showed) increased at lower TF 
concentration. TF concentration at 1 pM was chosen to trigger coagulation in all 
my plasma assays (unless otherwise stated) as duplicates were good and this is 
compatible with what is currently in use in the literature to trigger coagulation in 
plasma.240,241,253,254 The stock concentration of recombinant TF in Innovin was 
considered to be 6000 pM, as estimated by P. Giesen in the Thrombogram guide 
of Synapse b.v. Hence, a 1:6000 dilution of the TF stock was performed to obtain 
1 pM final concentration in the assay. 
 
 
Figure 3.8 TF initiation of coagulation in protein S deficient plasma. 
A titration of TF (0.0625-1 pM) was performed in protein S deficient plasma from Affinity 
Biologicals supplemented with 50 µM phospholipids and 65 µg CTI per ml plasma in a final 
volume of 100 µl to assess the amount of thrombin generated. 
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To evaluate the activity of both endogenous protein C and TFPI in the protein S 
deficient plasma, polyclonal antibodies against APC (150 nM) and polyclonal 
antibodies against TFPI (100 nM) were used. When these were added to the 
plasma, no change in thrombin generation was observed (Figure 3.9). Addition of 
120 nM plasma purified protein S to protein S deficient plasma had no effect on 
thrombin generation (Figure 3.9). Results suggest that APC and TFPI in protein S 
deficient plasma under these experimental conditions do not appreciably regulate 
thrombin generation, either in the presence or absence of protein S. The lack of 
APC influence is not surprising, considering that protein C does not circulate in its 
active form and that EPCR and TM (absent in these experiments) are important 
for physiological activation of protein C by thrombin. The lack of influence of TFPI 
was attributed to co-depletion of protein S and TFPI from the plasma during its 
preparation by the manufacturer (see section 3.4.1). Consequently, APC or TFPI 
were supplemented to the plasma preparations to evaluate cofactor activities of 
protein S. APC from Enzyme Research Laboratories was used unless otherwise 
stated. 
 
 
Figure 3.9 Activity of endogenous APC and TFPI in protein S deficient plasma.  
Thrombin generation was performed in protein S deficient plasma in the presence and absence of 
130 nM polyclonal antibodies against protein C (Sigma-Aldrich), 100 nM polyclonal antibodies 
against TFPI (Haematologic Technologies Inc) and in the presence of 120 nM protein S. Ab; 
antibody. PC, protein C. 
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3.3.2 Evaluation of APC cofactor activity of protein S by CAT 
To assess the APC cofactor activity of protein S, thrombin generation was 
measured by CAT using protein S deficient plasma from Affinity Biologicals 
supplemented with recombinant WT protein S and its variants in conditioned 
media. Under the conditions of the assay, in the absence of added protein S, 
APC (0-10 nM) did not influence thrombin peak height, ETP, lag time or time to 
peak, in protein S deficient plasma (Figure 3.10, Panel A). When (0-120 nM) WT 
protein S was introduced into the assay in the presence of APC, dose-dependent 
changes were observed, primarily on reduction of the peak height and of ETP 
values (Figure 3.10, Panel B). The extent of inhibition of peak height and ETP 
was dependent both on the concentration of APC and protein S. For example, the 
higher the APC concentration, the less protein S was necessary to completely 
inhibit thrombin generation. Under these experimental conditions, 10 nM APC and 
120 nM protein S reduced both the peak height and ETP by ~84%. To verify that 
those effects were a direct consequence of APC cofactor activity of protein S, 
polyclonal antibodies against either protein S (Figure 3.10, Panel C) or protein C 
(Figure 3.10, Panel D) were used. As seen in Figure 3.10 these completely 
inhibited the anticoagulant APC-protein S activity.  
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Figure 3.10 APC and protein S anticoagulant activity in plasma.  
Thrombin generation was performed in protein S deficient plasma containing 100 nM inhibitory 
antibodies against TFPI. Up to 10 nM APC had no effect on thrombin generation in the absence of 
protein S; all concentrations generate lines that are superimposable (A). Following addition of 120 
nM protein S (at 0-10 nM APC) an APC dose-dependent effect was observed (B). The upper 
single line represents 0-10 nM APC in the absence of protein S. Protein S in the presence of no or 
2.5 nM APC generated lines that were superimposable. Conditions used are noted adjacent to the 
peak heights to which they refer. The anticoagulant activity of 10 nM APC and 120 nM protein S 
was inhibited by polyclonal antibodies against protein S (1.5 μM, DAKO) (□) (C) or against protein 
C (130 nM, Sigma-Aldrich) (x) (D). PS, protein S; PC, protein C. Representative experiments are 
shown (n=3).  
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To compare the anticoagulant activity of recombinant WT protein S in 
concentrated conditioned media with that of protein S purified by different 
techniques, the former was compared to protein S purified first by anion 
exchange chromatography and thereafter by immunoaffinity chromatography, or 
alternatively by barium citrate precipitation followed by anion exchange 
chromatography (see sections 2.3.1 and 2.3.2). All protein S preparations showed 
a similar inhibition of thrombin generation as can be seen in Figure 3.11. As 
protein S in concentrated conditioned media showed a similar activity to purified 
protein S, and furthermore also considering that protein S in media is essentially 
monomeric, conditioned media samples rather than fully purified protein S 
samples were preferably used to evaluate thrombin generation by CAT. In some 
experiments where purified protein S was used to assess APC cofactor activity, 
these preparations were purified by anion exchange chromatography followed by 
immunoaffinity chromatography. 
 
Figure 3.11 APC cofactor activity of different preparations of protein S in plasma. 
The anticoagulant activity of protein S in conditioned media was compared with that of protein S 
purified either by anion exchange chromatography followed by affinity purification (purified protein 
S 1, dotted lines) or protein S purified by barium citrate precipitation followed by anion exchange 
chromatography (purified protein S 2, dashed lines), 90 nM, in the presence of 4 nM APC (Xigris). 
APC from Xigris was used in this experiment and was more active than the commercial APC 
preparation mostly used in this thesis (Enzyme Research Laboratories). 
 
 
Having optimised the CAT assay for APC-dependent protein S cofactor activity, I 
then aimed to screen my panel of protein S variants to identify those with a 
functional deficit. The screening of the protein S variants for their APC cofactor 
activity was performed at a high concentration of APC (16 nM) to achieve almost 
complete inhibition of thrombin generation in the presence of 100 nM WT protein 
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S (Figure 3.12). Figure 3.12 shows the % peak height obtained for each protein S 
variant in comparison with the peak height obtained in the absence of protein S. 
When % ETP values were plotted instead of % peak height a very similar graph 
was obtained (result not shown). In total, 28 variants were screened for their APC 
cofactor activity. As previously reported,224 the cofactor activities of Face1 and of 
Face2 for APC were reduced. Importantly, these screening experiments identified 
a single point variant in EGF1 of protein S, D95A, which had a severely impaired 
APC cofactor activity that had not previously been implicated in protein S 
function. Under all conditions used (4, 9 or 16 nM APC, 60, 90 or 100 nM protein 
S), the reduction in APC cofactor activity of protein S D95A was greater than that 
observed for the previously reported variant with 7 amino acids exchanged 
(prothrombin residue swap), Face2. 
 
Figure 3.12 Screening of protein S variants for APC cofactor activity.  
The APC cofactor activity of protein S was evaluated at 16 nM APC and 100 nM protein S by 
CAT. The peak height in the absence of protein S was set to 100%. A high concentration of APC, 
leading to almost complete inhibition of thrombin generation with 100 nM WT protein S, was 
chosen specifically for screening purposes as this allows widening of the assay window at which 
variants with reduced APC cofactor activity are visualised.  
 
 
As Saller et al.225 did not investigate the APC cofactor activity of protein S Face1 
and Face2 variants in the CAT assay, I titrated both variants alongside WT 
protein S (0-120 nM) in the presence of 16 nM APC (Figure 3.13). Protein S 
Face1 (Panel B) had almost completely abolished APC cofactor activity while the 
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cofactor activity of Face2 (Panel C) was partially reduced (Figure 3.13). These 
results from the CAT assay, corroborate the results obtained by Saller et al.225 
using clotting assays. Saller et al., however, showed a 9-fold reduction in protein 
S Face1 binding to phospholipids. They could therefore not conclude whether the 
residues comprising the variant were important or not for a cofactor interaction 
with APC. Protein S Face2, however, bound phospholipids and domain specific 
monoclonal antibodies with similar Kd(app) values to those of WT protein S.
224 
 
Figure 3.13 APC cofactor activity in plasma of WT protein S, Face1 and Face2 variants. 
Thrombin generation was measured in protein S deficient plasma supplemented with 16 nM APC, 
and 0-120 nM WT protein S (A), protein S Face1 (B) or protein S Face2 (C). Legends are 
positioned adjacent to the peak heights to which they refer.  
 
 
To further evaluate the APC cofactor activity of protein S D95A, a titration (0-120 
nM) of the variant (Figure 3.14, Panel B) was performed alongside WT protein S 
(Figure 3.14, Panel A), using 9 nM APC. Protein S D95A had a severely impaired 
APC cofactor activity, a finding replicated when a different concentration of APC 
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(4 nM) was used. The severely impaired APC cofactor function of protein S D95A 
was also confirmed in protein S deficient plasma supplied by Hyphen Biomed to 
ensure that these effects were not plasma specific (n=1, results not shown). While 
the cofactor activity of WT protein S is highly dependent upon the APC 
concentration used (see Figure 3.10, Panel B) that of protein S D95A is not, 
explaining the difference in fold activity between WT protein S and protein S 
D95A in Figure 3.12 and Figure 3.14. 
Using 9 nM APC, (Figure 3.14, Panel A and B), 120 nM of WT protein S reduced 
peak height and ETP by ~80%, while 120 nM of protein S D95A only reduced 
peak height and ETP by ~10%.  
Protein S is susceptible to proteolysis in the TSR domain and this may impair its 
APC cofactor function.175-177 To ensure that any difference in activity between WT 
protein S and protein S D95A was not due to difference in TSR proteolytical 
cleavage, samples were analysed by Western blot under reducing conditions. No 
cleavage was observed either in WT protein S or in the D95A variant, showing 
that the different APC cofactor activity was not a result of different cleavage of the 
two preparations (results not shown). 
Asp95 in protein S is β-hydroxylated and while it has not been shown to bind 
calcium, it is part of a partially conserved calcium binding motif. To ensure 
disruption of β-hydroxylation or loss of coordination of a calcium ion was not the 
reason behind the impaired APC cofactor activity of protein S D95A, Asp95 was 
also substituted with Asn, rather than Ala. Asn is structurally more similar to Asp 
than Ala and it can also be β-hydroxylated and potentially coordinate a calcium 
ion. When the protein S D95N variant was titrated, it was observed that it also 
had severely reduced APC cofactor activity (Figure 3.14, Panel C), with 120 nM 
of the D95N variant inhibiting peak height and ETP by only ~20%. 
All results in Figure 3.14A-C were conducted with protein S and its variants in 
concentrated conditioned media. Concentrated conditioned media from cells not 
expressing protein S was used as a control and had no influence on thrombin 
generation (results not shown). The % change in peak is represented in Figure 
3.14, Panel F. To confirm that the differences in APC cofactor activity I observed 
arose from protein S rather than the media, WT protein S and the protein S D95A 
variant were purified to homogeneity using anion exchange and immunoaffinity 
chromatography (see section 2.3.1). Figure 3.14D shows SDS-PAGE gel 
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visualised with silver staining which suggests that the protein S preparations were 
essentialy pure. Addition of 90 nM of purified WT protein S to protein S deficient 
plasma in the presence of 9 nM of APC, appreciably attenuated thrombin 
generation (Figure 3.14, Panel D), replicating the findings with WT protein S in 
conditioned media. When 90 nM purified protein S D95A was used, only a 
minimal effect on thrombin generation was seen (Figure 3.14, Panel D) 
corroborating the results from the experiments using concentrated conditioned 
media.  
Inspection of a model of Gla-TSR-EGF1 domains of protein S193 suggested that 
two residues with solvent exposed R groups, Asp78 and Gln79, are in close 
proximity to that of Asp95. These residues were not included in the first round of 
screening (shown in Figure 3.12). These were therefore mutated to alanine and 
expressed in HEK293T cells as described in sections 2.1.2 and 2.2.2. When 
protein S D78A and Q79A in concentrated conditioned media were analysed in 
the thrombin generation assay alongside WT protein S, a severely reduced APC 
cofactor activity was also observed for both (Figure 3.14, Panel E). The proximity 
of these residues to Asp95 suggests these three residues could form a possible 
cluster of residues involved in APC cofactor activity of protein S. 
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Figure 3.14 APC cofactor activity in plasma of WT protein S, protein S D95A, D95N, D78A 
and Q79A variants.  
Thrombin generation was measured in protein S deficient plasma supplemented with 9 nM APC, 
100 nM antibodies against TFPI and 0-120 nM WT protein S (A), protein S D95A (B), protein S 
D95N (C) or 90 nM purified WT (dashed line) or purified protein S D95A (dotted line) (D). Protein 
S concentrations are positioned adjacent to the peak heights they refer to. The cofactor activity of 
60 nM WT protein S and protein S variants D95A (▼), D78A (◊) and Q79A (○) was compared at 9 
nM APC (E). Typical experiments are shown (n=3). Dose response data from titrations with WT 
protein S, protein S D95A, and protein S D95N in the presence of 9 nM APC are shown in Panel F 
(data is expressed as mean ± SD of two independent experiments performed in duplicate). Inset 
in Panel B shows recognition of WT protein S and protein S D95A in media by polyclonal 
antibodies (pAb) and a monoclonal antibody recognising only γ-carboxylated Gla domains (α-Gla). 
Inset in Panel D shows the See Blue prestained marker, plasma purified protein S from Enzyme 
Research Laboratories (ERL, lane 1), purified recombinant WT protein S (lane 2) and purified 
protein S D95A (lane 3) visualised with silver staining. 
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3.3.3 Binding of protein S to phospholipid surfaces 
As phospholipid binding is a prerequisite for protein S function, the binding of WT 
protein S and of protein S D95A to phospholipids was evaluated. Partially purified 
(using barium citrate precipitation) protein S, 0-120 nM, was incubated for 2 hours 
on a plate coated with 25 µg/ml phospholipids and bound protein S was detected 
by an HRP-conjugated antibody against protein S. As shown in Figure 3.15, both 
WT protein S and protein S D95A were able to bind phospholipids, with Kd(app) of 
5.7 ± 1.2 and 9.5 ± 2.3 nM (n=3), respectively (Table 3.3). 
Kd(app) values were analysed by the Mann Whitney test and were found not to be 
statistically different (p>0.05). Binding was observed in the presence of Ca2+, but 
not in the presence of EDTA or in the absence of phospholipids, as expected, 
confirming the specificity of the assay. These findings are broadly consistent with 
previously reported Kd(app) values for protein S binding to phospholipid 
surfaces.182,190,223-225 My results suggest the loss of APC cofactor activity 
observed for protein S D95A is not due to reduction or loss of binding to 
phospholipid surfaces. 
 
 
Figure 3.15 Binding of protein S to phospholipid surfaces.  
Protein S (0-120 nM) was incubated in a plate coated with 25 µg/ml phospholipids. Bound protein 
S was detected with an HRP-conjugated polyclonal antibody against protein S. A representative 
experiment is shown. The Kd(app) values, 5.69 ± 1.24 and 9.54 ± 2.26 nM for WT protein S and 
protein S D95A, respectively, were obtained by calculating the mean ± SD of three independent 
experiments performed in duplicate for each concentration of protein S. 
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3.3.4 Binding of protein S to domain specific monoclonal antibodies  
Substituting residues in a domain can sometimes affect the overall folding of the 
protein, the structure of the domain in which the substitution has been introduced 
or the structure of adjacent domains. To assess the integrity of the domain 
structure and folding of protein S variants, binding of protein S to conformational 
domain specific antibodies was evaluated. Protein S in concentrated conditioned 
media was incubated in a plate coated with monoclonal antibodies recognising 
either the Gla domain (MK21), the EGF1 domain (MK54) or the C-terminal SHBG 
domain (MK61). Bound protein S was detected with polyclonal antibodies as 
described in the Methodology. Binding curves were fitted with a one site binding 
equation and the Kd(app) values were obtained. 
Table 3.3 represents the mean ± SD Kd(app) values of three independent 
experiments performed in duplicate. Kd(app) values were analysed by the Mann 
Whitney test and were found not to be statistically different (p>0.05). The results 
suggest that substitution of Asp95 does not result in a significant change in the 
domain structure of protein S. 
 
 
DOPS/DOPC/DOPE 
vesicles 
MK21 
(Gla) 
MK54 
(EGF1) 
MK61 
(SHBG) 
WT protein S 5.69 ± 1.24 2.18 ± 0.97 0.81 ± 0.11 5.31 ± 1.11 
Asp95 protein 
S variant  
9.54 ± 2.26 2.53 ± 1.06 0.83 ± 0.03 5.39 ± 0.54 
 
Table 3.3 Binding of protein S to phospholipids and domain specific monoclonal 
antibodies.  
Kd(app) values (nM) of WT protein S and the Asp95 protein S variant for phospholipid vesicles and 
domain specific monoclonal antibodies are expressed as mean ± SD of three independent 
experiments performed in duplicate. Binding of WT protein S and the Asp95 variant to 
phospholipids and domain specific monoclonal antibodies was analysed by Mann Whitney test 
and the differences were found not to be statistically significant (p>0.05). 
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3.3.5 Protein S enhancement of APC mediated cleavage of FVa at Arg306  
Protein S cofactor function towards APC was initially assessed in the CAT assay 
(described above), which assesses thrombin generation in plasma. To more 
precisely measure and quantify the influence of protein S variants on APC 
cofactor function, a purified system was used that examines cleavage of FVa. 
The FVa variant, R506Q/R679Q, was used to evaluate protein S enhancement of 
APC mediated cleavage at Arg306 in FVa. FVa inactivation was performed in the 
presence or absence of 0.5 nM APC and a titration of purified protein S (0-100 
nM) was performed as described in the Methodology (section 2.6.3). After 10 
minutes the remaining FVa activity was measured using a prothrombinase assay. 
Using this approach, WT protein S efficiently enhanced APC mediated cleavage 
at Arg306 of FVa, in contrast to protein S D95A and protein S Face2 which 
showed almost no enhancement of APC activity (Figure 3.16, Panel A). 
To quantify the rate of cleavage at FVa Arg306 in the presence and absence of 
protein S, time course experiments were performed. In the absence of protein S, 
or in the presence of protein S D95A or protein S Face2, 3 nM APC was used 
and aliquots were quenched at different time points (0-20 min). In the presence of 
WT protein S the APC concentration was lowered to 0.5 nM, as APC is efficiently 
enhanced by WT protein S. The remaining FVa activity at all time points was 
measured in the prothrombinase assay (Figure 3.16, Panel B). It is observed that 
approximately 6-fold more APC is needed in the presence of protein S D95A and 
protein S Face2 to obtain a similar amount of APC-mediated FVa R506Q/R679Q 
inactivation as with WT protein S. Using the FVa inactivation curves obtained, the 
apparent pseudo-first order rate constants were calculated (see section 2.6.3) 
and corrected for the APC concentrations used. Rate constants for APC, 
APC+WT protein S, APC+protein S D95A and APC+protein S Face2 were 
respectively 6.1±1.2•105, 8.3±1.6•106, 1.1±0.2•106 and 2.0±0.3•106 and were 
broadly consistent with those previously reported in the same laboratory.141 Under 
these experimental conditions, APC mediated cleavage at FVa Arg306 was 
enhanced by WT protein S by 13.9 ± 3.6-fold, while protein S D95A was only able 
to enhance APC by 1.8 ± 0.4-fold and protein S Face2 by 3.3 ± 0.3-fold. 
Accordingly, protein S D95A had 12.9% and protein S Face2 30.3% of the activity 
 97 
of WT protein S. Protein S had no effect on FVa activity in the absence of APC 
(not shown). 
 
Figure 3.16 Protein S enhancement of APC mediated cleavage of FVa at Arg306.  
Protein S (0-120 nM) in the presence of 0.5 nM APC was incubated with 0.8 nM FVa 
R306Q/R679Q in the presence of phospholipids for 10 minutes. The remaining FVa activity was 
measured with a prothrombinase assay. Results are plotted as mean ± SD from three 
independent experiments performed in duplicate (A). A time course experiment was performed to 
calculate the apparent pseudo-first-order rate constants of WT protein S, protein S D95A and 
protein S Face2 (B).  
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3.3.6 Discussion 
Initially, 28 protein S variants with substitutions in the Gla, TSR, EGF1 and EGF2 
domains were constructed and expressed. I evaluated their ability to enhance 
APC mediated anticoagulant activity in plasma. The anticoagulant function of 
these 28 variants, and the subsequently expressed variants protein S D78A, 
D79A and D95N, was assessed by a thrombin generation assay, the specificity of 
which was demonstrated by utilising polyclonal antibodies both against protein S 
and protein C that completely inhibited the anticoagulant response observed 
when adding protein S in the presence of APC. The advantage of the thrombin 
generation assay conducted in plasma is that it shows very clearly how APC is 
heavily dependent upon protein S.218 In the absence of protein S, 10 nM APC has 
no effect on thrombin generation. In contrast, in the presence of protein S, 
maximal anticoagulant activities with near ablation of thrombin generation are 
obtained with APC concentrations of around 10 nM. 
My initial screening results identified three protein S variants with appreciable 
reduction in APC cofactor function. These were the already reported protein S 
Face1 and Face2 variants (a 4 and a 7 residue composite variant in the Gla 
domain, respectively) and the novel protein S D95A point variant in the EGF1 
domain. The Face2 variant, in the report by Saller et al., retained binding to 
phospholipids and yet had appreciably reduced APC cofactor activity, while 
Face1 was shown to have an approximate 9-fold reduced phospholipid binding.224 
It is suggested that the 7 residues substituted in the protein S Face2 variant 
collectively present a face of the Gla domain to APC and form a potential contact 
region. This variant was selected for investigation here, because it is a well-
characterised protein S variant with substantially reduced APC cofactor activity 
and could therefore act as a representative control for a dysfunctional protein S. 
Saller et al., however, did not assess protein S Face2 and Face1 APC cofactor 
activity in the CAT assay. I confirmed a reduction in APC cofactor activity in 
plasma, assessed by CAT.  
The natural protein S variants T103N255 and K155E256,257 have been reported to 
have reduced APC cofactor activity. I could not observe any significant reduction 
in APC cofactor activity of protein S T103A in the CAT assay. It is, however, 
important to point out that defective APC cofactor activity of protein S T103N was 
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not observed in the APC mediated inactivation of WT FVa.255 In addition, at 
higher concentrations of APC (8 nM) no difference was observed between WT 
protein S and protein S T103N in the FVIIIa degradation assay.255 Protein S 
Tokushima (K155E) has been described in the literature to have a cofactor 
activity towards APC of 31% 256 and 58% 257 of that of WT protein S. I did observe 
a decrease in protein S K155A cofactor activity towards APC, although this was 
quite moderate under conditions used in my screening assay. However, as this 
reduction was appreciably less than that for protein S D95A, it was not further 
analysis during my PhD project. 
Considering pooled results from multiple assays (n=3), protein S S99A and 
N154A seem to be the variants that have most enhanced APC cofactor activity. It 
would also be interesting to further analyse these variants. A full titration in the 
CAT assay would allow an assessment of the extent of increased activity. It would 
be interesting to elucidate their importance in APC cofactor activity by assessing 
their activity in a purified assay and their ability to bind phospholipids.  
The substitution of Asn136 in protein S abolishes the calcium binding site in the 
EGF2 domain of protein S.258 I did not observe a reduction in APC cofactor 
activity. However, it was secreted in significantly lower levels than WT protein S 
and all other protein S variants from stably transfected cells (see section 3.2.1). 
As APC cofactor activity appeared normal I did not further investigate the 
expression of protein S N136A, but it is likely that mutating Asn136 to Ala 
influences the structure of protein S leading to intracellular retention of incorrectly 
folded protein S.  
Protein S variants R49Q and Q52R in the TSR domain of protein S and protein S 
variants K97Q and P106S in the EGF1 domain were assessed in Dahlbäck’s 
laboratory (He et al.),244 and found to be important for species specificity towards 
APC. Following substitution of the human protein S residues into the 
corresponding residues of bovine protein S, an increased cofactor activity 
towards human APC was observed. They were also shown to specifically 
increase the activity of human protein S towards bovine APC. During my project I 
did not mutate Gln52 and as the substitution R49Q was part of the composite 
variant TSR it is not possible to directly compare my results with those previously 
reported. My protein S P106A variant had slightly increased activity in comparison 
with WT protein S, in accordance with previous results.244 Protein S K97A, 
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however, had decreased activity in comparison with WT protein S. This is in 
discrepancy with the results of the K97Q variant of He et al. but is likely to depend 
on the different substitution, to alanine or glutamine. It is interesting that residues 
previously found to be important for species specificity (residues Arg49, Gln52, 
Lys97, Pro106) are spatially located in close proximity to residues Asp95, Asp78 
and Gln79 here shown to be important for APC cofactor activity (Figure 3.17). 
 
 
Figure 3.17 Location of residues important for species specificity in relation to Asp95, 
Asp78 and Gln79. 
Residues Arg49, Gln52 in the TSR domain of protein S and residues Lys97 and Pro106 in the 
EGF1 domain of protein S have been reported to be important for species specificity
244
 and are 
here highlighted in cyan. Residues Asp95, Asp78 and Gln79 important for APC cofactor activity 
are highlighted in green. This N-terminal model of the Gla-TSR-EGF1 domains of protein S is 
adapted from the model of Villoutreix et al..
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Analysis of protein S function can be complicated due to its propensity to 
multimerise upon purification.191,192 Accordingly, I have performed APC cofactor 
assays with unpurified protein S in concentrated conditioned media as well as 
with fully purified preparations. My results were consistent between protein S 
preparations. Both forms of the protein S D95A variant, purified or in concentrated 
conditioned media, had an appreciable reduction in APC cofactor activity when 
compared to the respective WT protein S preparation. In all comparison 
experiments carried out, the protein S D95A variant had less APC cofactor than 
the protein S Face2 variant. This suggests that Asp95 in protein S may occupy a 
pivotal position with respect to its interaction with APC. The importance of Asp95 
in APC cofactor activity was further confirmed by the severely reduced activity 
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observed when mutating to alanine the two residues in close proximity to Asp95, 
Asp78 and Gln79. Asp78, Gln79 and Asp95 are conserved across species with 
the exception of Asp78 that is replaced by the structurally similar Asn78 in birds 
(Figure 3.18). Using a working model of the Gla-TSR-EGF1 domains of protein S, 
I demonstrate the likely proximal spatial location of these three residues, see 
Figure 3.19, and their relationship to protein S Face2 residues. 
 
 
Figure 3.18 Conservation of Asp78, Gln79 and Asp95 across species. 
The sequence of human protein S between amino acid residue 76 and 114 is shown. Asp95 (in 
red), and Gln79 (in purple) are conserved throughout species. Asp78 (in blue) is conserved 
across species with the exception of birds where Asp78 is replaced by the structurally similar 
Asn78. 
 
 
Figure 3.19 Location of Asp78, Gln79, Asp95 and Face2 within the protein S Gla-TSR-EGF1 
model. 
Domains are labelled on the right hand side cartoon model. Residues mutated in the protein S 
Face2 variant, Asp78, Gln79 and Asp95 are in light gray in the left hand side surface model. 
Residues Asp78, Gln79 and Asp95 are highlighted by the box to show their proximal spatial 
location. The model is that of Villoutreix et al..
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I have investigated the mechanism of reduction of activity of protein S Asp95 
variants. Asn136, in the EGF2 domain, Asn178 in the EGF3 domain and Asn217 
in the EGF4 domain are all β-hydroxylated. These and other residues that are 
part of the calcium binding sequence motif in the respective domains have all 
been shown to coordinate a calcium ion with high affinity (Figure 3.20).258 The 
EGF1 domain of protein S has not been shown to contain a calcium binding 
site.258 The calcium binding motif in EGF1 is only partially conserved and 
according to the protein S Gla-TSR-EGF1 model of Villotreux et al.193 residues of 
the calcium binding sequence motif before the first Cys residue and between the 
third and fourth Cys residues are localised on opposite sides of the EGF1 
domain. However, to be sure that substitution of Asp95 to Ala did not result in 
disruption of a potential calcium binding site, I substituted Asp95 to Asn rather 
than Ala. Asn is structurally similar to Asp, can be β-hydroxylated and is able to 
coordinate a calcium ion (as has been observed in EGF2, 3 and 4).  
 
Figure 3.20 EGF domains of protein S and binding to calcium. 
β-hydroxylated residues in the EGF domains of protein S are highlighted in yellow. The Kd values 
of each domain for calcium is shown above each domain. Kd values were taken and the EGF 
diagram modified from Stenflo et al..
258
 The calcium binding sequence motif is shown in the box, 
in the red squares in the sequence alignment of the EGF domains of protein S and the specific 
residues are circled in red in the EGF diagram. 
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However, as the protein S D95N variant also had reduced activity, it is unlikely 
that disruption of a calcium binding site is responsible for this effect as this variant 
would be predicted to bind calcium normally. Furthermore, while Asp95 is known 
to be β-hydroxylated it has previously been shown that β-hydroxylation itself is 
not a requirement for anticoagulant activity of protein S.179 My work favours a 
direct effect of Asp95 in APC cofactor activity. However, I can not discount the 
possibility that the dramatic effect on protein S activity of the Asp95 residue 
substitution could be through a conformational repositioning of other functional 
domains. To assess this I performed binding to phospholipids, as this property 
underpins all protein S function. Plate binding assays, however, indicated no 
major functional defect on phospholipid binding. Furthermore, domain specific 
monoclonal antibody binding to WT and variant protein S (against the Gla 
domain, the EGF1 domain and the C-terminal SHBG domain) was also normal, 
suggesting that substitution of Asp95 does not reduced APC cofactor function by 
disrupting adjacent domain structure.  
A current view of protein S enhanced APC cofactor activity suggests a functional 
repositioning of the APC cleavage site away from FVa Arg506 towards FVa 
Arg306.228 I therefore performed a FVa inactivation assay using a FVa variant, 
FVa R506Q/R679Q, that cannot be cleaved at position 506 and 679. This allowed 
me to specifically analyse cleavage at Arg306 by APC. This is the APC cleavage 
site in FVa that is mainly enhanced by protein S. Using both concentration 
dependent and time course assays, I was able to confirm reduced cleavage of 
this variant by APC in the presence of protein S D95A or protein S Face2. 
Importantly, the single point variant protein S D95A had more impaired cofactor 
activity towards APC mediated cleavage of FVa R506Q/R679Q than the 
previously described 7 amino acid prothrombin swap variant Face2. 
The available results therefore suggest that Asp95 of protein S may play an 
important and a direct role in APC recognition, resulting in enhanced APC 
function. This is compatible with the study performed by Hackeng et al.,246 who 
used the isolated EGF1 domain of protein S to functionally disrupt the protein S 
and APC interaction. They showed a direct binding of EGF1 to APC suggesting 
EGF1 as a potentially important APC contact site on protein S. My results 
suggest that Asp95 constitutes a critical residue within EGF1 mediating the APC 
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cofactor function. Together with Asp78 and Gln79, Asp95 could form an important 
functional interaction site for APC. 
The importance of residues in protein S Face2 should be further investigated. 
Phospholipid binding and binding to monoclonal antibodies were not evaluated in 
my thesis but should also be reassessed. Saller et al. found no significant 
difference in binding to monoclonal antibodies, however, binding of protein S 
Face2 to the monoclonal antibody MK54 against the EGF1 domain had a slightly 
higher Kd(app) value (5.0 ± 1.7 nM) in comparison with that of WT protein S (1.6 ± 
0.3 nM).224 It is possible that protein S Face2 has reduced APC cofactor activity 
primarily because so many residues have been substituted: this may cause a 
conformational change in regions important for direct interaction with APC. In all 
my experiments the APC cofactor activity of the single point variant protein S 
Asp95 was more pronounced than that of the 7 residue prothrombin swap in 
protein S Face2. Thus, to identify the mechanism of reduced APC cofactor 
activity of Face2 binding to monoclonal antibodies should be repeated and point 
variants of the 7 amino acids substituted in protein S Face2 should be made and 
evaluated in functional assays. 
Face1 had previously been shown not to bind phospholipids.224 Interestingly, 
when protein S Face1 was evaluated for its binding to phospholipids surfaces, I 
found that it was able to bind phospholipids with a similar affinity to WT protein S 
(n=1). Analysis of protein S Face1 to phospholipids (n=3) has been subsequently 
further evaluated by my colleague Dr Josefin Ahnstöm, who found no statistical 
difference between WT protein S and protein S Face1 in binding to phospholipids. 
To identify which residue(s) in the composite variant protein S Face1 is important 
for APC cofactor activity she made the individual point variants contained in 
protein S Face1; protein S N33S, protein S P35T, protein S E36A and protein S 
Y39V. Analysis by CAT showed that variants protein S P35T and E36A were 
those with most reduced APC cofactor activity (similar to the reduced activity of 
protein S Face1) (as these are results of Dr Josefin Ahnstöm, I have not shown 
them). As proline is known to be important for protein folding and stability, only 
protein S E36A was further investigated (Dr Josefin Ahnstöm). Protein S E36A 
bound phospholipids with a Kd(app) similar to that of WT protein S. The binding of 
protein S Face1 and protein S E36A to domain specific monoclonal antibodies 
against the Gla domain (MK21 and MK47) and the TSR domain (MK67) was also 
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evaluated by my colleague Dr Josefin Ahnström. No difference between protein S 
Face1, protein S E36A and WT protein S was found. When she analysed the 
cofactor activity of protein S E36A in the FVa inactivation assay she found that it 
had only 11.3% of the cofactor activity of WT protein S (n=4). This reduction in 
protein S cofactor activity towards APC mediated cleavage in Arg306 of FVa was 
similar to that of protein S D95A (12.9%) and both were more pronounced than 
that of protein S Face2 (30.3%).  
Residues Asp95, Asp78, Gln79 (red), Gla36 (green) and residues in Face2 (blue) 
are highlighted in the working model of the Gla-TSR-EGF1 domains of protein S 
showing their likely spatial location (Figure 3.21). 
 
Figure 3.21 Location of residues found to have reduced APC cofactor activity. 
The novel residues found to have reduced APC cofactor activity in my project Asp95, Asp78 and 
Gln79 in EGF1 are highlighted in red. Residues in the previously reported protein S Face2 variant 
are shown in blue. The novel residue identified by my colleague Dr Josefin Ahnström, Gla36, is 
highlighted in green. The model is taken from Villoutreix et al..
193
 
 
 
These results suggests that Gla36 of protein S seems to be equally important as 
is Asp95 for APC cofactor function, suggesting that possibly both the Gla and 
EGF1 domains of protein S are important for APC cofactor activity. 
Collectively, our results suggest that Asp95 and Glu36 constitute critical residues 
within the EGF1 and Gla domain of protein S mediating the APC cofactor 
function. 
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3.4 Evaluation of TFPI cofactor activity of protein S 
3.4.1 Evaluation of TFPI cofactor activity of protein S by CAT 
From preliminary results described in section 3.3.1, I decided to use 1 pM TF to 
trigger coagulation in all my plasma assays and to supplement TFPI in the protein 
S deficient plasma. Hence, TFPI cofactor activity of protein S was assayed by 
CAT in protein S deficient plasma supplemented with recombinant TFPI and 
protein S. When 0-5 nM TFPI and 0-120 nM protein S were supplemented in 
protein S deficient plasma from Affinity Biologicals only a very small prolongation 
of lag time and reduction in peak height were observed. I therefore evaluated the 
protein S enhancement of TFPI in protein S deficient plasma supplied by two 
different companies, Affinity Biologicals and Hyphen Biomed. I observed that the 
effect on thrombin generation of TFPI (3 nM) with or without protein S (120 nM) 
varied depending on the source of plasma (Figure 3.22), with a more pronounced 
protein S/TFPI anticoagulant activity being observed in plasma supplied from 
Hyphen Biomed (Panel B) in comparison with that from Affinity Biologicals (Panel 
A). As can be seen in Figure 3.22, while the total protein S/TFPI anticoagulant 
activity in plasma from Affinity Biologicals prolonged the lag time by ~210% and 
reduced the peak height by ~20%, in plasma from Hyphen Biomed the lag time 
was prolonged by ~340% and the peak height reduced by ~65% (Figure 3.22). To 
investigate the difference between the two different sources of plasma my 
colleague, Verity Hockey, determined the amount of total TFPI in an in-house 
ELISA (n=1). This suggested that protein S deficient plasma from Affinity 
Biologicals contained approximately 25%, and Hyphen Biomed approximately 
50%, of the amount of total TFPI present in normal plasma. During the course of 
this thesis it was shown by Castoldi et al. that TFPI can be co-depleted when 
protein S is immunodepleted from normal plasma in the production of protein S 
deficient plasma.241 They also analysed the amount of TFPI in protein S deficient 
plasma from Affinity Biological and found it contained 25.5% of normal TFPI 
antigens levels which is in accordance with our findings. In subsequent 
experiments, protein S deficient plasma supplied by Hyphen Biomed was used, 
as it allowed better visualisation of the protein S/TFPI anticoagulant activity. 
However, to ensure that the effect observed in protein S deficient plasma from 
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Hyphen Biomed was not unique to this plasma, protein S deficient plasma 
supplied from Enzyme Research Laboratories was also tested. Both plasma from 
Hyphen Biomed and Enzyme Research Laboratories showed a similar 
prolongation of the lag time and reduction of the peak height following addition of 
TFPI in the presence and absence of protein S (results not shown). 
In my initial experiments, I used TFPI in concentrated conditioned media that I 
had expressed from a stable cell line in our lab. This was quantified by a 
preliminary ELISA by my colleague Verity Hockey. Later in my project, purified 
TFPI (kind gift of the Chemoserotheraputic Institute Kaketsuken) was used. 
Unless specifically stated, protein S in concentrated conditioned media was used 
in all experiments. 
 
 
Figure 3.22 TFPI anticoagulant activity in the presence or absence of protein S in plasma. 
Purified TFPI (3 nM) was incubated in the presence or absence of protein S (120 nM) in protein S 
deficient plasma from Affinity Biologicals (A) and Hyphen Biomed (B), in the presence of 50 µM 
phospholipids, 65 µg CTI per ml plasma and 1 pM TF. 
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The specificity of the anticoagulant activity seen when supplementing TFPI in the 
plasma in the presence or absence of protein S was confirmed by performing 
CAT assays in presence or absence of inhibitory polyclonal antibodies. Polyclonal 
antibodies against TFPI (100 nM, Figure 3.23, Panel A) or polyclonal antibodies 
against protein S (1.5 µM, Figure 3.23, Panel B) were used. These completely 
inhibited the effect seen when supplementing TFPI and protein S in concentrated 
conditioned media to the plasma. Concentrated conditioned mock media not 
containing protein S and TFPI had no effect on thrombin generation (results not 
shown). 
 
 
Figure 3.23 Influence on thrombin generation of polyclonal antibodies against TFPI and 
against protein S. 
TFPI (2.5 nM) in concentrated conditioned media was incubated in the presence or absence of 
protein S (60 nM) in protein S deficient plasma from Hyphen Biomed. The activity observed by 
supplementing the plasma with TFPI and protein S was reversed by use of 100 nM polyclonal 
antibodies against TFPI (A) or 1.5 µM polyclonal antibodies against protein S (B). 
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While protein C does not circulate in its activated form, there remained a 
possibility that endogenous protein C might be activated in low levels by thrombin 
generated during the assay. To eliminate this possibility, TFPI and protein S were 
supplemented in the protein S deficient plasma in the presence or absence of 130 
nM polyclonal antibodies against protein C (Figure 3.24). The polyclonal 
antibodies had previously been shown to be inhibitory against APC (see Figure 
3.10). No difference in thrombin generation was observed following addition of 
inhibitory antibodies against protein C. This demonstrated that the thrombin 
generated during these assay conditions (i.e. in the absence of TM and EPCR) 
was unable to significantly activate protein C. Any anticoagulant activity of protein 
S was therefore independent of its APC cofactor function. 
 
Figure 3.24 TFPI and protein S anticoagulant activity in plasma in the presence and 
absence of polyclonal antibodies against protein C. 
The effect of TFPI in concentrated conditioned media (2.5 nM) in the absence (Panel A) and 
presence (Panel B) of protein S (60 nM) was assessed in the presence and absence of 130 nM 
polyclonal antibodies against protein C (PC). A representative experiment is shown. The results of 
addition of antibodies against protein C in the presence of TFPI and protein S was confirmed in 
additional experiments (n=3). 
 
 
Once the assay conditions had been set up to guarantee the visualisation and 
specificity of the protein S enhancement of TFPI, I wanted to ensure that my 
different WT protein S preparations all enhanced TFPI to a similar extent. Thus, 
the activity of WT protein S in concentrated conditioned media in the presence of 
TFPI was compared with that of WT protein S purified by either purification 
protocol (see Methodology, section 2.3). Results (n=3) were analysed by a paired 
Wilcoxon test and no statistical difference in terms of thrombin peak height or lag 
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time was observed between the different preparations. Consequently, and 
because of its ready availability, monomeric protein S in concentrated conditioned 
media was preferentially used.  
The TFPI cofactor activity of WT protein S in concentrated conditioned media was 
evaluated by titrating protein S (0-120 nM) in the presence of 3 nM TFPI. As can 
be seen in Panel A of Figure 3.25, WT protein S enhanced TFPI in a dose-
dependent manner. To evaluate whether residues in protein S variants with 
reduced APC cofactor activity (see section 3.3.2) were also important for TFPI 
cofactor activity, protein S Face2 (Panel B), protein S D95A (Panel C), protein S 
D95N (Panel D), protein S D78A (Panel E) and protein S Q79A (Panel F) were 
titrated alongside WT protein S to evaluate their TFPI cofactor activity (Figure 
3.25). To more easily visualise the difference in peak height and lag time between 
the variants and WT protein S, the results were plotted as % change in lag time 
and peak height in comparison with the control (Figure 3.26). Interestingly, Figure 
3.25 and Figure 3.26 show that all variants were able to enhance TFPI 
anticoagulant function. However, protein S variants D95A, D78A and Q79A were 
somewhat less efficient than WT protein S. They all had a reduced lag time (by 
~10-20%) and increased peak height (by ~5-20%) in comparison with WT protein 
S. Protein S D95N had a similar lag time to WT protein S, but an increased peak 
height (by ~10-25%). While protein S Face2 had a reduced effect on the lag time 
(by ~10-20%) compared to WT protein S, its effect on the peak height was 
enhanced (by up to 60%). The titration of WT protein S and protein S D95A was 
performed twice but the percentage effect on peak height and lag time could not 
be expressed as mean ± SD due to the different assay conditions (3 nM vs 2.5 
nM TFPI). The TFPI cofactor activities of protein S variants D95A, D95N, D78A 
and Q79A were in addition evaluated using single protein S concentrations (n=3), 
which confirmed the results obtained from the titration. When the cofactor activity 
of protein S Face2 was reassessed, however, it was generally similar to that of 
WT protein S in terms of lag time, while the effect on peak height was more 
pronounced, suggesting that this variant has enhanced TFPI cofactor activity. To 
further assess the TFPI cofactor activity of protein S Face2 and protein S D95A 
these variants were purified and assessed in the FXa inhibition assay (see 
section 3.4.2.2). 
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Figure 3.25 Thrombin generation in the presence of TFPI and WT protein S, protein S 
Face2, D95A, D95N, D78A or Q79A. 
Thrombin generation was assessed at 3 nM TFPI in concentrated conditioned media in the 
presence of 0-120 nM WT protein S (A), protein S Face2 (B), protein S D95A (C), protein S D95N 
(D), protein S D78A (E) or protein S Q79A (F). Protein S D95N, protein S D78A and protein S 
Q79A could not be evaluated at higher concentrations than those described here due to their 
stock concentrations. 
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Figure 3.26 Change (%) in peak height and lag time of WT protein S, protein S Face2, D95A, 
D95N, D78A and Q79A in comparison with the control. 
The effects of TFPI and protein S on peak height and lag time from Figure 3.26 were expressed 
as a % change in comparison with the control. The % change of WT protein S, protein S D95A, 
protein S D95N and protein S Face2 on lag time and peak height is shown in Panel A and B 
respectively. The % change of WT protein S, protein S D78A and protein S Q79N on lag time and 
peak height is shown in Panel C and D, respectively. 
 
 
 113 
Additional experiments were performed with the EGF1 and EGF2 protein S point 
variants produced by my collaborator Dr S.M Rezende (Universidade Federal de 
Minas Gerais, Brazil). These were screened at 90 nM using 2.5 nM TFPI (Figure 
3.27 and Figure 3.28). The TFPI cofactor activity of protein S T108A, protein S 
N136A, protein S S153A and protein S K155A could not be evaluated due to lack 
of material. As can be seen, observing the lag times and peak heights in Figure 
3.27 and Figure 3.28, most protein S variants had a similar cofactor activity 
towards TFPI to that of WT protein S. Several protein S variants showed a slightly 
enhanced prolongation of the lag time and reduction in the peak height, however, 
none of the 19 variants tested, exhibited greatly reduced TFPI cofactor activity. 
 
 
 
Figure 3.27 Thrombin generation in the presence of TFPI and WT protein S and protein S 
EGF1 and EGF2 point variants.  
Thrombin generation was assessed in protein S deficient plasma supplemented with 2.5 nM TFPI 
in concentrated conditioned media. The cofactor activity of protein S variants, 90 nM, towards 
TFPI was assessed.  
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Figure 3.28 Thrombin generation in the presence of TFPI and WT protein S and protein S 
EGF1 and EGF2 point variants. 
Thrombin generation was assessed in protein S deficient plasma supplemented with 2.5 nM TFPI 
in concentrated conditioned media. The cofactor activity of protein S variants, 90 nM, towards 
TFPI was assessed.  
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As stated in section 3.4.1, two different sources of TFPI were available, TFPI in 
concentrated conditioned media and purified TFPI. When 90 nM WT protein S 
was evaluated for its TFPI cofactor activity towards 2.5 nM purified TFPI (Figure 
3.29, Panel A), a more pronounced anticoagulant activity was observed both in 
terms of prolongation of the lag time and reduction of the peak heights to that 
previously observed when using TFPI in concentrated conditioned media. When 
the anticoagulant activity of TFPI in concentrated conditioned media was 
compared with that of purified TFPI, a difference was observed both in the 
absence and presence of protein S (Figure 3.29, Panel B).  
 
Figure 3.29 Thrombin generation in the presence of purified TFPI and TFPI in concentrated 
conditioned media in the presence and absence of protein S. 
Thrombin generation in protein S deficient plasma was analysed in the presence of 2.5 nM 
purified TFPI in the presence or absence of 60 nM protein S (A). The anticoagulant activity of 
purified TFPI in the presence or absence of protein S was compared to that of TFPI in 
concentrated conditioned media (B). 
 
 
To determine the reason for this discrepancy, I assessed how dependent the total 
anticoagulant activity of TFPI/protein S is upon the concentration of TFPI. 
Consequently, purified TFPI was titrated (2.5, 5 and 7.5 nM) in the presence or 
absence of 60 nM protein S (Figure 3.30). I observed that a small difference, in 
terms of anticoagulant activity, between 2.5, 5 and 7.5 nM TFPI in the absence of 
protein S translated into a large difference in the presence of protein S. Previous 
results (Figure 3.25), in which a titration of protein S was performed at a fixed 
concentration of TFPI, showed only small changes in cofactor activity between 30 
nM increments in concentration of protein S. Taken together, these results 
(Figure 3.25 and Figure 3.30) suggest that the total TFPI anticoagulant activity in 
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the presence of protein S is more dependent upon the TFPI concentration than 
upon the protein S concentration.  
The different anticoagulant activities of TFPI in concentrated conditioned media or 
in fully purified TFPI is likely attributable to inaccuracies in determination of the 
concentration of TFPI in concentrated conditioned media, as this and the initial 
experiments were performed prior to complete optimisation of our in-house TFPI 
ELISA. As TFPI in conditioned media was expressed in HEK293 cells and my 
purified TFPI was expressed in Chinese hamster ovary cells, the glycosylation will 
be different. However, this is unlikely to be the reason behind the discrepancy, as 
the purified TFPI from the Chemoserotheraputic Institute Kaketsuken was shown 
to have the same activity as plasma purified TFPI,259 and the glycosylation from 
human HEK293 cells is likely to be broadly similar to that of plasma TFPI. In 
addition, Huang et al. evaluated the inactivation of FXa both by bacterial and 
mammalian expressed TFPI and found no significant difference, suggesting post-
translational modifications do not play a major role.72 To determine the reason 
behind the discrepancies between the two different sources of TFPI, I believe that 
the ELISA should be repeated in future studies and the TFPI from HEK293 cells 
purified and assessed alongside TFPI from the Chemoserotheraputic Institute 
Kaketsuken in functional assays. 
 
Figure 3.30 Protein S enhancement of TFPI at different concentrations of TFPI.  
Thrombin generation in the presence of different concentrations of TFPI (2.5, 5 and 7.5 nM) was 
assessed in the absence (A) and presence (B) of 60 nM protein S. 
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To ascertain whether the different assay conditions (i.e. source of TFPI and TFPI 
concentration) influenced the outcome of the initial screenings (Figure 3.25, 
Figure 3.27 and Figure 3.28), the activity of some of the protein S variants (60 
nM) was reassessed using 5 nM purified TFPI. Protein S variants Face2, D95N, 
Q79A, T103A and K112A, previously assayed in the presence of 2.5 nM TFPI in 
conditioned media (Figure 3.25 and Figure 3.28) were reassessed using 5 nM 
purified TFPI (Figure 3.31B,C,D). The results obtained with these protein S 
variants were consistent with earlier results, showing that protein S D95N and 
Q79A had somewhat reduced TFPI cofactor activity, while protein S Face2, 
T103A, K112A had slightly enhanced TFPI cofactor activity. This suggests that 
while the total effect of protein S in the presence of TFPI varies between different 
assay conditions, variants with reduced, normal or enhanced TFPI cofactor 
activity in comparison with WT protein S are reproducibly visualised in both assay 
conditions. Protein S variants Face1, Gla1 and TSR, that had not previously been 
assessed for TFPI cofactor activity, were also analysed (Figure 3.31A,C). Of the 
newly screened variants, protein S Gla1 had a similar TFPI cofactor activity to 
that of WT protein S, protein S Face1 had reduced cofactor activity and protein S 
TSR an increased TFPI cofactor activity (Figure 3.31). To further assess protein S 
variants with altered TFPI cofactor activity, protein S TSR, in addition to protein S 
D95A and protein S Face2, were purified and evaluated in the FXa inhibition 
assay. Protein S Face1 has been investigated by my colleague Dr Josefin 
Ahnström.  
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Figure 3.31 Thrombin generation in the presence of TFPI and WT protein S and protein S 
variants.  
Thrombin generation was assessed in protein S deficient plasma supplemented with 5 nM purified 
TFPI. The cofactor activity of protein S variants towards TFPI was assessed at 60 nM.  
 
 
Of the variants screened up to this point for their TFPI cofactor activity in the CAT 
assay, none had completely impaired cofactor activity, in terms of both impaired 
prolongation of the lag time and an impaired reduction of the peak height. In a 
further attempt to identify residues of protein S important for TFPI cofactor 
activity, additional variants in the Gla-TSR-EGF1 domains were made. The Gla-
TSR-EGF1 model193 was used to identify potential new residues to substitute. 
However, not many residues were left to mutate in the Gla domain once those 
close to the ω-loop, γ-carboxylated residues, alanine residues, cysteine residues, 
residues with a buried side chain and those already substituted, were excluded. 
All charged residues in the TSR had already been substituted and had been 
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incorporated into the protein S TSR variant. Polar residue Asn74 in the TSR was, 
however, chosen to create an additional point substitution, protein S N74A, as it is 
in close proximity of the partially conserved calcium binding motif in the EGF1. A 
small cluster of amino acid residues with an exposed R group, not conserved in 
the EGF1 domains of other coagulation factors, were identified on one side of 
EGF1. These were substituted to create the composite variant, protein S NEDM 
(N86A/E87Q/D88A/M91A). Asn74 was also incorporated in this composite variant 
creating composite variant protein S NNEDM. As single point variants might not 
be enough to disrupt protein S cofactor activity towards TFPI, a composite variant 
composed of the previously examined point substitutions K94A, T103A and 
K105A was also made, generating the variant protein S KTK. These residues 
were selected as T103N is a natural protein S variant in which reduction in APC 
cofactor activity could not be fully explained using purified FVa and FVIIIa 
inactivation assays.255 Residues Lys94 and Lys105 were selected as they were 
charged and in close proximity to Thr103, and these three residues formed a 
cluster on a separate side to that of NEDM.  
The new variants were screened by CAT at 60 nM in the presence of 2.5 nM 
purified TFPI (Figure 3.32, Panel A and B). The protein S variants were also 
simultaneously evaluated for their APC cofactor activity as this had not been done 
previously (Figure 3.32, Panel C and D). Protein S N74A had a normal APC 
cofactor activity (Panel C) and a slightly enhanced TFPI cofactor activity (Panel 
A). Composite variants protein S NEDM and protein S KTK had normal APC 
cofactor activity (Panel C), but reduced TFPI cofactor activity (Panel A). The 
addition of the N74A substitution to protein S NEDM, creating protein S NNEDM, 
resulted in a variant with both reduced APC cofactor activity (Panel D) and TFPI 
cofactor activity (Panel B). As can be seen in Figure 3.32 protein S NNEDM has 
reduced APC cofactor activity in comparison with protein S NEDM, however both 
variants have a similar TFPI cofactor activity. To further analyse these variants, 
protein S N74A, KTK, NEDM and NNEDM were purified to assess them in the 
FXa inhibition assay. Purification of protein S NEDM was not successful and it 
could not be re-expressed and purified, due to the time constraints of writing up 
this thesis. Protein S N74A, protein S KTK and protein S NNEDM were, however, 
successfully purified and further analysed in the FXa inhibition assay (see section 
3.4.2.2). 
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Figure 3.32 WT protein S, protein S N74A, KTK, NEDM and NNEDM studied by thrombin 
generation in the presence of TFPI or APC. 
Thrombin generation was assessed in protein S deficient plasma supplemented with protein S 
either in the presence of 2.5 nM TFPI (A, B) or 4 nM APC (Xigris) (C, D). Protein S was used at 60 
nM to evaluate TFPI cofactor activity and 90 nM to evaluate APC cofactor activity. Protein S 
N74A, KTK and NEDM all had normal APC cofactor activity (C). Addition of substitution N74A to 
protein S NEDM creating protein S NNEDM resulted in a partial loss of APC cofactor activity (D). 
Protein S N74A had an increased TFPI cofactor activity, while the cofactor activity of protein S 
KTK and NEDM towards TFPI was reduced (A). Addition of substitution N74A to protein S NEDM 
did not affect its cofactor activity towards TFPI (Panel B in comparison with Panel A). Note that 
APC from Xigris was used in this experiment and was more active than the commercial APC 
preparation mostly used in this thesis (Enzyme Research Laboratories). 
 
3.4.2 Evaluation of TFPI cofactor activity of protein S in the FXa inhibition 
assays 
3.4.2.1 Evaluation of FXa inhibition by WT purified TFPI and protein S 
The FXa inhibition assay was optimised with purified TFPI (Chemoserotheraputic 
Institute, Kaketsuken) and purified plasma protein S (Enzyme Research 
Laboratories). Importantly, a recent paper by Mori et al., (from the 
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Chemoserotheraputic Institute Kaketsuken) showed that the protease inhibitior 
activity of the recombinant purified TFPI towards FXa and TF/FVIIa was identical 
to that of plasma purified TFPI.259 Protein S in media could not be used as an 
unknown protease in both this preparation and the mock media (without protein 
S) was able to cleave the FXa substrate in a dose-dependent manner (results not 
shown). 
To assess the specificity of FXa inhibition by TFPI, purified TFPI (0-8 nM) was 
titrated and was shown to inhibit FXa in a dose-dependent manner (Figure 3.33). 
To assess the cofactor activity of protein S, low concentrations of TFPI (0.5-2 nM) 
were used to maximise the detection of the enhancing effect in the presence of 
protein S. Purified plasma protein S (0-160 nM) was titrated in the presence of 1.5 
nM TFPI (Figure 3.34). A dose-dependent enhancement of TFPI was observed 
suggesting that the activity of TFPI was specifically enhanced by protein S. 
Importantly, protein S did not affect FXa activity in the absence of TFPI (as shown 
in subsequent figures), confirming the high specificity of the assay. 
 
Figure 3.33 Dose-dependent inhibition of FXa by TFPI.  
TFPI (0-8 nM) was incubated with phospholipids (10 µM), CaCl2 (5 mM) and the FXa chromogenic 
substrate S-2765 (200 µM) in a 20 mM Tris-HCl, 140 mM NaCl, 5 mg/ml BSA buffer. The assay 
was started by the addition of FXa (0.5 nM) and the absorbance at 405 nm was read over time. 
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Figure 3.34 Dose-dependent enhancement of TFPI activity by protein S. 
TFPI (1.5 nM) was incubated with 0-160 nM protein S, phospholipids, CaCl2 and the FXa 
chromogenic substrate S-2765. The assay was started by the addition of FXa and the absorbance 
at 405 nm was read over time. 
 
 
As previously reported, the TFPI cofactor activity of protein S was phospholipid 
dependent (Figure 3.35).81 In accordance with the literature,72 TFPI mediated 
inhibition of FXa did not require phospholipids although its activity was 
moderately enhanced by their presence (see effect of TFPI on FXa inhibition in 
Panel A and B of Figure 3.35). This could be due to co-localisation of FXa and 
TFPI on the phospholipid surfaces. FXa binds phospholipids through its Gla 
domain and it has been suggested that the positively charged C-terminal tail of 
TFPI may interact with negatively charged phospholipid surfaces and cell 
surfaces74-76 and FXa79,80. No difference in TFPI inhibition of FXa and protein S 
cofactor activity towards TFPI was observed between 10 and 50 µM 
phospholipids suggesting that saturating amounts of phospholipids were present 
at 10 µM phospholipids. This is potentially important, as protein S has previously 
been shown to have a protein S direct activity (independent of APC and TFPI) 
due to competition for phospholipid surfaces when these are present in limiting 
amounts.189,190,242 
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Figure 3.35 Inhibition of FXa by TFPI and protein S in the absence and presence of 
phospholipids. 
TFPI (1.5 nM) and protein S (20 nM) were incubated with CaCl2, S-2765 with no phospholipids 
(A), 10 µM phospholipid vescicles (B) or 50 µM phospholipid vescicles (C). The assay was started 
by the addition of FXa and the absorbance at 405 nm was measured over time. TFPI inhibition of 
FXa cleavage of S-2765 was observed in the absence of phospholipids (Panel A) but was 
enhanced by their presence (Panel B and C). Protein S enhanced the TFPI mediated inhibiton of 
FXa in the presence (Panel B and C) but not in the absence (Panel A) of phospholipids. Protein S 
did not affect FXa cleavage of S-2765 in the absence of TFPI in any of the experimental 
conditions. 
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3.4.2.2 Evaluation of domains and amino acids of protein S involved in TFPI 
cofactor activity by use of domain specific monoclonal antibodies and 
protein S variants 
In an attempt to identify the domains of protein S important for TFPI cofactor 
activity, monoclonal domain specific antibodies against protein S (kind gift of 
Professor Björn Dahlbäck and Sofia Carlsson, University of Lund, Sweden) were 
used to inhibit protein S enhancement of TFPI. Protein S (20 nM) was 
preincubated in the presence or absence of monoclonal antibody (200-400 nM) in 
the presence of CaCl2 (as some of the antibodies are calcium dependent, the 
final concentration of CaCl2 in the well was 5 mM) for up to 30 minutes. 
Phospholipids and the FXa chromogenic substrate were subsequently added and 
the reaction was started by addition of 0.5 nM FXa (Figure 3.36). None of the 
monoclonal antibodies tested completely inhibited protein S enhancement of 
TFPI. The antibodies against the Gla domain of protein S, MK21 and MK47, 
showed the most inhibition of protein S cofactor activity. However, these 
monoclonal antibodies have previously been reported to inhibit phospholipid 
binding, which is a prerequisite for protein S function.243 It was therefore not 
possible to conclude whether the Gla domain of protein S is involved in an 
interaction with TFPI. Monoclonal antibodies against the TSR domain, the EGF1 
domain, the EGF3-4 domain and the SHBG domain had no or little effect upon 
protein S enhancement of TFPI (Figure 3.36). While this would suggest that the 
epitopes recognised by these antibodies are not involved in an interaction with 
TFPI, it is possible that other amino acid residues within the respective domains 
may be involved and remain accessible. Interestingly, the epitope of the 
monoclonal antibody MK54 against the EGF1 domain of protein S includes 
residue Lys97.260 It is therefore likely that this antibody would inhibit a potential 
interaction involving Asp95 in protein S with TFPI. No monoclonal antibody 
directed against the EGF2 domain was available. 
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Figure 3.36 Inhibition of protein S cofactor activity towards TFPI by monoclonal domain 
specific antibodies. 
Protein S (20 nM) was preincubated in the presence or absence of 200-400 nM of the domain 
specific monoclonal antibody against protein S in the presence of CaCl2 for up to 30 minutes. 
TFPI (1.5 nM), S-2765 and phospholipids were subsequently added and the reaction was started 
by addition of FXa. Monoclonal antibodies against the Gla domain, TSR domain and the EGF1 
domain are shown in Panel A. Monoclonal antibodies directed against the EGF3-4 domain and 
the SHBG domain are shown in Panel B. All data point were normalised against the control. 
Results represents the mean from two different experiments performed in duplicate. The labelling 
TFPI + protein S has been omitted in the presence of the antibody. The domain against which the 
antibody is directed precedes the name of each antibody. 
 
 
Of the over 30 protein S variants screened for their TFPI cofactor activity in 
plasma (section 3.4.1), those of interest were purified and assessed in the FXa 
inhibition assay. Protein S Face2 and protein S TSR had been purified by anion 
exchange chromatography followed by immunoaffinity chromatography and were 
compared with WT protein S purified using the same method. Figure 3.37 shows 
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the protein S Face2 and protein S TSR cofactor enhancing activity in the FXa 
assay compared with that of WT protein S (20 nM) using 1.5 nM TFPI. Both 
protein S Face2 and protein S TSR showed a similar TFPI cofactor activity to that 
of WT protein S. The same results were observed over a range of TFPI (0.75-2 
nM) and protein S (5-40 nM) concentrations (not shown) suggesting residues 
mutated in these variants are not critical for TFPI cofactor activity. This is in 
agreement with the results obtained in the plasma assay. 
 
 
Figure 3.37 TFPI inhibition of FXa in the presence and absence of WT protein S, protein S 
Face2 and protein S TSR. 
TFPI (1.5 nM) was incubated with 20 nM protein S, phospholipids, CaCl2 and the FXa 
chromogenic substrate S-2765. The assay was started by the addition of FXa and the absorbance 
at 405 nm was read over time. 
 
 
When protein S D95A (purified by anion exchange chromatography followed by 
immunoaffinity chromatography) was tested in the FXa inhibition assay, it 
appeared to have a reduced cofactor activity for TFPI. Due to lack of material, 
protein S D95A in conditioned media was re-purified by barium citrate 
precipitation followed by anion exchange chromatography alongside WT protein 
S, protein S N74A, KTK and NNEDM. Protein S variants (20 nM) were screened 
for their TFPI cofactor activity at 1.5 nM TFPI and were compared with WT 
protein S purified in the same way. Protein S KTK and protein S N74A had TFPI 
cofactor activities similar to that of WT protein S, as can be seen in Figure 3.38. 
The cofactor activities of protein S D95A and protein S NNEDM were, however, 
reduced in comparison with that of WT protein S (Figure 3.38). These results are 
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in agreement with those obtained in plasma, with the exception of protein S KTK 
which exhibited reduced cofactor activity in plasma. 
None of the protein S preparations affected FXa cleavage of S-2765 in the 
absence of TFPI (results not shown). To further investigate the protein S cofactor 
activity for TFPI, kinetic assays were performed to allow determination of the Ki 
values and, consequently, to quantify the difference between WT protein S and 
protein S variants. 
 
 
Figure 3.38 TFPI inhibition of FXa in the presence and absence of WT protein S, protein S 
D95A, protein S N74A, protein S KTK and protein S NNEDM. 
TFPI (1.5 nM) was incubated with 20 nM protein S, phospholipids, CaCl2 and the FXa 
chromogenic substrate S-2765. The assay was started by the addition of FXa and the absorbance 
at 405 nm was read over time. 
 
 
3.4.2.3 Kinetic analysis of TFPI mediated inhibition of FXa in the presence and 
absence of protein S 
To calculate the inhibition constant, Ki, of TFPI for FXa, the Km for the hydrolysis 
of the chromogenic substrate S-2765 by FXa was first determined. The FXa 
inhibition assay was performed as described in section 2.7 but in the absence of 
TFPI and protein S and at a fixed concentration of FXa (0.5 nM). The substrate 
was titrated (0-1200 µM) and the initial velocity V0 was plotted against the 
substrate concentration (Figure 3.39). Curve fitting of the initial velocities allowed 
determination of the Km. A Km of 46.3 ± 11.7 µM was obtained from four different 
experiments performed in duplicate. This is compatible with the Km of 42.6 ± 2.3 
µM reported by Broze and colleagues.72 
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Figure 3.39 Determination of the Km of FXa for the chromogenic substrate S-2765. 
The Km of the hydrolysis of S-2765 by FXa was determined by titrating the substrate over the 
range 0-1200 µM in the presence of phospholipids and CaCl2 and in the absence of TFPI and 
protein S. A representative experiment is shown (A). The mean ± SD of the V0 from four 
independent experiments performed in duplicate was plotted against the concentration of the 
substrate (B). A Km of 46.3 ± 11.7 µM was obtained.  
 
 
When the FXa inactivation assay was started either by the addition of FXa (as 
described by Ndonwi et al.238) or substrate and TFPI (similar to what was 
described by Hackeng et al.81), a difference in the V0 was observed in the 
presence of TFPI and protein S. While the respective absorbance values at 30 
minutes were similar, the shapes of the curves were appreciably different. When 
the assay was started with FXa, the data points describing the protein S 
enhancement of TFPI formed a distinctive curve with a high V0 (Figure 3.40, 
Panel A). However, when the assay was started with the addition of substrate and 
TFPI, the protein S enhancement of TFPI was more linear and resulted in a lower 
V0 (Figure 3.40, Panel B). These differences can be more easily visualised by 
looking at the first 5 minutes of the assay (Figure 3.40 C and D). An explanation 
for these discrepancies is not yet available.  
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Figure 3.40 FXa inhibition assay started by the addition of FXa or by the addition of TFPI 
and S-2765. 
Protein S (100 nM) enhancement of TFPI (0-4 nM) was evaluated. The assay was started either 
by addition of FXa (A) or addition of TFPI and S-2765 (B). Panels C and D shows the first 5 
minutes of the results shown in Panel, A and B, respectively. Representative graphs are shown. 
 
 
As the Ki of TFPI for FXa is dependent upon calculation of the V0, the FXa 
inhibition assay was started with TFPI and S-2765 where a change in V0 is more 
readily seen. The Ki values of TFPI in the presence or absence of protein S 
determined in the literature were derived by starting the FXa inhibition assay with 
FXa and then, after approximately 5 minutes, dispensing TFPI.81 To determine 
the Ki, the timepoint at which TFPI was added was considered to be timepoint 
zero. As no dispenser was available for my experiments, the Ki values of TFPI in 
the presence or absence of protein S were determined by starting the FXa 
inhibition assay with a mix of substrate and TFPI. Titration of 0-8 nM TFPI was 
performed in the absence of protein S. As protein S efficiently enhances TFPI, the 
concentration of TFPI was lowered to 0-4 nM when using 100 nM protein S. 
Figure 3.41 shows the activity of TFPI in the absence (Panel A) and presence of 
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WT protein S purified by anion exchange chromatography followed by 
immunoaffinity chromatography (Panel B) or of WT protein S purified by barium 
citrate precipitation followed by anion exchange chromatography (Panel C). This 
is expressed in Figure 3.41, Panel D as a change in V0 at increasing 
concentrations of TFPI in the presence or absence of protein S. The V0, derived 
from the fitted equations in PanelA-C, has been expressed as a percentage of 
Vmax (which corresponds to the V0 obtained in the absence of TFPI). The results 
in Panel D represent the mean ± SD of three independent experiments. As can 
be seen in Panel D of Figure 3.41 both WT preparations enhanced TFPI to a 
similar extent. 
 
Figure 3.41 FXa inhibition by TFPI in the presence and absence of WT protein S. 
TFPI (0-8 nM) was titrated in the absence (A) or presence of 100 nM WT protein S purified by 
anion exchange chromatography followed by immunoaffinity chromatography (B), or by barium 
citrate precipitation followed by anion exchange chromatography (C). The change in V0 at 
increasing concentrations of TFPI in the presence or absence of WT protein S is shown in Panel 
D as mean ± SD from three independent assays. Anion chr, purified by barium citrate precipitation 
followed by anion chromatography; Affinity chr, purified by anion exchange chromatography 
followed by immunoaffinity chromatography. 
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Protein S D95A and protein S Face2 previously found to be critical for APC 
cofactor activity and protein S NNEDM, which had reduced TFPI and APC 
cofactor activity in the plasma assay, were assessed at 100 nM, at increasing 
concentrations of TFPI (0-4 nM). Protein S KTK was also assessed. Protein S 
KTK had normal APC cofactor activity. While plasma assays suggested it had 
reduced TFPI cofactor activity, its activity in the FXa inhibition assay seemed 
normal. The change in V0 in the presence or absence of the protein S variants in 
comparison with WT protein S purified in the same way is shown in Figure 3.42. 
Protein S Face2 (Panel A), protein S KTK (Panel B) and protein S D95A (Panel 
C) all showed similar dose-dependent changes in V0 to that of WT protein S. 
Protein S NNEDM (Panel D), however, had a reduced cofactor activity towards 
TFPI, visualised as a smaller reduction in V0. 
 
 
Figure 3.42 Change in V0 at increasing concentrations of TFPI in the presence or absence 
of protein S.  
TFPI (0-8 nM) was titrated in the presence or absence of 100 nM protein S. The graphs show the 
change in V0 at increasing concentrations of TFPI in the presence or absence of protein S Face2 
(A), protein S KTK (B), protein S D95A (C) and protein S NNEDM (D). Data points are expressed 
as the mean ± SD from three independent experiments. Anion chr, purified by barium citrate 
precipitation followed by anion exchange chromatography; Affinity chr, purified by anion exchange 
chromatography followed by immunoaffinity chromatography. 
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To quantify the difference between WT protein S and the protein S variants, the Ki 
values were determined. This was done by plotting the Vmax/V0 against the 
concentration of TFPI. The x intercept was then used to calculate the Ki, as 
described in section 2.7.3. Differences in Ki values obtained were analysed using 
an unpaired t-test. 
There was no significant difference between the Ki values obtained with WT 
protein S purified by anion exchange chromatography followed by immunoaffinity 
chromatography (Ki= 0.13 ± 0.03 nM) or WT protein S purified by barium citrate 
precipitation followed by anion exchange chromatography (Ki= 0.19 ± 0.04 nM) 
(Table 3.4).  
When protein S variants were compared to WT protein S purified using the same 
method, there was no significant difference between protein S Face2 and WT 
protein S in terms of Ki values (Table 3.4). This is in agreement with what I had 
seen in the single concentration screening assay (Figure 3.37). Confirming what 
was observed in the single concentration screening assay (Figure 3.38), protein S 
KTK enhancement of TFPI inhibition of FXa was not significantly different from 
WT protein S (Table 3.4). Interestingly, while protein S D95A seemed to have 
reduced cofactor activity towards TFPI at 20 nM in the screening assays (Figure 
3.38), no difference was observed at 100 nM protein S which was used to 
determine the Ki of TFPI activity (Table 3.4). Importantly, my experiments with 
protein S NNEDM confirmed results obtained in the screening assay (Table 3.4).  
Protein S NNEDM had reduced TFPI cofactor activity (Ki = 0.91 ± 0.35 nM) in 
comparison with WT protein S (Ki = 0.19 ± 0.04 nM). While some of the residues 
in protein S NNEDM might be important for cofactor activity towards TFPI 
mediated inhibition of FXa, this variant also had reduced APC cofactor activity. 
Evaluation of protein S NEDM, which had normal APC cofactor activity might 
therefore provide interesting results in future experiments.  
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 Ki (nM) 
TFPI 3.49 ± 0.96 
WT protein S (anion chr) 0.19 ± 0.04 
Protein S 95A 0.21 ± 0.06 
Protein S KTK 0.24 ± 0.05 
Protein S NNEDM 0.91 ± 0.35 
WT protein S (affinity chr) 0.13 ± 0.03 
Protein S Face2 0.12 ± 0.02 
 
Table 3.4 Inhibition constants for TFPI inhibition of FXa in the presence or absence of 
protein S. 
Ki values (nM) for WT protein S and protein S variants were determined from the x intercept 
obtained by plotting the Vmax/V0 values against TFPI concentration. Results are expressed as the 
mean ± SD from three independent experiments. WT protein S (anion chr) is protein S purified by 
barium citrate precipitation followed by anion exchange chromatography. WT protein S (affinity 
chr) is protein S purified by anion exchange chromatography followed by immunoaffinity 
chromatography. 
 
 
3.4.3 Discussion 
The CAT assay to assess protein S cofactor activity towards TFPI was initially set 
up. This assay allows evaluation of the cofactor activity of protein S towards TFPI 
in a plasma milieu, potentially representing a more physiological environment 
than purified systems. When I began my thesis, a method to evaluate protein S 
cofactor activity towards TFPI by CAT in protein S deficient plasma had not been 
published. However, recently Maurissen et al. were able to reproducibly study the 
TFPI/protein S anticoagulant activity by CAT in normal plasma.240 This was 
achieved by using inhibitory polyclonal antibodies against TFPI and protein S. 
During my thesis, I noticed differences in the anticoagulant activity of TFPI and 
protein S supplemented to protein S deficient plasma from different suppliers. 
Generally, as can be seen by the different peak heights (Figure 3.22), the protein 
S deficient plasma from Hyphen Biomed was less procoagulant that that of 
Affinity Biologicals. This is likely to influence the total TFPI/protein S anticoagulant 
activity as the latter has been shown to be dependent upon TF concentrations, 
and therefore the procoagulant environment.218 Alternatively, the reported 
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difference in the concentration of endogenous TFPI between the different plasma 
preparations might be important. Co-depletion of full-length TFPI following 
removal of protein S during the production of protein S deficient plasma has 
recently been shown by Castoldi et al..241 However, differences in endogenous 
TFPI concentrations alone, are unlikely to explain the differences I observed 
between the different plasma preparations. Firstly, because the exogenous full-
length TFPI (~2.5 nM) supplemented to the protein S deficient plasma exceeds 
by far the endogenous full-length TFPI (~0.25 nM) the total amount of TFPI in the 
two different plasma preparations were fairly similar. Secondly, the anticoagulant 
activity of 5 nM TFPI and protein S in plasma from Affinity Biomed was less than 
that observed using 2.5 nM TFPI and protein S in plasma from Hyphen Biomed 
(results not shown). Therefore, it is possible that co-depletion of other coagulation 
factors might account for the differences observed between the two plasma 
preparations, Affinity Biological and Hyphen Biomed. 
It is interesting to note that the protein S/TFPI anticoagulant activity influences 
both the peak height, ETP and the lag time. This is in contrast with what is 
observed in the presence of APC, where protein S cofactor enhancement results 
mainly in an effect on peak height and ETP. Compatibly with my results, Hackeng 
and Rosing observed both a reduction in peak height and prolongation of the lag 
time following addition of TFPI to TFPI depleted plasma.261 Other studies 
evaluating protein S enhancement of TFPI anticoagulant activity have been 
carried out in normal plasma. When Brodin et al. evaluated the effect of addition 
of recombinant TFPI to normal plasma, they noticed a prolongation of the lag time 
but saw no effect on the ETP.253 Similarly, when they inhibited endogenous TFPI 
with antibodies, a shortening in the lag time but no effect on the ETP was 
observed. Previous reports have also shown that protein S, in the absence of 
APC, affects the lag time but not the ETP.262 This study, however, combined 
protein S deficient plasma with different percentages of normal plasma, thus 
potentially confounding any effect of differences in other coagulation factors 
between the two plasma preparations. In contrast, when I supplemented TFPI to 
normal plasma (results not shown) I observed both an effect on the peak height 
and a prolongation of the lag time. Maurissen et al. assessed TFPI anticoagulant 
activity and its enhancement by protein S in normal plasma using inhibitory 
antibodies and showed a change in peak height, but not in lag time.240 The 
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discrepancies between results from different protein S deficient plasma 
preparations and between protein S deficient plasma and normal plasma do not 
have a coherent explanation. It is possible that co-depletion of other coagulation 
factors contribute to the different TFPI/protein S anticoagulant activity observed 
between different plasma preparations. Considering that plasma levels of FV 
have been shown to correlate with full-length TFPI plasma levels, that TFPI and 
FV potentially form a complex in vivo,263 that depletion of full-length TFPI results 
in co-depletion of FVa,241 together with the observation that FV levels have been 
shown to influence the lag time in the CAT assay,262 it should be evaluated if 
differences in FV level could contribute to the differences observed between 
normal and protein S depleted plasma. 
To decrease intra-assay variability, variability between different sources of 
plasma and variabilities between different laboratories, parameters such as 
supplier of the plasma, potential differences between lyophilised and frozen 
plasma, batch variability of the plasma, source of TF, source of phospholipids, 
preincubation of additional components to the plasma, plasma dilution and 
temperature should all be carefully considered.218,262,264,265 
In this thesis, the TFPI anticoagulant activity in the presence or absence of 
protein S was evaluated in protein S deficient plasma from Hyphen Biomed and 
the specificity of the assay was demonstrated with inhibitory antibodies against 
TFPI, protein S or protein C. As observed for APC (section 3.3.2), no significant 
difference in TFPI cofactor activity was observed between protein S in 
concentrated conditioned media and purified protein S. The assay developed 
during this thesis allowed visualisation of a clear TFPI effect and its enhancement 
by protein S. I also showed that the protein S activity in the presence of TFPI is 
highly dependent on the TFPI concentration and its anticoagulant activity. This is 
compatible with results of Hackeng and Rosing in their recent review paper in 
which TFPI depleted plasma was supplemented with TFPI in the presence or 
absence of inhibitory antibodies against protein S.261 The dependence of the 
protein S/TFPI anticoagulant activity upon the TFPI concentration might be 
partially explained by the fact that the normal concentration of protein S present in 
plasma (free ~145 nM, total ~362 nM) is in vast excess over that of free full-length 
TFPI (~0.25 nM).  
 136 
The inter-assay variability was quite large making it difficult to pool data from 
multiple assays. The CAT assay used in this thesis was, however, an efficient 
screening tool to identify protein S variants with reduced, normal or enhanced 
TFPI cofactor activity in comparison to WT protein S. Protein S variants in 
concentrated conditioned media were evaluated both for their ability to reduce the 
peak height of thrombin generated and to prolong the lag time. Of the 31 protein 
S variants screened for their TFPI cofactor activity by CAT none had completely 
ablated activity. Twenty-three protein S variants had normal to enhanced activity 
in comparison with WT protein S (Table 3.5). The protein S variants previously 
found to have reduced APC cofactor activity protein S D95A, D95N, D78A and 
Q79A had approximately 80% of WT protein S cofactor activity towards TFPI 
(Figure 3.25). Interestingly, protein S Face2, which had decreased APC cofactor 
activity, reduced the peak height of thrombin to approximately half of that of WT 
protein S (at 90-120 nM) in the presence of TFPI (Figure 3.25 and Figure 3.31). 
Protein S KTK, NEDM, NNEDM and Face1 (Table 3.5) showed reduced cofactor 
activity towards TFPI in comparison with WT protein S when screened by CAT 
(Figure 3.31 and Figure 3.32). This was visualised mainly as a change in lag time 
rather than in a change of peak height in comparison to WT protein S.  
 
TFPI cofactor activity 
compared to WT protein S 
Protein S variants 
Normal to enhanced 
Gla1, Face2, TSR, N74A, K94A, K97A, S99A, T101A, T103A, 
K105A, P106A, Q109A, E111A, K112A, D135A, T137A, 
Y141A, H142A, S144A, K146A, N154A, K156A, D157A 
Reduced Face1, KTK, NEDM, NNEDM, D78A, Q79A, D95A, D95N 
 
Table 3.5 TFPI cofactor activity of protein S variants in comparison with WT protein S in 
plasma studied by CAT assay.  
Any variant which in the CAT assay had shorter lag time or increased peak in comparison with 
WT protein S was classified in this table as having reduced activity compared to WT protein S. 
 
 
Protein S variants Face2 and D95A, found to be important for APC cofactor 
activity, were purified and evaluated for their TFPI cofactor activity in the FXa 
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inhibition assay. Protein S KTK and NNEDM which had reduced TFPI cofactor 
activity in plasma were also purified and assessed in the FXa inhibition assay. 
Protein S N74A and TSR which had normal APC cofactor activity and normal to 
enhanced TFPI cofactor activity in plasma were also analysed in the FXa 
inhibition assay. 
The FXa inhibition assay has the advantage of being a well established assay 
and allows specific evaluation of TFPI mediated inhibition of FXa without the 
complexity associated with normal plasma assays.68,72,78,81,237 Importantly, 
purified protein S alone does not affect FXa cleavage of the chromogenic 
substrate S-2765 in the absence of TFPI ensuring the assay specifically assesses 
TFPI cofactor activity of protein S. A screening assay using 1.5 nM purified TFPI 
and 20 nM purified protein S was performed. Results from the screening assay 
showed that protein S variants Face2, TSR, KTK and N74A all had similar TFPI 
cofactor activity to that of WT protein S. Protein S D95A and protein S NNEDM, 
however, had a reduced TFPI cofactor. My colleague Dr Josefin Anhnström 
evaluated the cofactor activity of protein S E36A (a substitution present in the 
Face1 variant that had reduced APC cofactor activity, see section 3.3.6) and 
found it enhanced TFPI mediated inhibition of FXa to the same extent as WT 
protein S. 
To more accurately quantify the differences between WT protein S and protein S 
variants, I derived the Ki values for TFPI inhibition of FXa in the presence of 
protein S. WT protein S reduced the Ki of TFPI in the absence of protein S from 
3.49 nM to 0.13-0.19 nM, enhancing TFPI inhibition of FXa by 18-27-fold. The Ki 
values of protein S Face2, D95A, KTK and NNEDM were determined. No 
statistical difference between the Ki obtained in the presence of protein S Face2, 
D95A, KTK with that of WT protein S was found. Protein S NNEDM, however, 
enhanced TFPI inhibition of FXa only by ~3.8-fold in contrast to the ~18-fold of 
WT protein S. These kinetic results were in agreement with results from the 
screening in the FXa inhibition assay, with the exception of protein S D95A. While 
protein S D95A had reduced TFPI cofactor activity in the screening experiment in 
the FXa inhibition assay, the Ki value obtained with 100 nM protein S was not 
statistically different from that of WT protein S. It is possible that while at lower 
protein S concentrations protein S D95A is not as efficient as WT protein S, this is 
overcome at saturating concentrations of protein S. Overall, results from the FXa 
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inhibition assay correlate relatively well with those from the plasma assay, 
considering the intrinsic differences of the two assays. The main exception is 
protein S KTK, which had reduced TFPI cofactor activity in plasma and normal 
TFPI cofactor activity for the inhibition of FXa. The reason for this discrepancy still 
needs to be evaluated. 
Importantly, results from the plasma based assay and the purified FXa inhibition 
assay suggest that protein S D95A, protein S Face2 and protein S E36A (result of 
Dr Josefin Anhnström, not shown) were able to enhance TFPI mediated inhibition 
of FXa to a similar extent as WT protein S. This is of considerable importance as 
it suggests distinct residues in protein S interact with APC and TFPI.  
Further work has to be done to identify residues in protein S involved in TFPI 
cofactor activity. Experiments with protein S KTK should be repeated to evaluate 
if there are any significant differences between the plasma based assay and the 
purified assay, and if so to determine the reason for any discrepancy. Protein S 
NNEDM had reduced TFPI cofactor but also reduced APC cofactor activity. 
Importantly, protein S NEDM had reduced TFPI cofactor activity and normal APC 
cofactor activity. Protein S NEDM should be purified and analysed in the FXa 
inhibition assay. 
Further work also needs to be done in order to fully optimise the plasma based 
assay and potentially also the FXa inhibition assay. In the first instance the inter-
assay variability of the plasma based assay has to be improved. Secondly, the 
different effect on V0 in the FXa inhibition assay according to how the assay is 
started (Figure 3.40) has to be rationalised. While the reason for this is not clear, 
it might explain why Ndonwi et al.238 quantifies the protein S enhancement of 
TFPI as a change in Vs determining the EC50 and Hackeng et al.
81 as a change in 
V0 determining the Ki. To get accurate V0 results a dispenser should also be 
used. Protein S enhancement of TFPI mediated inhibition of TF/FVIIa should also 
be assessed as this potentially represents a mechanism that occurs in plasma. 
Results obtained during my thesis would suggest that substitution of a single 
residue of protein S is not enough to disrupt its cofactor activity towards TFPI. 
Even if protein S and TFPI interact through multiple interaction sites it is unlikely 
that residues substituted in my thesis and found to have normal to enhanced 
TFPI cofactor activity are involved in a critical way in the interaction with TFPI. 
Figure 3.43 shows the residues in protein S substituted in the Gla-TSR-EGF1 
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domain and analysed in this thesis (blue). Red residues in Figure 3.43 represent 
amino acids potentially involved in phospholipid binding, alanine residues or 
cysteine residues and are therefore not good candidates to substitute. Similarly, 
yellow residues represent residues which are predicted to have their R group 
buried inside the protein S structure. This leaves only few clusters of residues in 
these domains, of which only two charged residues, that have not been mutated 
during this thesis (gray) and could be evaluated alongside protein S KTK and 
NEDM. Alternatively, the interaction site between protein S and TFPI is not 
located at the sites and domains evaluated in this thesis. 
 
 
Figure 3.43 Residue substitutions in the Gla-TSR-EGF1 domains made during this project. 
Residues substituted during this project, either as single or composite variants, are coloured in 
blue. Residues in red and yellow were not mutated because their likely involvement in 
phospholipid binding, because they are alanine or cysteine residues or because their R group is 
buried within the protein S structure. Protein S model from Villoutreix et al..
193
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4 CONCLUDING REMARKS 
It is well established that protein S acts as a cofactor for APC. Recently, different 
groups have shown that protein S is also able to act as a cofactor for TFPI.81,237 
The aim of my project was to elucidate the molecular mechanism behind these 
interactions by identifying the residues in protein S involved in APC and TFPI 
cofactor activity. To address this aim, more than 30 protein S variants were 
created by site-directed mutagenesis, expressed and characterised for their 
cofactor activities towards both APC and TFPI. In this concluding chapter, I will 
attempt to put into context the results achieved during my PhD with what is 
already known in the literature. I will first address the issue of protein S cleavage, 
multimerisation and binding to phospholipids. I will postulate an interaction 
mechanism between protein S and APC, I will discuss the potential interaction 
and mechanisms regulating TFPI cofactor activity of protein S, and I will 
speculate on the regulation of protein S cofactor activity in vivo based on the 
novel results in this thesis and on recent results from the literature. 
 
4.1 Protein S cleavage, multimerisation and its binding to 
phospholipids 
It has been shown that 10-15% of plasma protein S circulates in a cleaved 
form.178 The protease responsible for this cleavage in vivo is still not known and 
the effect of cleavage upon APC-dependent and APC-independent cofactor 
activity of protein S is still under debate.175-177 It has been suggested that 
cleavage at both Arg49 and Arg70 affects protein S binding to phospholipids.176 
During this thesis cleavage of protein S was sometimes observed in processed 
concentrated conditioned media. Because of this, cleavage of protein S was 
minimised by keeping the time of processing of protein S as short as possible. 
Because of the issue of cleavage, I preferred using protein S in concentrated 
conditioned media rather than purified samples. I also aliquoted protein S to avoid 
extensive freeze thawing. Cleavage of protein S variants was formally assessed 
by performing SDS-PAGE under reducing conditions. WT protein S, protein S 
D95A and protein S Face2 in concentrated conditioned media were all analysed 
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by Western blot and this confirmed that no cleavage products were present. 
Purified WT protein S, protein S D95A and protein S Face2 were analysed by 
silver staining to make sure they were not more cleaved than WT protein S. 
These precautions suggest that reduced APC cofactor activity of these variants 
was not a consequence of increased cleavage. 
The formation of protein S multimers is well documented in the literature.189-192 It 
is not yet clear what causes multimer formation or how to prevent it. While some 
reports suggest that protein S multimers already exists in the blood,189,190 others 
claim it is a consequence of in vitro manipulation.191,192 It has been hypothesised 
that it is a result of 1) purification, 2) removal of Ca2+ ions, 3) concentration, or 4) 
spontaneously occurs over time. The effect of multimers on the ability of protein S 
to bind to phospholipids and to act as a cofactor for APC or TFPI is still being 
debated.189-192 It has been shown that multimeric protein S is able to bind to 
phospholipids with a higher affinity than monomeric protein S.191 APC- and TFPI-
independent activities of purified multimeric protein S due to competition for 
phospholipids have also been documented at limiting amounts of 
phospholipids.191,192,216,217 
Multimer formation was analysed during my work using Western blot of protein S 
from native gels. Protein S in concentrated conditioned media and plasma protein 
S both appeared monomeric. Partial purification on the anion exchange QFF 
column by FPLC resulted in protein S preparations that were largely monomeric 
with trace amounts of dimers being present. Purification by immunoaffinity 
chromatography or by barium citrate precipitation of protein S, however, definitely 
lead to multimer formation. Commercial plasma purified protein S from Enzyme 
Research Laboratories also appeared multimeric using this technique. 
Accordingly, functional assays to assess protein S cofactor activity towards APC 
and TFPI were carried out both with monomeric protein S in concentrated 
conditioned media (where assay conditions permitted this) as well as with 
multimeric purified protein S. Saturating amounts of phospholipids are also used 
in all assays. 
Protein S is a plasma protein whose functionality is dependent upon its ability to 
bind to phospholipid surfaces through its Gla domain. Binding to phospholipids 
requires post transcriptional γ-carboxylation of the glutamic acid residues in the 
Gla domain of protein S by the vitamin K-dependent γ-carboxylase.171 Variations 
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in the efficiency of γ-carboxylation of protein S variants secreted from HEK293 
cells can therefore potentially influence the cofactor activity of protein S measured 
in the functional assays. Variants of interest in concentrated conditioned media 
were analysed by Western blot and protein S was detected either by a polyclonal 
antibody or an antibody recognising only γ-carboxylated protein S. No difference 
in band intensity with the latter antibodies were observed between WT protein S 
and protein S D95A, suggesting both preparations contained a similar amount of 
γ-carboxylated protein S. γ-carboxylation was also controlled for by purifying WT 
protein S and the variants of interest by methods that selectively removes non γ-
carboxylated protein S. Lastly, protein S was assessed for its ability to bind to 
phospholipids in a plate binding assay. My recombinant barium citrate 
precipitated WT protein S bound to phospholipids with a Kd(app) similar to that 
reported in the literature.182,223-225 Importantly, my colleague Dr Josefin Ahnström 
also confirmed that there was no difference in binding to phospholipid between 
partially and fully purified protein S (results not shown). Protein S D95A was 
assessed for its binding to phospholipid surfaces and there was no significant 
difference in Kd(app) compared to WT protein S. While not formally assessed in this 
thesis, when protein S in concentrated conditioned media was evaluated for its 
ability to bind phospholipid surfaces, a much lower affinity was observed.  
In summary, my results are compatible with those published studies showing that 
monomeric and multimeric protein S have different affinities for phospholipids, 
that protein S circulates in plasma as a monomer and that multimerisation is a 
result of in vitro manipulation.191,192 
 
4.2 APC cofactor activity of protein S; interaction sites and a 
suggested mechanism 
Protein S has been suggested to act as a cofactor for APC in three distinct ways; 
by increasing the affinity of APC to phospholipid surfaces, by relocating the active 
site of APC and by overcoming the protective effect of FVa following binding to 
FXa.127,137,221,228,229  
Protein S circulates in plasma as a monomer and consequently its affinity for 
phospholipids is reduced compared to that reported in the literature for multimeric 
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protein S. The reported affinity of monomeric protein S for phospholipids (Kd(app) 
=250 nM)191 is, however, higher than that of APC (2-7 µM)226,227 suggesting 
protein S enhancement of APC binding to phospholipids might have a 
physiological relevance.  
It is well accepted that protein S enhances mainly the APC mediated cleavage at 
Arg306 of FVa. It has been shown that binding of protein S to APC results in 
relocalisation of the active site of APC closer to the membrane surface.228,229,266 
This relocalisation was proposed to be the mechanism behind protein S induced 
preferential cleavage at Arg306. Binding of protein S might cause a major 
conformational change in APC, resulting in the relocalisation of its active site. A 
recent paper using a FVa variant R306Q/R506Q/R679Q, identified additional 
APC cleavage sites in FVa (in close proximity to Arg306 or Arg506). Protein S 
equally enhanced the cleavage of all these residues (Lys309, Arg313, Arg316, 
Arg317 and Arg505).130 While this does not contradict protein S mediated 
relocalisation of the active site of APC, it argues against the suggestion that this 
relocalisation is how protein S changes the preferential cleavage site of APC from 
Arg506 to Arg306. Tran et al. suggest their results argue against the hypothesis 
that Arg306 and Arg506 are located at different heights above the phospholipid 
surface. Relocalisation of the active site of APC closer to the membrane surface 
has also been observed following construction of APC chimeras containing the 
Gla domain of either FX or prothrombin.228,267 In contrast to WT APC, protein S 
was not able to enhance the APC anticoagulant activity of these chimeras. 
Because cleavage at Arg506 of FVa by APC does not require phospholipids, the 
affinity between the two proteins may be sufficiently high for them to bind to each 
other in the absence of membrane surfaces. It is possible that following cleavage 
at Arg506 the affinity of APC for FVa decreases. It has been shown that protein S 
binds with high affinity (Kd ~ 40 nM) to the 493-506 peptide of FV.
116 
Consequently, protein S could also act as an APC cofactor by stabilising the 
APC/FVa complex on the phospholipid membrane (through binding to both APC 
and FVa), thereby allowing cleavage at Arg306. 
The third mechanism by which protein S has been reported to enhance APC 
anticoagulant activity is by overcoming the protective effect of FXa on FVa 
cleavage.219 One proposed hypothesis is that this is due to competitive binding of 
protein S and FXa for FVa.116 If a competitive binding between protein S and FXa 
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for FVa exsists, I believe it is unlikely to play a physiological role in vivo, 
considering that binding of protein S to FVa is likely reduced once FVa is 
incorporated in the prothrombinase complex with its physiological substrate 
prothrombin. Prothrombin (1.39 μM) is also available in much higher 
concentrations than protein S (free protein S ~145 nM, total protein S ~362 nM). 
The alternative mechanism proposed was that protein S enhanced APC mediated 
cleavage of free FVa, thereby potentially affecting the equilibrium between free 
FXa and FVa, and the FXa/FVa complex.137 This would cause FVa to dissociate 
from the complex, consequently being more susceptible to cleavage by APC. This 
proposed mechanism seems to me more likely to occur in vivo, as protein S is 
known to enhance APC mediated cleavage of FVa. In addition, considering that 
the plasma concentration of FV (~30 nM) is less than that of FX (~136 nM), the 
available FVa is likely to influence the equilibrium between free FVa and FVa 
bound to FXa. It has also been proposed that FXa only protects Arg506 cleavage 
and that protein S enhances APC mediated cleavage at Arg306 even when FVa 
is bound to FXa.138 This proposed mechanism could occur in vivo, however, it is 
likely that it is reduced once the prothrombinase complex binds to its substrate 
prothrombin. 
Three residues in the Gla domain of APC, Asp36/Leu38/Ala39, have been 
reported to be essential for cofactor activity of protein S.90 When point 
substitutions of these residues in APC were analysed, Leu38 was shown to be 
the most critical residue for protein S cofactor activity.268 One study used Fab 
fragments against APC and suggested the EGF1 domain of APC was important 
for protein S cofactor activity.91 During this thesis, I identified Asp95, Asp78 and 
Gln79 in the EGF1 domain of protein S and my colleague Dr Josefin Ahnström 
identified Gla36 in the Gla domain of protein S as residues essential for APC 
cofactor activity. When residues Asn33, Pro35 and Tyr39 in protein S were 
substituted and evaluated by my colleague Dr Josefin Ahnström in the CAT 
assay, a reduced APC cofactor activity was also observed. This suggests amino 
acids in close proximity to Gla36 in protein S are also likely to contribute either 
directly or indirectly to APC cofactor function of protein S. I aligned the Gla and 
EGF1 domains of protein S and protein C (Figure 4.1A). Interestingly, residues of 
APC shown to be important for enhancement of its anticoagulant activity by 
protein S align with the residues of protein S identified as crucial for APC cofactor 
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activity. Similarly, when I highlighted these residues in the respective models of 
the proteins, they are predicted to be located at a similar distance from the N-
terminal residues comprising the ω-loop involved in binding to the phospholipid 
membrane (Figure 4.1, B and C). It is likely that the pronounced APC cofactor 
activity of protein S depends on the formation of a functional complex between 
the two proteins. Protein interactions are usually mediated through multiple 
residue reciprocal contacts and can involve distinct interaction sites. However, it 
is unlikely, because of charge considerations, that the identified residues of 
negative charge in the respective domains (Asp95 and Gla36 in protein S and 
Asp71 and Asp36 in APC) interact directly with each other. The possibility that 
Leu38 of APC in conjunction with surrounding residues (such as Asp36 and 
Ala39), interact with a cluster of residues in protein S composed in part by 
residues such as Asn33, Pro35, Gla36 and Tyr39 (see arrow Figure 4.1) needs to 
be further investigated. While a monoclonal antibody directed against the EGF1 
of APC, with Asp71 being part of its epitope, inhibited protein S enhancement of 
the anticoagulant activity of APC,91 Asp71 is not necessarily involved in an 
interaction with protein S. However, it is interesting that Asp71 in APC 
coordinates a calcium ion91 and that Asp95 in protein S is part of a partially 
conserved calcium binding site. It is possible that the calcium ion in EGF1 of 
protein C masks part of the negative charges in this region. It is difficult for me to 
predict how these residues (Asp95 in the EGF1 domain of protein S and Asp71 in 
the EGF1 domain of APC) might interact, and I suggest that further studies on 
these EGF domains of APC and protein S are required before a plausible model 
can be proposed. Nevertheless, it is worth noting that at least two distinct 
domains, Gla and EGF1, have been implicated in both APC and protein S 
mediated APC cofactor activity. Co-operative multidomain interactions could form 
the basis of further investigation.  
To further assess protein S interaction with APC and relocation of the active site 
of APC by protein S, my colleague Dr Josefin Ahnström is planning to perform 
FRET analysis with WT protein S, protein S D95A, protein S E36A, WT APC and 
APC D36A/L38D/A39V. 
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Figure 4.1 Location of residues in protein S and protein C shown to be important for APC 
cofactor activity of protein S. 
The alignment of the Gla domains and EGF1 domains of protein S and protein C is shown in A. 
The model of protein S
193
 (B) and APC
88
 (C) show the Gla domains in yellow, the TSR domain of 
protein S in light green and the EGF1 domains in cyan. Residues found to be important for APC 
cofactor activity of protein S are shown as red sticks. Arrows indicate potential interaction sites 
between protein S and APC. 
 
 
4.3 TFPI cofactor activity of protein S; possible interaction sites 
and mechanism 
Hackeng et al. showed that the anticoagulant activity of truncated TFPI, lacking 
its K3 domain and its C-terminal tail, was not enhanced by protein S.81 In our lab, 
we have shown that protein S is able to enhance TFPI lacking its C-terminal tail to 
the same extent as full-length TFPI (unpublished results of my colleague Verity 
Hockey) suggesting the C-terminal tail is not directly involved in the interaction 
with protein S. Recently, it was demonstrated that the K3 domain of TFPI is 
essential for protein S cofactor activity.238 Within the K3 domain the P1 residue, 
 147 
Arg199, was reported to play an important role.238 Direct binding of protein S to 
the K3 domain was also shown.238 Verity Hockey has constructed composite 
variants of charged residues in the K3 domain of full-length TFPI. These were 
shown inhibit FXa to the same extent as WT TFPI, however, the cofactor activity 
of protein S for E226Q/E234Q/R237Q and D194Q/R195Q/R199Q was reduced 
approximately 7 and 3-fold in comparison with WT TFPI (unpublished results). 
The TFPI variant K213Q/R215Q/K232Q was enhanced normally by protein S 
(unpublished results).  
Protein S variants constructed during my thesis have failed to clearly identify 
residues in protein S critical for TFPI cofactor activity. However, I did identify a 
potentially interesting variant in the EGF1 domain, protein S NEDM, that needs to 
be further investigated. Considering the pronounced TFPI cofactor activity of 
protein S and the low concentrations of plasma full-length TFPI (~0.25 nM), their 
binding affinity in vivo must be much higher than those derived from surface 
plasmon resonance (SPR) experiments (Kd> 150 nM).
238,241 Binding experiments 
by blotting and SPR were performed in the absence of phospholipids. It is 
possible that the presence of phospholipids would increase the affinity of TFPI for 
protein S. Interestingly, co-immunoprecipitation studies have suggested full-
length TFPI and free protein S do exist in plasma as a complex.241 If protein S 
and TFPI interact in vivo, they are likely to do so through multiple sites, potentially 
explaining why substitution of single residues within protein S failed to completely 
disrupt protein S enhancement of TFPI. Alternatively, the interaction site on 
protein S for TFPI might be located in domains that were not evaluated during this 
thesis. 
The mechanism by which protein S enhances TFPI is not yet completely 
understood. It is possible that, as for APC, protein S enhances the affinity of TFPI 
for negatively charged phospholipid surfaces. Protein S could also, by binding 
both TFPI and FXa, co-localise the proteins on the phospholipid surface and 
increase their affinity for each other by forming a trivalent complex. Alternatively, 
protein S could induce a conformational change and thereby facilitate TFPI 
binding and inhibition of FXa. I believe it is unlikely that protein S, by binding to 
the K3 domain of TFPI, induces a conformational change in the K2 domain of 
TFPI as the Kunitz domains of TFPI are connected through quite long (30 amino 
acid) linker regions. It is more plausible that protein S induces a conformational 
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change in FXa, as it has been suggested to do for APC. Interestingly, FXa and 
APC have a very similar domain structure and protein S is reported to bind FXa 
with a high affinity (~15 nM).214 Conceivably, protein S binding to FXa induces a 
conformational change in its active site causing it to be more susceptible to 
inhibition by the K2 domain of TFPI.  
While recent publications suggest a direct interaction of protein S with TFPI and 
possibly the K3 domain, the reported affinities are surprisingly low (Kd >150 nM) 
in comparison to those reported for protein S binding to FXa (Kd ~15 nM).
238,241 
The interaction of the K3 domain of TFPI with protein S would represent an 
unusual interaction since Kunitz domains usually bind in active site clefts. It has 
been shown that FXa is able to cleave the K3 domain of TFPI after its P1 residue 
Arg199 in vitro.71 While the physiological importance of this is questionable, it 
suggests that under certain conditions the K3 domain of TFPI is able to bind the 
active site of FXa. While not supported by current binding studies between protein 
S and TFPI, the possibility that protein S induces a conformational change in FXa 
that favours a stronger and quicker inhibition of FXa by the K3 domain of TFPI 
rather than a weaker and slower inhibition by the K2 domain of TFPI, needs to be 
examined further. If this is the case, the deletion or substitutions in the K3 domain 
of TFPI would result in loss of protein S cofactor activity, not because of lack of 
binding to protein S but because of lack of binding to the active site of FXa. This 
hypothesis could easily be tested by evaluating FXa inhibition by synthetic K2 and 
K3 domains in the presence and absence of protein S.  
 
4.4 Protein S direct activity 
It was initially thought that protein S could directly inhibit the prothrombinase 
complex by direct binding to FVa and FXa. This APC-independent anticoagulant 
activity of protein S was termed “protein S direct”. Later, it was shown that this 
activity of protein S in purified systems was due to competition of protein S 
multimers for limiting amounts of phospholipids.191,192,216,217 However, an APC-
independent activity of protein S was observed in plasma also at saturating 
amounts of phospholipids.218 This was identified as protein S cofactor activity 
towards TFPI in 2006.81 However, Heeb and colleagues have observed an APC- 
and TFPI-independent activity of protein S also at saturating amounts of 
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phospholipids.189,190,242 They claim that protein S can directly inhibit FXa and 
TF/FVIIa through direct binding. That protein S direct has not been observed in 
many other laboratories has been potentially explained by Heeb and colleagues 
by showing that purification of protein S often lead to loss of binding to a zinc ion, 
which correlates with loss of protein S direct activity.242 The low IC50 reported 
(~120 nM)190 for protein S inhibition of the prothrombinase complex contrasts with 
the huge cofactor activity observed for APC and TFPI suggesting that while 
protein S direct might in some instances be evident in vitro, it has little in vivo 
relevance. 
 
4.5 In vivo regulation of coagulation by protein S 
Protein S plays a central role in regulating haemostasis and its importance is 
underpinned by the severe outcome of patients with protein S deficiencies, with 
homozygous deficiencies generally being incompatible with life.201-203 
The recent finding that protein S acts as a cofactor not only for APC but also for 
TFPI raises the question whether APC and TFPI compete for binding to protein S 
in vivo. While it is yet too early to give a definitive answer, a first indication is 
given by the results obtained in this thesis. Both protein S Asp95 and protein S 
Gla36 had almost no APC cofactor activity but were still able to enhance the 
anticoagulant activity of TFPI. While this does not rule out a competition between 
APC and TFPI for protein S, it suggests that APC and TFPI interact with distinct 
residues of protein S. It has been shown that addition of APC to plasma increases 
the anticoagulant activity of TFPI/ protein S.241 The reason behind this is probably 
twofold. Firstly, APC reduces the procoagulant response and delays the start of 
massive thrombin generation. This allows time for the slow binding and inhibition 
of FXa by TFPI to occur. Secondly, inactivation of FVIIIa and FVa by APC results 
in a reduced rate of activation of FX and could result in a shift in the equilibrium 
from FXa/FVa towards free FXa. This overcomes the protective effect of 
prothrombin on TFPI inhibition of FXa when FXa is incorporated in the 
prothrombinase complex.77 It would therefore, seem that the APC/protein S and 
the TFPI/protein S anticoagulant activities act in synergy rather than the two 
pathways competing for protein S. Considering also the excess plasma 
concentration of protein S (free protein S ~145 nM, total protein S ~362 nM) over 
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that of protein C (~65 nM) and TFPI (full-length ~0.25 nM, total ~2.5 nM) and the 
different phases of regulation by APC and TFPI (propagation phase and initiation 
phase, respectively), I believe that it is unlikely that these two proteins compete 
for binding to protein S in vivo. 
While in vitro assays represent valuable and powerful tools to analyse the 
biochemical interactions and processes that occur in vivo they inevitably exclude 
many of the variables present in vivo. In my plasma based assay, performed by 
CAT, phospholipids were used to provide a surface for coagulation factors on 
which to interact. While this simplifies the assay and decreases inter-assay 
variability, it represents a simplified model for platelets, platelet activation and its 
components such as platelet protein S, TFPI and FV. The procoagulant and 
anticoagulant activity of coagulation factors also seem to be differently regulated 
by the membrane composition and distribution.125,269 In addition, anticoagulant 
coagulation factors seem more susceptible to plasma dilution than procoagulant 
factors.264 Cell-free plasma based assays differs from in vivo assays as they lead 
to the formation of coagulation in suspension rather than on a surface. In my 
assays I have used 1 pM TF. However, it is unclear how this relates to the local 
concentrations of TF in vivo. The concentration of TF is also likely to vary during 
the course of the haemostatic response in vivo, following platelet plug formation 
above the subendothelial cells. A limiting factor of the in vitro plasma assays is 
that it inevitably leads to depletion of coagulation factors during its course. This is 
likely to be of particular importance for those factors that are present in small 
amounts such as TFPI. Based upon the vast amount of results derived from in 
vitro assays and those from in vivo assays it is, however, reasonable to speculate 
how coagulation is likely to occur in vivo. 
Following vessel wall injury, the ECM and TF are exposed to the blood.10 VWF 
binds to exposed collagen in the ECM allowing platelet adherance, aggregation 
and activation.1,5 This leads to exposure of phosphatidylserine on the outer leflet 
of the platelet membrane which provides a surface for the binding of coagulation 
factors.9 Simultaneusly, as the primary platelet plug is forming, TF triggers 
coagulation through binding to and activation of FVIIa. TF/FVIIa activates FIX and 
FX. TFPI is the main regulator of the initiation of coagulation as it inhibits FXa 
and, in a FXa dependent manner, inhibits TF/FVIIa on the subendothelial cells.66-
68 The finding that protein S enhances TFPI may be physiologically fundamental. 
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In the presence of protein S, the Ki for TFPI inhibition of FXa falls within the 
physiological plasma concentration of TFPI, allowing the TFPI pathway to play a 
potentially major anticoagulant role. While protein S only enhances free TFPI 
containing its K3 domain,81 truncated forms of TFPI have been shown to be able 
to inhibit FXa and TF/FVIIa.78-80 These free truncated TFPI variants in plasma 
(~5% of plasma TFPI) are unlikely to play a major role in regulating initiation of 
coagulation as they represent half the amount of free full-length plasma TFPI 
(~10% of plasma TFPI) and are not enhanced by protein S. They could, however, 
have a role in regulating the haemostatic balance under condition in which no 
tissue damage occurs. The majority (~80%) of plasma TFPI is, however, bound to 
lipoproteins and their anticoagulant role is still not clear.64,65 Cell suface bound 
TFPI (~80% of total TFPI) has been shown to have some anticoagulant activity.43 
Considering vascular smooth muscle cells express TFPI in addition to TF, this 
pool of TFPI is likely to regulate the local initiation of coagulation on 
subendothelial cells exposed to the blood. TFPI on intact endothelial cells 
surrounding the tissue damage might also play a significant role in regulating 
coagulation by inhibiting FXa that escapes the site of vascular injury, therefore by 
confining the haemostatic plug. It is still not clear if protein S is able to act as a 
cofactor for endothelial bound TFPI. Free full-length TFPI circulates in plasma in 
low concentrations (~0.25 nM). This does exceed the predicted amount of TF (pM 
range) that triggers coagulation. However, it is far lower than the amount of FXa 
predicted to be generated from FX (total plasma concentration of FX ~136 nM) 
potentially explaining why TFPI is only able to inhibit initiation of coagulation. FXa 
that escapes inhibition by TFPI/protein S generates trace amount of thrombin. 
Thrombin produces a feedback mechanism by activating FVIII and FV.12 This 
leads to massive generation of FXa which can no longer be significantly inhibited 
by TFPI. The feedback mechanism of thrombin finally results in a massive 
amplification of itself and is usually refered to as propagation of the coagulation 
cascade. Thrombin that escapes the immediate site of injury binds to TM on the 
endothelial cells surrounding the vessel damage. This leads to activation of 
protein C which acts as a potent anticoagulant together with its cofactor protein 
S.114 Results in my thesis and previous reports show that the APC anticoagulant 
activity is highly dependent upon its cofactor protein S.218 As protein C is 
activated at the edge of the vessel injury it is likely to play a role in spatially 
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confining the haemostatic plug. APC/protein S are also able to bind to the 
activated platelets through their Gla domains and inactivate FVa and FVIIIa on 
the growing haemostatic plug. Following the initial formation of the loose platelet 
plug over the subendothelial cells, it has been suggested that soluble TF or TF in 
microparticles continue to trigger coagulation on the surface of the growing 
platelet plug.16-18 While this requires further investigation, it is seems plausable 
that TFPI secreted by platelets is an important regulator of this source of TF. As 
TFPI in platelets exists in its full-length form it is likely that even the activity of 
platelet TFPI is dependent upon its cofactor protein S.63 
To conclude, protein S is crucial in regulating haemostasis. It does so by 
substancially enhancing the enzymatic activity of both TFPI and APC, thereby 
regulating both initiation and propagation of the coagulation cascade. Further 
work is necessary to unravel the complex molecular mechanism behind protein S 
function including, elaboration of the potential molecular interactions between 
residues found to be crucial in APC and protein S, the interacting residues 
between protein S and TFPI, and the molecular mechanism governing protein S 
enhancement of the anticoagulant activity of TFPI. 
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APPENDIX 
 
Sequencing primers 
 
 Nucleotide sequence 
Area of protein S 
covered 
T7 primer 5’ taatacgactcactataggg 3’ ATG-middle EGF4 
Nt456 primer 5’ tattcactgctgcacgtcag 3’ TSR- beginning SHBG 
Nt769 primer 5’ gatgtggatgaatgctctttg 3’ EGF3- middle SHBG 
BGH reverse  5’ tagaaggcacagtcgagg 3’ SHBG-stop 
 
 
 
Mutagenesis primers 
All mutants were made by using the pcDNA6/protein S vector containing the WT protein 
S cDNA sequence, with the exception of NNEDM which was made by introducing the 
N74A substitution in the vector containing the NEDM substitutions and KTK which was 
made by introducing the T103A/K105A substitution in the vector already containing the 
K94A mutation (made by Dr S.M. Rezende). Please note that sequencing primers 
designed to introduce subsequent mutations in a region already mutated are designed to 
be complementary to the mutated template cDNA (with the exception of the new 
mutation to introduce) and not to the WT protein S template. All sequencing primers are 
from 5’ to 3’. The name of each sequencing primer corresponds to the amino acid 
mutated, its numerical location in the mature protein S, followed by the residue into which 
it was mutated. f; foreward, r; reverse. 
 
Gla1 composite mutants 
fD38N cccggaaacgaattatttttatcc 
rD38N ggataaaaataattcgtttccggg 
fV46G ccaaaatacttaggttgtcttcgctc 
rV46G gagcgaagacaacctaagtattttgg 
fK97Q gcaaagatggacaagcttcttttacttgcac 
rK97Q gtgcaagtaaaagaagcttgtccatctttgc 
 
 
TSR composite mutant 
fR49Q ccaaaatacttagtttgtcttcagtcttttcaaactgggttattcac 
rR49Q gtgaataacccagtttgaaaagactgaagacaaactaagtattttgg 
fR60Q tgggttattcactgctgcacagcagtcaactaatgcttatcc 
rR60Q ggataagcattagttgactgctgtgcagcagtgaataaccca 
fD68N R70Q cagtcaactaatgcttatcctaacctacaaagctgtgtcaatgcc 
rD68N R70Q ggcattgacacagctttgtaggttaggataagcattagttgactg 
fD78N gctgtgtcaatgccattccaaaccagtgtagtcct 
rD78N aggactacactggtttggaatggcattgacacagc 
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NEDM composite mutant 
fN86A E87Q D88N M91A cctctgccatgcgctcaaaatggatatgcgagctgcaaag 
rN86A E87Q D88N M91A ctttgcagctcgcatatccattttgagcgcatggcagagg 
 
 
KTK composite mutant 
fT103A 
K105A 
gcttcttttacttgcgcttgtgcaccaggttggcaaggag 
rT103A 
K105A 
ctccttgccaacctggtgcacaagcgcaagtaaaagaagc 
 
 
Point mutants 
fN74A cctgacctaagaagctgtgtcgctgccattccagaccagtg 
rN74A cactggtctggaatggcagcgacacagcttcttaggtcagg 
fD78A gtcaatgccattccagcccagtgtagtcctctgccatgc 
rD78A gcatggcagaggactacactgggctggaatggcattgac 
fQ79A gtgtcaatgccattccagacgcgtgtagtcctctgccatgc 
rQ79A gcatggcagaggactacacgcgtctggaatggcattgacac 
fD95N ggatatatgagctgcaaaaatggaaaagcttcttttacttg 
rD95N cctatatactcgacgtttttaccttttcgaagaaaatgaac 
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THROMBOSIS AND HEMOSTASIS
Activated protein C cofactor function of protein S: a critical role for Asp95 in the
EGF1-like domain
Helena M. Andersson,1 Ma´rcia J. Arantes,2 James T. B. Crawley,1 Brenda M. Luken,1 Sinh Tran,3 Bjo¨rn Dahlba¨ck,3
David A. Lane,1 and Suely M. Rezende4
1Department of Haematology, Faculty of Medicine, Imperial College London, London, United Kingdom; 2Nu´cleo de Açco˜es e Pesquisa em Apoio Diagno´stico
(NUPAD), Faculdade de Medicina, Universidade Federal de Minas Gerais, Minas Gerais, Brazil; 3Department of Laboratory Medicine, Division of Clinical
Chemistry, The Wallenberg Laboratory, Lund University, Malmo¨, Sweden; and 4Departamento de Clínica Me´dica, Faculdade de Medicina, Universidade Federal
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Protein S has an established role in the
protein C anticoagulant pathway, where it
enhances the factor Va (FVa) and factor
VIIIa (FVIIIa) inactivating property of acti-
vated protein C (APC). Despite its physio-
logical role and clinical importance, the
molecular basis of its action is not fully
understood. To clarify the mechanism of
the protein S interaction with APC, we
have constructed and expressed a library
of composite or point variants of human
protein S, with residue substitutions intro-
duced into the Gla, thrombin-sensitive
region (TSR), epidermal growth factor 1
(EGF1), and EGF2 domains. Cofactor
activity for APC was evaluated by cali-
brated automated thrombography (CAT)
using protein S–deficient plasma. Of
27 variants tested initially, only one, pro-
tein S D95A (within the EGF1 domain),
was largely devoid of functional APC co-
factor activity. Protein S D95A was, how-
ever, -carboxylated and bound phospho-
lipids with an apparent dissociation
constant (Kdapp) similar to that of wild-
type (WT) protein S. In a purified assay
using FVa R506Q/R679Q, purified protein
S D95A was shown to have greatly re-
duced ability to enhance APC-induced
cleavage of FVa Arg306. It is concluded
that residue Asp95 within EGF1 is critical
for APC cofactor function of protein S and
could define a principal functional interac-
tion site for APC. (Blood. 2010;115(23):
4878-4885)
Introduction
Protein S, a vitamin K–dependent plasma anticoagulant protein,
functions as an enhancing cofactor to activated protein C (APC) in
the inactivation of activated factors V (FVa) and VIII (FVIIIa).1
Protein S also has an APC-independent activity that has recently
been attributed to its ability to enhance tissue factor pathway
inhibitor (TFPI).2,3 Protein S has an important role in vivo, as is
shown clinically by infants with complete deficiency, who suffer
purpura fulminans, and by heterozygous carriers of PROS1 gene
deletions and point mutations, who are at enhanced risk of venous
thromboembolism.4,5 The importance of protein S has also been
demonstrated in murine knockouts, which fail to survive
development.6,7
Protein S binds phospholipids and helps to localize APC to the
membrane surface, in proximity to FVa and FVIIIa. In doing so,
rather than the preferential cleavage at Arg506 of FVa by APC,
Arg306 is then favored, with cleavage enhanced approximately
20-fold.8 Although this effect has generally been accepted to be due
to protein S repositioning of the active site of APC,9 this has
recently been questioned.10 Cleavage at Arg506 and Arg306 fully
inactivates FVa, thereby efficiently down-regulating coagulation.11
APC also inactivates FVIIIa by cleaving first at Arg336 and
thereafter at Arg562. In the presence of protein S, it has been shown
that the efficiency of cleavage after Arg336 by APC is enhanced
approximately 3-fold.12
Protein S is a 635–amino acid glycoprotein, circulating at a
plasma concentration of approximately 350nM. It is composed
of an N-terminal Gla domain (amino acids 1-45), a thrombin-
sensitive region (TSR; amino acids 46-75), 4 epidermal growth
factor (EGF)–like domains (EGF1, amino acids 76-116; EGF2,
amino acids 117-160; EGF3, amino acids 161-202; EGF4,
amino acids 203-242), and a C-terminal sex hormone–binding
globulin (SHBG)–like domain (amino acids 243-635).13,14 Ap-
proximately 60% of protein S circulates as a noncovalent,
high-affinity complex with -chain containing C4b binding
protein.15 This interaction is mediated through the SHBG
domain of protein S. Although it has been generally understood
that the free form ( 40%) of protein S alone is important in
anticoagulant function, this has recently been questioned.16
Whereas the functions of the domains of protein S have been
extensively studied, the APC cofactor function of protein S
remains poorly understood at the molecular level. Several basic
and clinical studies have confirmed that alteration of protein S
can disrupt phospholipid binding and thereby impair function of
protein S.17,18 Saller et al prepared protein S/prothrombin
chimeras and, on the basis of functional studies supported by
molecular modeling, identified a cluster of protein S Gla do-
main residues (termed Face2), which may provide an APC
interaction site.19
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Additional studies have focused on the possible role of TSR and
EGF domains. Several studies have reported that cleavage in the
TSR of protein S affects its APC cofactor activity.20-22 Dahlba¨ck et
al23 and Giri et al24 used domain-specific monoclonal antibodies
directed against protein S and their Fab fragments and suggested
that the TSR and EGF1 domains may be involved in APC cofactor
activity. The TSR and EGF1 domains of protein S have also been
reported to be responsible for species specificity.25 Using EGF-like,
modules Stenberg et al concluded the EGF1 module to be crucial
for interaction with APC.26 Hackeng et al demonstrated that the
isolated EGF1 domain of protein S could inhibit full-length protein
S anticoagulant enhancing function against APC: direct binding of
the domain to APC was also demonstrated.27 Mille-Baker et al
prepared EGF2 domain deletion and substitution mutants of protein
S and demonstrated reduced anticoagulant activity, in the presence
of normal phospholipid binding.28 Collectively, these investigators
have suggested Gla, TSR, EGF1, and EGF2 domains may each
contain recognition elements on protein S needed for APC cofactor
function.
Because these diverse approaches have not yet fully defined the
functional interaction site(s) on protein S for APC, we have
investigated the role of individual and groups of residue substitu-
tions in Gla, TSR, EGF1, and EGF2 domains of protein S. Using a
library of 27 protein S variants, we performed thrombin generation
assays in protein S–deficient plasma to which APC and these
protein S variants were added. We report here that EGF1 has a
critical role in anticoagulant function of protein S, provided
specifically by Asp95, the mutation of which almost completely
abolishes APC cofactor activity.
Methods
Generation and expression of protein S and its variants
A previous reported pcDNA6/protein S vector containing the cDNA for
wild-type (WT) protein S29 was used to generate recombinant full-length
WT protein S and as a template to produce protein S mutants by polymerase
chain reaction site-directed mutagenesis (QuikChange XL Site-Directed
Mutagenesis Kit; Stratagene) using mutagenic oligonucleotide primers
(Thermo Scientific). Single and composite residue variants produced are
shown in Table 1.
Residues to mutate were selected based on nonconserved residues in
domains of other human coagulation factors (Gla mutants) and charge (TSR
mutant). Residues in the B and C regions (between the third/fourth and
fifth/sixth Cys residues, respectively) of both EGFs were mutated, as these
regions on the EGF-like domains are likely to be involved in protein
interaction as suggested by (1) the highly divergent sequence of the
B region,30 (2) the association of dysfunctional proteins with natural PROS1
mutations in these regions,4 and (3) the location in these regions of many
mutations associated with dysfunctional proteins in the other coagulation
genes coding for EGF domains, such as FVII, FIX, and protein C.
WT and mutant protein S expression vectors were either transiently or
stably transfected into HEK293T or HEK293 cells (ATCC), respectively.
Stably transfected cells were selected with 5 g/mL Blasticidin-HCl
(Invitrogen) for 4 weeks. Protein S was expressed in OptiMem I (Invitro-
gen) with 10 g/mL vitamin K (Roche Products Ltd) for 3 days. Media
containing protein S was harvested, centrifuged, filtered, dialyzed in
20 mM Tris (tris(hydroxymethyl)aminomethane)–HCl (pH 7.5), 140 mM
NaCl (TBS), and concentrated, as required. All variants were successfully
expressed into the media and could be readily detected by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) followed by West-
ern blotting and by enzyme-linked immunosorbent assay (ELISA). We have
previously reported that the protein S expressed in this way is functionally
active in APC cofactor assays and can be fully -carboxylated.17,31
Purification of protein S
WT protein S and selected variants were either partially purified by
barium citrate precipitation as previously described32 for use in phospho-
lipid binding analysis or extensively purified by chromatography for use
in APC-dependent functional assays. Chromatography was performed
using an A¨ KTA purifier UPC-10 and the Unicorn 5.11 (Build 407)
software, strategy Version 1.00 (both from GE Healthcare). Concen-
trated and dialyzed conditioned media containing protein S supple-
mented with 4 mM EDTA (ethylenediaminetetraacetic acid) was applied
to an anionic Q Sepharose Fast Flow (5 mL of HiTrap QFF) column (GE
Healthcare) equilibrated with 20mM Tris-HCl (pH 7.4), 100mM NaCl,
4mM EDTA, and 5mM benzamidine-HCl (Sigma-Aldrich). The column
was washed with 20mM Tris-HCl (pH 7.4), 100mM NaCl, and 5mM
benzamidine-HCl. Protein S was eluted from the column with 20mM
Tris-HCl (pH 7.4), 0.5M NaCl, and 5mM benzamidine-HCl.
Two volumes of 7.5mM CaCl2 were added to the elution fraction from
the anionic QFF column to lower the ionic strength, before injecting the
fraction onto an affinity column prepared by coupling 2.5 mg of monoclo-
nal antibody against protein S, MK21, to a 1-mL HiTrap NHS HP column
(GE Healthcare), according to the manufacturer’s instructions. All monoclo-
nal antibodies against protein S used in this study are described in the paper
of Dahlba¨ck et al.23 The protein S–containing fraction was applied to the
equilibrated column (equilibration buffer: 50mM Tris-HCl [pH 7.5],
150mM NaCl, 2mM CaCl2). After washing with 1M NaCl, the ionic
strength was lowered by passing additional 3 column volumes of equilibra-
tion buffer over the column prior to elution of protein S with 50mM
Tris-HCl (pH 7.5), 150mM NaCl, and 10mM EDTA. An excess of CaCl2
was present in the tubes collecting the eluted protein S to neutralize the
EDTA. The column was regenerated by stripping with 0.1M glycine-HCl
(pH 2.7). Purified protein S was dialyzed in TBS and concentrated, as
required.
Determination of protein S concentration by ELISA
Protein S concentrations in media were determined by an in-house ELISA.
Polyclonal rabbit anti–protein S antibody (1 g/mL; DAKO) was immobi-
lized in a 96-well Nunc Maxisorp microplate in 50mM sodium carbonate
buffer (pH 9.6) at 4°C overnight. Washing steps were performed in
triplicate with 250 L of phosphate-buffered saline, 0.1% Tween between
each step. Wells were blocked with phosphate-buffered saline containing
3% bovine serum albumin (BSA; Sigma-Aldrich) for 2 hours. Bound
protein S was detected by a mouse monoclonal antibody directed against
the EGF3-4 domain of protein S, MK55, followed by a horseradish
peroxidase (HRP)–conjugated goat anti–mouse antibody (DAKO). The
plate was developed with 100 L/well chromogenic substrate O-phenylene
diamide dihydrochloride; OPD (Sigma-Aldrich), the enzymatic reaction
was stopped with 50 L/well 2M H2SO4, and the absorbance was read at
492 nm.
SDS-PAGE and Western blotting
SDS-PAGE and Western blotting were performed using standard tech-
niques. Briefly, 4% to 12% or 10% precast NuPAGE Novex Bis-Tris gels
(Invitrogen) were used. For silver staining and Western blotting, standard
techniques were used. The SeeBlue-prestained marker from Invitrogen was
Table 1. Protein S variants generated by site-directed mutagenesis
GLA1 D38N/V46G/K97Q
GLA2/Face2 L21T/N23S/K24Y/R28F/D34S/Y41W/L45T
TSR1 R49Q/R60Q/D68N/R70Q/D78N
EGF1 single-residue variants K94A, D95A, K97A, S99A, T101A, T103A,
K105A, P106A, W108A, Q109A, E111A, K112A
EGF2 single-residue variants D135A, N136A, T137A, Y141A, H142A, S144A,
K146A, S153A, N154A, K155A, K156A, D157A
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used. Protein S was detected either by a polyclonal rabbit anti–protein S
antibody followed by an HRP-conjugated goat anti–rabbit antibody or by a
monoclonal mouse antibody recognizing only -carboxylated Glu residues
(American Diagnostica Inc), followed by a goat anti–mouse HRP-
conjugated antibody (DAKO).
Phospholipid vesicle preparation
Phospholipids mixtures (Avanti Polar Lipids Inc) in chloroform were
prepared and the chloroform was evaporated under a nitrogen stream. The
phospholipids were resuspended in TBS or 25mM N-2-hydroxyethylpipera-
zine-N-2-ethanesulfonic acid (pH 7.7), 150mM NaCl (HN) for the plasma
and purified assays, respectively. Unilamellar phospholipids vesicles were
obtained by sonicating the phospholipids in an ice container at amplitude
22% for 7 minutes. Extruded phospholipids were prepared as previously
described33 and used in the FVa inactivation assay. Synthetic phospholipids
1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-Dioleoyl-sn-
glycero-3-phosphoserine (DOPS), and 1,2-Dioleoyl-sn-glycero-3-phospho-
ethanolamine (DOPE) were used in the plasma assay and the plate-binding
assay. Natural phospholipids L--phosphatidylserine (PS; brain extract),
L--phosphatidylethanolamine (PE; egg extract), and L--phosphatidylcholine
(PC; egg extract) were used in the FVa inactivation and prothrombinase assays.
Binding of protein S to phospholipids
Phospholipids vesicles (DOPS/DOPC/DOPE, 20:60:20), 25 g/mL, were
coated as described for the ELISA. Washing steps were performed in
triplicate with 250 L/well TBS, 5mM CaCl2, 0.3% BSA between each step
and incubations were carried out in a plate shaker at 37°C. Wells were
blocked with TBS, 5mM CaCl2, 3% BSA for 2 hours. Protein S partially
purified by barium citrate precipitation, 0 to 120nM, was incubated in the
wells in duplicate for 2 hours and was detected with an HRP-conjugated
anti–protein S antibody for 45 minutes (Affinity Biologicals). Data were
analyzed with GraphPad Prism 4.03 and curves were fitted to a one-site
binding hyperbola.
Binding of protein S to domain-specific monoclonal antibodies
Domain-specific monoclonal antibodies MK21 (Gla domain), MK54
(EGF1 domain), and MK61 (SHBG domain), 1 g/mL, were coated as
described for the ELISA. Washing steps were performed in triplicate with
250 L of TBS, 3mM CaCl2, 0.1% Tween between each step. Incubations
were carried out in a plate shaker at 37°C for 1 hour unless stated otherwise.
Wells were blocked with 200 L of TBS, 3mM CaCl2, 3% BSA for
2 hours. Protein S, 0 to 160nM was incubated in the plate for 1 hour and was
detected by a rabbit polyclonal antibody against protein S followed by a
goat anti–rabbit HRP-conjugated antibody.
Thrombin generation assay by calibrated automated
thrombography
Thrombin generation was assessed using a Fluoroscan Ascent FL Plate
Reader (Thermo Lab System) in combination with Thrombinoscope
software (SYNAPSE BV). Protein S–deficient plasma (Affinity Biologi-
cals), 80 L, was incubated with 65 g of corn trypsin inhibitor (Haemato-
logic Technologies Inc) per milliliter of plasma to inhibit contact activation,
50M phospholipid vesicles (DOPS/DOPC/DOPE, 20:60:20), 1pM tissue
factor (Dade Innovin; Dade Behring), 4 to 16nM APC (Enzyme Research
Laboratories Ltd) with 0 to 120nM protein S, in a final volume of 100 L
(all concentrations are final). A polyclonal antibody against TFPI (Haemato-
logic Technologies Inc), 100nM, was used to inhibit any protein S cofactor
activity toward TFPI. Although protein S cofactor activity toward TFPI was
not observed at low concentrations of APC, it was observed to a small
extent when lower amounts of thrombin were generated (eg, at higher
concentrations of APC in the presence of protein S). Polyclonal antibodies
against protein S and protein C were used to show the specificity of the
system and were from, respectively, DAKO and Sigma-Aldrich. Thrombin
generation was initiated by automatic dispensation of 20 L of 2.5mM
Z-GlyArg-AMC-HCl (Bachem), 2.5% Me2SO, 20mM Tris-HCl (pH 7.5),
60 mg/mL BSA, 100mM CaCl2 into each well. The reaction was performed
at 37°C and measurements were performed with an excitation and emission
wavelength of 390 nm and 460 nm, respectively.
Protein S–dependent APC-mediated factor FVa inactivation
assay
A previously prepared and reported34 double mutant of FV, FV R506Q/
R679Q, was activated with 0.5 U/mL human thrombin at 37°C for
10 minutes. The reaction was stopped by the addition of hirudin (5 U/mL,
final concentration). The activated FVa variant was used as a substrate for
APC to determine the ability of protein S to enhance cleavage of Arg306 of
FVa by APC. The highly purified protein S preparations, 0 to 100nM, were
incubated with 0.5nM APC, 25M phospholipids vesicles (PS/PC/PE,
10:70:20), and 0.8nM FVa R506Q/R679Q in HN, 5mM CaCl2, 5 mg/mL
BSA (HNBSACa2) in a total volume of 50 L (all concentrations are
final). The solution was incubated at 37°C for 10 minutes, and the reaction
was stopped by performing a 1:25-fold dilution in ice-cold HNBSACa2.
The remaining FVa activity was measured in a prothrombinase assay.
Time course experiments were also performed to derive the rate
constant of FVa cleavage. APC, 0.5 and 3nM, and 50nM protein S were then
used and aliquots were quenched at intervals between 0 and
20 minutes. The remaining FVa activity was again measured in a
prothrombinase assay. To calculate the pseudo–first-order rate constant for
APC-mediated cleavage at Arg306, the previously reported equation33 was
used: Vat  Va0 	 e
k306 	 t  C 	 Va0 	 (1 
 e
k306 	 t).
Vat represents the cofactor activity determined at time t, Va0 is the
cofactor activity determined at time point 0, C is the remaining procoagu-
lant cofactor activity of FVa after cleavage at position 306, and k306 is the
rate constant of cleavage at position 306.
Prothrombinase assay
An aliquot, 25 L, of the FVa inactivation reaction was incubated with
phospholipid vesicles (PS/PC 10:90) and FXa in the presence of CaCl2. The
reaction was initiated by the addition of prothrombin, in a final volume of
125 L. The buffer contained HN and 0.5 mg/mL ovalbumin. Final
concentrations were 50M PS/PC, 5nM FXa, and 0.5M prothrombin. The
solution was incubated at 37°C for 2 minutes and the reaction was
terminated by an 8-fold dilution in 50mM Tris-HCl (pH 7.9), 100mM NaCl,
20mM EDTA, 1% PEG 6000. The amount of thrombin generated was
measured by cleavage of its chromogenic substrate S-2238 (Chromogenix)
at 405 nm for 15 minutes at 30-second intervals.
Results
Screening of protein S mutants for APC cofactor activity in
plasma
Concentrated and dialyzed conditioned media samples containing
WT protein S and the 27 protein S variants were normalized with
respect to protein S concentration, using the protein S–specific
ELISA. Western blotting revealed single-band protein S in all
samples (nonreducing conditions).
To assess the APC cofactor activity of protein S, thrombin
generation was assessed by calibrated automated thrombography
(CAT) using protein S–deficient plasma supplemented with recom-
binant WT protein S and its variants in conditioned media. Under
the conditions of the assay, APC (0-10nM) did not affect peak,
endogenous thrombin potential (ETP), lag time, or time to peak,
when coagulation was initiated in protein S–deficient plasma
(Figure 1A). Concentrated conditioned media from cells not
expressing protein S had no influence on thrombin generation (data
not shown). When 120nM WT protein S was progressively
introduced into the assay, dose-dependent effects were observed,
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primarily on reduction of the peak and of ETP values (Figure 1B).
The extent of inhibition of peak and ETP was dependent both on
the concentration of APC and protein S. The higher the APC
concentration, the less protein S was necessary to completely
inhibit thrombin generation. In these experimental conditions,
10nM APC and 120nM protein S reduced both the peak and ETP by
approximately 84%. To verify that those effects were a direct
consequence of APC cofactor activity of protein S, polyclonal
antibodies against either protein S (Figure 1C) or protein C (Figure
1D) were used. These inhibited the anticoagulant APC–protein
S effect.
The screening of the protein S variants for their APC cofactor
activity was performed at high concentration of APC (16nM) to
achieve almost complete inhibition of thrombin generation with
100nM WT protein S (Figure 2). These screening experiments
identified a single point mutant in EGF1 of protein S, D95A, which
had a severely impaired APC cofactor activity. Under all conditions
used, the reduction in cofactor activity was greater than that
observed for the previously reported variant with 7 amino acids
exchanged (prothrombin residue swap), GLA2/Face2.
Evaluation of the importance of Asp95 for APC cofactor activity
of protein S in plasma
To further evaluate the APC cofactor activity of protein S D95A, a
titration (0-120nM) of the mutant (Figure 3B) was performed
alongside WT protein S (Figure 3A), using 9nM APC. The protein
S D95A had a severely impaired APC cofactor activity, a finding
replicated when different concentrations of APC were used (results
not shown). In these experimental conditions, whereas 120nM WT
protein S reduced peak and ETP by approximately 80%, 120nM
protein S D95A reduced peak and ETP by only approximately 10%.
To confirm the importance of Asp95 in protein S APC cofactor
function, Asp95 was also substituted with Asn, rather than Ala. Asn
is structurally more similar to Asp than Ala and it can also be
-hydroxylated. When the protein S D95N mutant was titrated, it
was observed that it also had severely reduced APC cofactor
activity (Figure 3C) with 120nM D95N inhibiting peak and ETP by
approximately 20%. All results in Figure 3A through C were
conducted with protein S and its variants contained in concentrated
conditioned media. To confirm that they were not influenced by the
media, WT protein S and the protein S D95A variant were purified
to homogeneity using anion exchange and affinity chromatography
(see Figure 3D inset for SDS-PAGE gel visualized with silver
staining). Addition of 90nM purified WT protein S to protein
S–deficient plasma in the presence of 9nM APC appreciably
attenuated thrombin generation (Figure 3D), replicating the find-
ings with WT protein S in conditioned media. Moreover, addition
Figure 1. Effect of APC and protein S on thrombin generation.
Thrombin generation was performed in protein S–deficient plasma
with 100nM inhibitory antibodies against TFPI. Up to 10nM APC had
no effect on thrombin generation in the absence of protein S. All
concentrations generate lines that are superimposable (A). After
addition of 120nM protein S (at 0-10nM APC), an APC dose-
dependent effect was observed (B). The top single line represents
0 to 10nM APC in the absence of protein S. Protein S in the
presence of no or 2.5nM APC generated lines that were superimpos-
able. Conditions used are noted adjacent to the peaks to which they
refer. The anticoagulant effect of 10nM APC and 120nM protein S
was inhibited by polyclonal antibodies against protein S (C) or
against protein C (D). PS indicates protein S; PC, protein C.
Representative experiments are shown (n  3).
Figure 2. Screening of protein S variants for APC cofactor activity. The APC
cofactor activity of protein S was evaluated at 16nM APC and 100nM protein S by
CAT. The peak height in the absence of protein S was set to 100%. A high
concentration of APC, leading to almost complete inhibition of thrombin generation
with 100nM WT protein S, was chosen specifically for screening purposes as this
allows widening of the assay window at which mutants with reduced APC cofactor
activity are visualized. Results were confirmed by evaluating protein S (at 60 and
90nM) cofactor activity toward 4 or 9nM APC.
APC COFACTOR ACTIVITY OF PROTEIN S 4881BLOOD, 10 JUNE 2010  VOLUME 115, NUMBER 23
of 90nM purified protein S D95A to APC produced only a minimal
effect on thrombin generation (Figure 3D).
When analyzing a model35 of Gla-TSR-EGF1 domains of
protein S, 2 residues with a solvent-exposed R residue in close
proximity to that of Asp95 were identified, Asp78 and Gln79.
These were also mutated to alanine and expressed. When protein S
D78A and Q79A were analyzed in the thrombin generation assay
alongside WT protein S, a severely reduced APC cofactor activity
was also observed (Figure 3E). This further confirms the impor-
tance of this region of EGF1 in APC cofactor activity of protein S.
Dose-response experiments of WT protein S, protein S D95A, and
protein S D95N, shown in Figure 3F, confirm reduced APC
cofactor function of these variants.
Phospholipid binding of WT protein S and protein S D95A
As phospholipid binding is a prerequisite for protein S function, the
binding of WT protein S and of protein S D95A to phospholipids
was evaluated. Partially purified (using barium citrate precipita-
tion) protein S, 0 to 120nM, was incubated for 2 hours on a plate
coated with 25 g/mL phospholipids and was detected by an
HRP-conjugated antibody against protein S. As shown in Figure 4,
both WT protein S and protein S D95A were able to bind
phospholipids, with apparent dissociation constant (Kdapp) of 5.69
plus or minus 1.24 and 9.54 plus or minus 2.26nM, respectively
(Table 2). Kdapp values were analyzed by the Mann-Whitney test
and were found not to be statistically different (P  .05). Binding
was observed in the presence of Ca2, but not in the presence of
EDTA or in the absence of phospholipids, as expected. These
Figure 3. Effect of WT protein S, D95A, D95N, D78A, and Q79A variants on thrombin generation. Thrombin generation was measured in protein S–deficient plasma
supplemented with 9nM APC, 100nM antibodies against TFPI, and 0 to 120nM WT protein S (A), protein S D95A (B), protein S D95N (C), or 90nM purified WT (dashed line) or
purified protein S D95A (dotted line; D). Protein S concentrations are positioned adjacent to the peaks to which they refer. The cofactor activity of 60nM WT protein S and protein
S variants D95A, D78A, and Q79A was compared at 9nM APC (E). Typical experiments are shown (n  3). Whereas the cofactor activity of WT protein S is highly dependent on
the APC concentration used (Figure 1B), that of protein S D95A is not, explaining the difference in fold activity between WT protein S and protein S D95A in Figures 2 and 3.
Dose-response data from titrations with WT protein S, protein S D95A, and protein S D95N in the presence of 9nM APC are shown in panel F (data are expressed as mean
 SD of 2 independent experiments performed in duplicate). Inset in panel B shows recognition of WT protein S and protein S D95A in media by polyclonal antibodies and a
monoclonal antibody recognizing only -carboxylated Gla domains. Inset in panel D shows the SeeBlue-prestained marker, plasma-purified protein S from Enzyme Research
Laboratories Ltd (lane 1), purified recombinant WT protein S (lane 2), and purified protein S D95A (lane 3) visualized with silver staining.
Figure 4. Binding of protein S to phospholipid surfaces. Protein S (0-120nM) was
incubated in a plate coated with 25 g/mL phospholipids. Bound protein S was
detected with an HRP-conjugated polyclonal antibody against protein S. A represen-
tative experiment is shown. The apparent Kd values, 5.69 1.24 and 9.54 2.26nM
for WT protein S and protein S D95A, respectively, were obtained by calculating the
mean  SD of 3 independent experiments performed in duplicate. PL indicates
phospholipids.
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findings are broadly consistent with previously reported Kd values
for protein S binding to phospholipid surfaces.17-19,36,37 Our results
suggest the loss of APC cofactor activity observed for protein S
D95A is not due to loss of binding to phospholipid surfaces.
Binding to domain-specific monoclonal antibodies
Binding of protein S to conformational domain-specific antibodies
was evaluated to assess the integrity of the domain structure and
folding. Protein S in concentrated conditioned media was incubated
in a plate coated with monoclonal antibodies recognizing either the
Gla domain (MK21), the EGF1 domain (MK54), or the C-terminal
SHBG domain (MK61). Bound protein S was detected with
polyclonal antibodies. Binding curves were fitted with a one-site
binding equation, and the Kdapp values were obtained. Kdapp values
were analyzed by the Mann-Whitney test and were found not to be
statistically different (P  .05). Table 2 represents the mean plus or
minus SD Kdapp values of 3 independent experiments performed in
duplicate. The results suggest that mutation of Asp95 does not
result in a significant change in the domain structure of protein S.
Protein S enhancement of APC-mediated cleavage of FVa at
Arg306
The FVa variant, R506Q/R679Q, was used to evaluate protein
S–enhanced APC-mediated cleavage at Arg306 in FVa. FVa
inactivation was performed in the presence or absence of 0.5nM
APC and a titration of purified protein S (0-100nM) was per-
formed. After 10 minutes, the remaining FVa activity was mea-
sured in the prothrombinase assay. WT protein S efficiently
enhanced APC-mediated cleavage at Arg306 of FVa, in contrast to
the D95A mutant (Figure 5A).
To quantify the rate of cleavage at FVa Arg306 in the presence
and absence of protein S, time course experiments were performed
(Figure 5B). In the absence of protein S, or in the presence of
protein S D95A, 3nM APC was used and aliquots were quenched at
different time points (0-20 minutes). In the presence of WT protein
S, the APC concentration was lowered to 0.5nM, as APC is
efficiently enhanced by protein S. The remaining FVa activity at all
time points was measured in the prothrombinase assay. Using the
FVa inactivation curves obtained, the apparent pseudo–first-order
rate constants were calculated and corrected for the APC concentra-
tions used. Under these experimental conditions, protein S had no
effect on FVa activity in the absence of APC (data not shown).
APC-mediated cleavage at FVa Arg306 was enhanced by WT
protein S by 13.9-fold plus or minus 3.6-fold, whereas protein S
D95A was only able to enhance APC by 1.8-fold plus or minus
0.4-fold.
Discussion
We initially constructed and expressed 27 protein S variants with
mutations in the Gla, TSR, EGF1, and EGF2 domains and
evaluated their ability to enhance APC-mediated anticoagulant
activity in plasma. The anticoagulant function of these 27 variants,
and the subsequently expressed variants D78A, D79A, and D95N,
were assessed by a thrombin generation assay, the specificity of
which was demonstrated using polyclonal antibodies against either
protein S or protein C that completely inhibited the anticoagulant
response observed when adding protein S in the presence of APC.
The advantage of the thrombin generation assay conducted in plasma is
that it shows very clearly how APC is heavily dependent on protein S.38
In the absence of protein S, 10nM APC has no effect on thrombin
generation. In contrast, in the presence of protein S, maximal anticoagu-
lant effects with near ablation of thrombin generation are obtainable
with APC concentrations less than 10nM.
Our initial screening results identified 2 protein S variants with
appreciable reduction in APC cofactor function. These were the
already reported GLA2/Face2 variant (a 7-residue composite
mutant in the Gla domain) and the novel D95A point variant in the
EGF1 domain. The former variant, reported by Saller et al, retains
binding to phospholipids and yet has appreciably reduced APC
cofactor activity.19 It is suggested that the 7 residues substituted in
this variant collectively present a face of the Gla domain to APC
and form a potential contact region. It was selected for investiga-
tion here because it is a well-characterized protein S variant with
Table 2. Binding of protein S to phospholipids and domain-specific monoclonal antibodies
Phospholipid vesicles MK21 (Gla) MK54 (EGF1) MK61 (SHBG)
WT protein S 5.69  1.24 2.18  0.97 0.81  0.11 5.31  1.11
Asp95 protein S mutant 9.54  2.26 2.53  1.06 0.83  0.03 5.39  0.54
Kdapp values (nM) of WT protein S and the Asp95 protein S mutant for phospholipid vesicles and conformational domain-specific monoclonal antibodies are expressed as
mean plus or minus SD of 3 independent experiments performed in duplicate. Binding of WT protein S and the Asp95 mutant to phospholipids and domain-specific monoclonal
antibodies was analyzed by Mann-Whitney test; results were not statistically significant (P  .05).
Figure 5. Protein S enhancement of APC-mediated cleavage of FVa in Arg306.
Protein S (0-120nM) in the presence of 0.5nM APC was incubated with 0.8nM FVa
R506Q/R679Q in the presence of phospholipids for 10 minutes. The remaining FVa
actvity was measured with a prothrombinase assay. Results are plotted as
mean  SD from 3 independent experiments performed in duplicate (A). A time
course experiment was performed to calculate the apparent pseudo–first-order rate
constants of WT protein S and protein S D95A. It is observed that approximately
6-fold more APC is needed in the presence of protein S D95A to obtain a similar
amount of APC-mediated FVa R506Q/R679Q inactivation as with WT protein S (B).
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substantially reduced APC cofactor activity and could therefore act
as a representative control for a dysfunctional protein S. Saller et
al,19 however, did not assess GLA2/Face2 APC cofactor activity in
the CAT assay. We can confirm a reduction in APC cofactor activity
in plasma, assessed by CAT. The important novel results here, however,
concerned the protein S D95Avariant, which was almost devoid ofAPC
cofactor activity in plasma. The natural protein S variants T103N39 and
K155E40,41 have been reported to have reduced APC cofactor activity.
We could not observe any significant reduction in APC cofactor activity
of protein S T103A in the CAT assay. It is, however, important to point
out that defective APC cofactor activity of protein S T103N was not
observed in the APC-mediated inactivation of WT-FVa.39 In addition, at
higher concentrations of APC (8nM), no difference was observed
between WT protein S and protein S T103N in the FVIIIa degradation
assay.39 We did, however, observe a decrease in K155Acofactor activity
toward APC, although this was quite moderate under conditions used in
the screening assay.
Analysis of protein S function is complicated by its propensity
to multimerize upon purification.42,43 Accordingly, we have per-
formed APC cofactor assays with unpurified protein S in concen-
trated conditioned media as well as with fully purified preparations.
In the event, our results were all consistent. Both forms of the
protein S D95A variant, purified or in concentrated conditioned
media, had an appreciable reduction in APC cofactor activity
compared with the respective WT protein S preparation. Although
it has not been formally assessed, in all comparison experiments
carried out, the protein S D95A variant had less APC cofactor than
the GLA2/Face2 variant. This suggests that Asp95 in protein S may
occupy a pivotal position with respect to its interaction with APC.
The importance of Asp95 in APC cofactor activity was further
confirmed by the severely reduced activity observed when mutat-
ing to alanine the 2 residues in close proximity to Asp95, Asp78,
and Gln79. Asp78, Gln79, and Asp95 are conserved across species
with the exception of Asp78, which is replaced by the structurally
similar Asn78 in birds. Using a working model of the Gla-TSR-
EGF1 domains of protein S, we demonstrate the likely proximal
spatial location of these 3 residues (Figure 6) and their relationship
to GLA2/Face2 residues.
We have investigated the mechanism of reduction of activity of
protein S Asp95 variants. Whereas EGF1 of protein S has not been
shown to contain a calcium-binding site (in contrast to EGF2, EGF3,
and EGF4),44 Asp95 could be part of a partially conserved calcium-
binding motif. We therefore mutated Asp95 to Asn rather than Ala. Asn
is structurally similar to Asp, can be -hydroxylated, and is able to
coordinate a calcium ion (as has been observed in EGF2, EGF3, and
EGF4). As the protein S D95N variant also had reduced activity,
however, it is unlikely that a calcium-binding site is disrupted. Further-
more, whereas Asp95 is known to be -hydroxylated, it has previously
been shown that -hydroxylation itself is not a requirement for
anticoagulant activity of protein S.45 Our evidence favors a direct effect
of Asp95 in APC cofactor activity. Alternatively, the dramatic effect on
protein S activity of the Asp95 residue substitution could be through a
conformational repositioning of other functional domains. To assess
this, we performed binding to phospholipids, as this property underpins
all protein S function. Plate binding assays, however, indicated no major
functional defect on phospholipid binding. Furthermore, domain-
specific monoclonal antibody binding to WT and mutant protein S
(against Gla domain, EGF1 domain, and the C-terminal SHBG domain)
was also normal, suggesting that substitution of Asp95 does not reduce
APC cofactor function by disrupting adjacent domain structure.
A current view of protein S–enhanced APC cofactor activity
suggests a functional repositioning of the APC cleavage site away
from FVa Arg506 toward FVa Arg306.9 We therefore performed a
FVa inactivation assay using a FVa variant, FVa R506Q/R679Q,
that cannot be cleaved at position 506 and 679. This allowed us to
analyze directly cleavage at Arg306 by APC, which is at the site
enhanced mainly by protein S. Using both concentration-dependent
and time course assays, we were able to confirm reduced cleavage
of this variant by APC in the presence of protein S D95A.
The available results therefore suggest that Asp95 of protein S
may play an important and a direct role in APC recognition,
resulting in enhanced APC function. Our results are compatible
with the study performed by Hackeng et al,27 who used the isolated
EGF1 domain of protein S to functionally disrupt the protein S and
APC interaction. They suggested EGF1 as a potentially important
APC contact site on protein S. Our results suggest that Asp95
constitutes a critical residue within EGF1, mediating the APC
cofactor function. Together with Asp78 and Gln79, Asp95 could
form the principal functional interaction site for APC.
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Figure 6. Location of Asp78, Gln79, and Asp95 within the protein S Gla-TSR-EGF1
model. Domains are labeled on the right side of the model. Residues mutated in the GLA2
variant,Asp78, Gln79, andAsp95, are in light gray on the left side surface model. Residues
Asp78, Gln79, andAsp95 are highlighted by the box to show their proximal spatial location.
The model is taken from Villoutreix et al.35
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